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ABSTRACT
Liver cirrhosis is associated with cardiovascular dysfunction including decreased heart 
rate variability and impaired acceleration of the heart rate in response to sympathetic 
activation (chronotropic incompetence). In this thesis, the hypothesis that increased 
formation of reactive nitrogen species in cirrhosis causes nitration or S-nitrosation o f 
cardiac proteins and leads to impaired chronotropic function was assessed in an 
experimental model of cirrhosis. Cardiac chronotropic responsiveness to 13-adrenergic 
stimulation was assessed in vitro using spontaneous beating rat isolated atria. A novel 
mass spectrometric method was developed for dynamic assessment of nitration reactions 
based on the nitration of deuterium-labelled para-hydroxyphenyl acetic acid. Nitration o f 
cardiac proteins was measured by mass spectrometry and located by immunogold electron 
microscopy. Marked impairment of chronotropic responses of isolated atria to 
isoproterenol was observed in rats with cirrhosis, which normalized after the 
administration of N-acetylcysteine (a scavenger of reactive oxygen and nitrogen species) 
or L-NAME (a nitric oxide synthase inhibitor). The levels of protein-bound nitrotyrosine 
in atrial tissue increased from 16 ± 1 to 23 ± 3 pg/g tyrosine in rats with cirrhosis, and 
decreased to 15 ± 1 and 17 ± 1 pg/g after treatment with L-NAME and N-acetylcysteine, 
respectively (P<0.05). Immunogold electron microscopy demonstrated increased nitration 
o f filaments and mitochondria in the atria of rats with cirrhosis. A chemiluminescence- 
based method was developed to stabilise and measure S-nitrosothiols in tissues. There 
was no difference in cardiac S-nitrosothiols following induction of cirrhosis, and neither 
N-acetylcysteine nor L-NAME had any effect on the cardiac levels of S-nitrosothiols. 
Autonomic regulation of cardiac function was assessed by analysis of heart rate 
variability in anesthetized rats using Fast Fourier Transformation. Heart rate variability 
analysis showed impaired sympathovagal balance towards increase of cardiac 
sympathetic activity in rats with cirrhosis (P<0.05). However there was no change in the 
sympathovagal balance following N-acetylcysteine or L-NAME adminstration in cirrhotic 
rats. In conclusion, abnormal cardiac chronotropic function in cirrhosis is associated with 
increased nitration of cardiac proteins. Two independent treatments (N-acetylcysteine and 
L-NAME) that decrease nitration of cardiac proteins led to normalization of cardiac 
responses. Nitration of critical proteins in cardiac tissue may lead to abnormal cardiac 
function.
2
ACKNOWLEDGEMENTS
I wish to thanks my supervisor, Kevin Moore for the considerable time and care that 
he has devoted to my progress at all times during my staying in London.
Thanks are due to Sara Montagnese, Marsha Morgan, Richard Ollosson, Silvia 
Ippolito, Ahmad R. Dehpour, David Harry, Nelson Orie, Jim Owen, Pat Blake, 
Mohammad R. Ebrahimkhani, Leonard Damelin and Martin Hughes for their 
invaluable support and friendship.
I acknowledge the award o f a travelling fellowship by the Wellcome Trust UK
And again special thanks must go to Tara, Jelveh, Sotoodeh and Mohammad, for their
love and support
3
STATEMENT OF ORIGINALITY
The projects described in this thesis were designed and performed by myself except as 
stated below:
In chapter 4, the electron microscopy images were prepared by Mr Innes R 
Clatworthy (Electron Microscopy Unit, Hampstead Campus, UCL, London).
The human study presented in chapter 5 was performed in collaboration with Dr 
Marsha Y Morgan and Dr Sara Montagnese (Department o f  Medicine, Hampstead 
Campus, UCL, London). The electrophysio logical data from patients with cirrhosis 
were recorded by Dr Sara Montagnese (chapter 5). Mr Clive Jackson (Department o f  
N euro physio logy, Royal Free Hospital NHS Trust, London) prepared the software to 
detect R-R intervals which was used for heart rate variability analysis from human 
electro physio logical recordings (chapter 5). The plasma levels o f  inflammatory 
cytokines in patients with cirrhosis were measured by Dr Robert Stephens (Institute o f  
Child Health, UCL, London).
4
LIST OF CONTENTS
A bstract...................................................................................................................................... 2
Acknowledgements................................................................................................................... 3
Statement o f originality............................................................................................................4
List o f contents..........................................................................................................................5
List o f figures............................................................................................................................ 7
List o f tab le s ............................................................................................................................ 10
1. Chapter 1: cardiovascular dysfunction in liver c irrhosis...........................................11
1.1 C irrhosis............................................................................................................... 11
1.2 Consequences o f liver cirrhosis........................................................................ 11
1.3 Cardiac dysfunction in c irrhosis......................................................................20
1.3.1 Chronotropic incom petence.............................................................20
1.3.2 Cirrhotic cardiom yopthy.................................................................. 21
.3.3 Prolongation o f QT in terval...............................................................23
1.3.4. Decreased heart rate varianilty (H R V )........................................24
1.4 Reactive Nitrogen Species................................................................................26
1.5 Nitric O x id e ........................................................................................................ 26
1.6 Nitric Oxide synthesis in m am m als................................................................ 27
1.7 NOS regulation...................................................................................................27
1. 8  Nitric Oxide reaction and modification o f  proteins by N O ........................29
1.8.1 Metal C entres..................................................................................... 30
1.8.2 S-Nitrosation...................................................................................... 30
1.8.3 N itration.............................................................................................. 33
1.9 Measurement o f protein nitration and S-nitrosothiol form ation................ 37
1.9.1 Measurement o f S-nitrosothiol........................................................ 37
1.9.2 Measurement o f  protein n itration ....................................................39
1.9.3 Identification o f  protein targets to nitration and nitrosation 40
1.10 Aims and hypothsis..........................................................................................41
1.11 Overview o f this th esis .................................................................................... 41
5
2. Chapter 2: Dynamic assessment o f nitration reaction in v iv o .................................... 43
2.1 Introduction......................................................................................................... 43
2.2 Materials and methods I ....................................................................................44
2.3 Results I ................................................................................................................50
2.4 Discussion I ......................................................................................................... 62
3. Chapter 3: Stabilization and measurement o f S-nitrosothiols in tissu es .................. 65
3.1 Introduction......................................................................................................... 65
3.2 Materials and methods I I ................................................................................... 6 6
3.3 Results I I ..............................................................................................................74
3.4 Discussion I I ........................................................................................................ 85
4. Chapter 4: Role o f nitration and/or nitrosation o f cardiac proteins in pathogenesis o f  
cardiac dysfunction in rats with biliary cirrhosis..............................................................89
4.1 Introduction......................................................................................................... 89
4.2 Materials and methods I I I ..................................................................................93
4.3 Results I I I .......................................................................................................... 101
4.4 Discussion I I I ....................................................................................................116
5. Chapter 5. Decreased heart rate variability in patients with cirrhosis..................... 123
5.1 Introduction....................................................................................................... 123
5.2 Materials and methods I V ...............................................................................125
5.3 Results I V .......................................................................................................... 130
5.4 Discussion I V .................................................................................................... 137
6 . Summary and conclusions.............................................................................................. 141
7. R eferences......................................................................................................................... 147
8 . A bbreviation......................................................................................................................167
9. Appendix 1. Publications extracted from this th esis .................................................. 170
6
LIST O F FIGURES
Figure 1.1. Schematic representation o f  the pathophysiology o f  portal hypertension in 
hepatic cirrhosis....................................................................................................................... 1 2
Figure 1.2. Nitric oxide over-production in c irrhosis....................................................... 15
Figure 1.3. Heart rate variability...........................................................................................25
Figure 1.4. Reactive nitrogen species and modification o f p ro teins..............................29
Figure 1.5. Nitration o f tyrosine residues in p ro te ins....................................................... 34
Figure 1.6. Degradation o f nitrated proteins.......................................................................36
Figure 2.1. Structures and spectra from NICI scan o f the pentafluorobenzyl derivative 
o f NHPA and PH P A ............................................................................................................... 51
Figure 2.2. Typical chromatogram showing peak shape and resolution for both NHPA 
(A) and PHPA (B) in a urine sam ple...................................................................................52
Figure 2.3. Spectra from NICI scan o f  the pentafluorobenzyl derivative o f  authentic 
PHPA (lower panel) and deuterium-labelled PHPA (upper panel)................................53
Figure 2.4. Standard curves for NHPA and PHPA in human u rin e ...............................54
Figure 2.5. Urinary excretion o f  NHPA after intravenous injection o f
nitrotyrosine.............................................................................................................................. 56
Figure 2.6. Urinary excretion o f  NHPA after intravenous injection o f L P S ..................57
Figure 2.7. Chromatogram o f  a urine sample obtained from a rat injected with
[2 H6]P H P A ...............................................................................................................................59
t t
Figure 2.8. Urinary excretion o f [‘HsJNHPA and [~H6 ]PHPA after intravenous 
injection o f [2 H6]P H P A .........................................................................................................60
Figure 2.9. NHPA/PHPA ratio as an index o f RNS form ation......................................61
Figure 2.10. Two identified pathways, which can produce NHPA in v iv o .................. 63
Figure 3.1.CysNO decomposition by liver homogenate incubated with N-
ethylmaleimide/DTPA PBS at different temperatures (37°C vs 4 ° C )......................... 75
Figure 3.2. S-Nitrosothiol decomposition in presence o f liver homogenate at 4°C .. .76
Figure 3.3. CysNO decomposition in presence o f plasma, liver, kidney, heart, and 
brain homogenates (4 °C )....................................................................................................... 77
Figure 3.4. CysNO decomposition by fresh, heat-denatured liver homogenates or after
7
proteolysis by proteinase K. 78
Figure 3.5. CysNO decomposition in the presence o f whole liver homogenate and 
mitochondrial, microsomal, cytoplasmic, and low-molecular-weight fractions o f  rat 
liver at 4 ° C .............................................................................................................................. 79
Figure 3.6. CysNO decomposition by liver homogenate after 30 min incubation with 
some enzyme inhibitors......................................................................................................... 81
Figure 3.7. Formation o f  nitrite + nitrate (NOx) in liver homogenate after 2 h 
incubation with CysNO in jV-ethylmaleimide/DTPA b u ffe r........................................... 82
Figure 3.8. CysNO decomposition in the presence o f liver homogenates o f rats with
(A) acute sepsis or (B) biliary cirrhosis.............................................................................83
Figure 3.9. (A) Decomposition o f  endogenously formed nitroso compounds in liver 
obtained from a rat with acute sepsis .................................................................................. 84
Figure 3.10. Flow diagram for the measurement o f S-nitrosothiols, N-nitrosamines 
and iron-nitrosyl complexes in tissues................................................................................8 8
Figure 4.1. A schematic representation o f  the working hypothesis on the mechanism 
o f  decreased heart rate variability in cirrhosis.....................................................................92
Figure 4.2. The Poincare plot is a graphical presentation o f the correlation between 
the consecutive R-R intervals............................................................................................... 94
Figure 4.3. Time-dependent effect o f bile duct ligation on basal heart rate (A), short­
term HRV (B) and long-term HRV (C) in bile duct ligated (BDL) or sham operated 
(Control) r a ts .........................................................................................................................101
Figure 4.4. Basal heart rate (bpm: beat/min) in control or cirrhotic rats given saline, L- 
NAME, NAC, AM251, pentoxifylline or neomycin/polymixin B ............................... 102
Figure 4.5. Poincare’ plots in two representative control and cirrhotic r a ts .............. 103
Figure 4.6. Short-term heart rate variability (SD1) in control or cirrhotic rats given 
saline, L-NAME, NAC, AM251, pentoxifylline or neomycin/polymixin B  104
Figure 4.7. Long-term heart rate variability (SD2) in control or cirrhotic rats given 
Saline, L-NAME, NAC, AM251, pentoxifylline or neomycin/polymixin B  105
Figure 4.8. Chronotropic response o f  spontaneous beating isolated atria to cumulative 
concentrations o f isoproterenol ( 1  O'10- 1 0 "7) ..................................................................... 107
Figure 4.9. Western blot o f cannabinoid CB1 receptor, eNOS and iNOS protein in 
cardiac tissue obtained from control (C l, C2, C3) and bile-duct ligated (B l, B2, B3) 
r a ts ..........................................................................................................................................108
Figure 4.10. Protein-bound nitrotyrosine content o f atrial tissue obtained from control
and rats with cirrhosis given saline, N-acetylcysteine (NAC; A), or L-NAME
(B ) I l l
Figure 4.11. Protein-bound (upper panel, A-B) and free (lower panel, C-D) 
nitrotyrosine content o f ventricular tissue obtained from control and rats with cirrhosis 
treated with saline, N-acetylcysteine (NAC; A,C) or L-NAME (B ,D )........................112
Figure 4.12. Assessment o f nitration reactions in vivo using deuterated PHPA (2 H6 -
PHPA) as p ro b e .................................................................................................................... 113
Figure 4.13. Immunogold electron microscopy for nitrotyrosine in atria from control 
(A) and bile duct ligated (B) ra ts ........................................................................................115
Figure 5.1. Poincare plots depicting the correlation between consecutive R-R 
intervals, in four representative patients with cirrhosis, by degree o f hepatic 
dysfunction and neuropsychiatric s ta tu s ............................................................................133
Figure 5.2. Long-term heart rate variability (SD2, Mean values) in patient with liver 
c irrhosis.................................................................................................................................. 134
Figure 5.3. Factorial analysis o f long-term HRV (SD2) in patients with cirrhosis 
adjusted for neuropsychiatric status (HE) or degree o f liver dysfunction (Child) ... 134
Figure 5.4. Correlation o f  long-term heart rate variability index (SD2) and selected 
psychometric/EEG variables in patients with cirrhosis..................................................135
9
LIST OF TABLES
Table 4.1. Plasma nitrate + nitrite (/-iM) in control or cirrhotic rats given Saline, L-
NAME, NAC, AM251, pentoxifylline or neomycin + polymixin B ...........................109
Table 4.2. Comparison o f protein-bound nitrotyrosine levels between controls and 
cirrhotic tissues......................................................................................................................I l l
Table 4.3. Cardiac S-nitrosothiol and F2 -isoprostanes concentrations in control and 
cirrhotic rats treated with saline, N-acetylcysteine (NAC) or L -N A M E....................114
Table 5.1. Modified Child Classification o f  severity o f liver disease according to the 
degree o f ascites, the plasma concentrations o f bilirrubin and albumin, the 
prothrombin time (NIR), and the degree o f  encephalopathy (HE)................................ 126
Table 5.2. Heart rate variability indices in healthy volunteers and patients with 
cirrhosis by degree o f  hepatic encephalopathy (HE) and degree o f  hepatic dysfunction 
...................................................................................................................................................131
Table 5.3. The relationship between long-term HRV (SD2) and the degree o f  
neuropsychiatric impairment in patients with cirrhosis adjusted for indicators o f vagal 
modulation o f H R V .............................................................................................................. 132
Table 5.4. Correlations between plasma cytokine levels and heart rate 
variability/hepatic encephalopathy indices in patients with c irrhosis..........................136
10
Chapter 1: Cardiovascular dysfunction in liver cirrhosis
1.1 Cirrhosis
Liver cirrhosis is defined as a diffuse process with fibrosis and nodule formation in 
the liver (Sherlock and Dooley 2002). Liver injury leading to hepatic fibrosis occurs 
in response to a variety o f insults, which trigger a wound healing-like reaction. During 
chronic liver injury, hepatic stellate cells become activated and express a combination 
o f  matrix metalloproteinases which have the ability to induce global changes in the 
liver extra-cellular matrix. This pattern is characterised by increased degradation o f  
the sub-endothelial basement membrane, loss o f normal liver architecture, and 
inhibition o f degradation o f  liver collagen (Friedman 2007). Chronic liver injury 
leading to hepatic cirrhosis occurs in response to a variety o f  insults including chronic 
viral hepatitis (HBV, HCV), alcohol misuse, metabolic disorders (e.g. 
haemochromatosis and Wilson’s disease), prolonged cholestasis (e.g. primary biliary 
cirrhosis), autoimmune hepatitis and fatty liver disease.
1.2 Consequences of liver cirrhosis
Cirrhosis has certain clinical and pathological associations such as splenomegaly, 
ascites, oesophageal varices, hepatic encephalopathy, impaired coagulation and 
hypoalbuminemia. Cirrhosis results in two major events: portal hypertension and 
hepato-cellular failure. Prognosis and treatment depend on the magnitude o f these 
two factors (Sherlock and Dooley 2002).
Portal hypertension: Portal hypertension is the most common and lethal complication 
o f  chronic liver diseases; it is responsible for the development o f  oesophageal varices, 
variceal haemorrhage, ascites, splenomegaly and renal dysfunction observed in 
patients with cirrhosis. Portal hypertension is defined by a pathologic increase in 
portal pressure, in which the pressure gradient between the portal vein and inferior 
vena cava (the portal pressure gradient) is increased above the upper limit o f 5 mm Hg 
(Bosch et al. 2007). Portal hypertension becomes clinically significant when the portal 
pressure gradient increased above the threshold value o f  10 mm Hg (e.g. formation o f  
varices) or 12 mm Hg (e.g. variceal bleeding, ascites). Portal pressure gradient values 
between 6  and 10 mm Hg represent sub-clinical portal hypertension in humans (Bosch 
et al. 2007). Portal pressure gradient is determined be the product o f blood flow and
11
vascular resistance to portal blood flow and aggravated by an increased portal venous 
inflow.
Increased resistance to sinusoidal blood flow in cirrhosis represents not only 
disruption o f liver’s vascular structure by liver disease (e.g. fibrosis) but also a 
dynamic component resulting from the active contraction o f  vascular smooth muscles, 
myo-fibroblasts, and hepatic stellate cells (Bosch et al. 2007). Active contraction is 
caused by decreased intra hepatic production o f vasodilators such as nitric oxide (NO) 
and by increased release o f endogenous vasoconstrictors such as endothelins (Leivas 
et al. 1998). Apart from increased hepatic vasculature resistance in cirrhosis, 
increased portal venous inflow secondary to splanchnic vasodilatation usually 
aggravates elevation o f  portal pressure (Figure 1.1).
Liver injury
Hepatic cirrhosis
Architectural disturbances
( f i b r o s i s ,  t h r o m b o s i s ,  e t c )
Functional a lterations
( c o n t r a c t i o n  o f  v a s c u l a r  s m o o t h  m u s c l e s  a n d  s t e l l a t e  ce l l s )
Increased hepatic  resistance
I
*
I
Por ta l  h y p e r t e n s i o n
Increased portal 
blood inflow <-
Splanchnic vasodilatation Effective hypovolem ia
Sodium and w ater  
re ten tion
Figure 1.1. Schematic representation o f  the pathophysiology o f  portal hypertension in 
hepatic cirrhosis.
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Splanchnic vasodilatation: An increased portal venous inflow is characteristically 
observed in advanced stages o f  portal hypertension and is the result o f  marked 
arteriolar dilatation in the splanchnic organs draining into the portal vein (Bosch and 
Garcia-Pagan 2000). The increased blood flow contributes to the portal hypertensive 
syndrome. Different mechanisms have been suggested to explain the development o f  
these haemodynamic changes. Initial studies focused on the potential role o f increased 
levels o f circulating vasodilators. Several candidate mediators have been proposed, 
most o f them being vasodilator o f splanchnic origin that undergo hepatic metabolism 
and accumulate in systemic circulation when hepatic uptake is reduced in liver disease 
or during portosystemic shunting. Splanchnic vasodilatation present in portal 
hypertension is likely to be multi-factorial in origin, being promoted in part by an 
excessive release o f  glucagon, nitric oxide (NO), carbon monoxide, endocannabinoids 
and other vasoactive mediators. In addition, experimental studies suggest that when 
one o f  the vasoactive mediators is chronically inhibited, the enhancement o f  other 
vasoactive pathways may prevent the correction o f splanchnic vasodilation 
(Fernandez et al. 1996).
Glucason: Many studies have demonstrated that plasma glucagons levels are 
elevated in patients with cirrhosis and experimental models o f  portal hypertension. 
Hyper-glucagonemia results, in part, form a decreased hepatic clearance o f  glucagons, 
but more importantly from an increased formation o f  glucagons by pancreatic cells 
(Gomis et al. 1994). The support for a role o f glucagons in modulating splanchnic 
blood flow comes from physiologic studies showing that in rats with experimental 
portal hypertension, normalizing circulating glucagon levels by administering anti­
glucagon antibodies or infusing somatostatin partially reverses the increase in 
splanchnic blood flow, a response that can be specifically blocked by the concomitant 
infusion o f glucagon (Benoit et al. 1986; Kravetz et al. 1988). Glucagon might 
promote vasodilatation by a dual mechanism: Relaxing the vascular smooth muscle 
and decreasing its sensitivity to endogenous vasoconstrictors such as norepinephrine, 
angiotensin II and vasopressin (Pizcueta et al. 1991; Wiest et al. 2001). The role o f  
glucagon in the splanchnic hyperemia o f portal hypertension provides a rationale for 
the use o f  somatostatin and its analogues to treat portal hypertension (Bosch et al. 
2007).
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Nitric Oxide (NO): Experimental studies o f specific NO synthase (NOS) 
inhibitors have shown that NO is involved in the regulation o f  splanchnic and 
systemic hyperdynamic circulation in portal hypertension (the chemistry and 
physiological aspects o f NO is reviewed in chapter 1.4). Inhibition o f NOS in portal 
hypertensive rats reverses the vascular hypo-responsiveness to vasoconstrictors that 
develops in this model where is thought to contribute to systemic and splanchnic 
vasodilatation (Sieber and Groszmann 1992a,b). In addition, increased synthesis o f  
NO has been demonstrated in vitro in perfused mesenteric artery preparations from 
portal hypertensive rats (Hori et al. 1998). The finding o f  increased serum and urinary 
concentrations o f nitrite and nitrate in patients with cirrhosis, which are end-products 
o f  NO oxidation, also supports a role for NO in the genesis o f the circulatory 
disturbances o f portal hypertension (Guamer et al. 1993).
The role o f  different isoforms o f  NOS in increased NO synthesis in cirrhosis is 
controversial (see Farzaneh-Far and Moore 2001 for review). In portal hypertensive 
animals, increased NO synthesis by eNOS in the splanchnic circulation precedes the 
development o f hyperdynamic circulation and is mostly due to an up-regulation o f  
endothelial NOS (eNOS) catalytic activity, rather than eNOS over-expression (Wiest 
et al. 1999). Factors likely to activate eNOS include shear stress and pro- 
inflammatory mediators (Farzaneh-Far and Moore 2001). Indeed, eNOS 
phosphorylation by Akt seems to be the mechanism o f  the initial up-regulation o f  
eNOS activity (Iwakiri et al. 2002). Later on, other mechanisms become important, 
including an enhanced signalling o f  the molecular chaperone heat shock protein 90 
(Hsp90) (Garcia-Cardena et al. 1998; Shah et al. 1999). In addition, in cirrhotic rats 
with ascites, it was shown that bacterial translocation further increased eNOS activity 
in the mesenteric artery, probably in response to increased levels o f  tumor necrosis-a 
(TNF-a). TNF-a production was associated with elevated levels o f  
tetrahydrobiopterin (BH4), a TNF-ostim ulated cofactor and enhancer o f eNOS- 
derived NO biosynthesis and NOS activity (Wiest et al. 1999). Fig. 1.2 summarises 
the involvement o f NO in genesis o f  splanchnic and hyperdynamic circulation in 
cirrhosis.
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Figure 1.2. Nitric oxide over-production in cirrhosis. Liver injury results in increased 
nitric oxide synthesis by eNOS through a variety o f mechanisms. Once underway, this 
process is reinforced by the effects o f shear stress on endothelium which increases 
eNOS activity.
Nitric oxide paradox in cirrhosis: Nitric oxide displays an astonishing array o f  
biological functions. In liver disease, one or more o f these functions may be disturbed 
by either too much production o f NO or too little. Systemically, increased synthesis o f  
NO is a major contributing factor in the establishment o f the splanchnic vasodilatation 
and hyperdynamic circulation in cirrhosis. On the other hand, NO plays a protective 
role in maintaining the patency o f  the hepatic microvasculature and local deficiency 
o f  NO in the liver may contribute to portal hypertension. Alterations in eNOS-derived 
NO synthesis in the intrahepatic microcirculation and in the splanchnic and systemic 
vasculature are strikingly opposite. Liver cirrhosis is associated with endothelial 
dysfunction and deficiency o f  endothelial NO release in hepatic sinusoids (Loureiro- 
Silva et al. 2003). Deficiency o f  NO in the micro circulation results in impaired 
vasoregulation and enhanced vasoconstriction, leading to increased vascular tone. In
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contrast, the splanchnic and systemic vasculature exhibit increased endothelial NO 
synthesis. This increase in eNOS-derived NO-synthesis leads to arterial vasodilation 
and plays a crucial role in the development o f  the hyperdynamic circulation and its 
subsequent lethal complications o f chronic liver diseases. It is the up-regulation o f  the 
endothelial NO-synthesizing machinery in the splanchnic and systemic circulation 
that complicates the use o f nitro vasodilators for the delivery o f NO to the intrahepatic 
microcirculation. Any systemic administration o f  NO-donors (e.g. organic nitrates) 
will have a more marked and detrimental effect in the splanchnic and systemic 
circulation than a beneficial effect in the intrahepatic circulation. Therefore, the 
development o f liver specific NO-donors will be o f great importance for optimizing 
therapy o f liver cirrhosis.
Carbon monoxide: Recent studies have shown an increased expression and 
activity o f inducible form o f Haem oxygenase (HO), in splanchnic tissues form 
animals with portal hypertension (Fernandez and Bonkovsky 1999). In addition, the 
simultaneous inhibition o f  NOS and HO has been shown to completely reverse the 
reduced vasoconstrictor response to vasoconstrictors in the mesenteric vascular bed 
(Fernandez et al. 2001).
Endocannabinoids: Recent data suggest a role for endocannabinoids in the 
hyperdynamic circulation o f portal hypertension (Batkai et al. 2001; Ros et al. 2002; 
Moezi et al. 2006). Increased levels o f  the endogenous cannabinoid anandamide 
(arachidonyl ethanolamide) have been found in the monocyte fraction o f  blood from 
cirrhotic humans and rats, and an increased expression o f the cannabinoid receptor 
(CB1) was found in hepatic human endothelial cells (Batkai et al. 2001). In addition, 
CB1 receptor blockade has been found to reduce portal blood flow and pressure and 
increase arterial pressure in cirrhotic rats (Batkai et al. 2001; Ros et al. 2002). The 
mechanism o f  action is not well understood. It has been suggested that it could be due 
to, at least in part, to an increased NO production, mediated by the activation o f  CB1 
or Vanilloid (VR1) receptors (Moezi et al. 2006).
Other vasoactive mediators: Several other circulating vasodilators such as 
prostacyclin (PGH), calcitonin gene-related polypeptide (CGRP), and adenosine have 
been implicated in splanchnic vasodilatation (Bosch et al. 2007). Altogether, these 
data suggest that the splanchnic vasodilatation is likely to be multi-factorial in origin
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and coupling o f  several vasoactive systems may cause the splanchnic vasodilatation 
seen in portal hypertensive states.
Hyperdynamic circulation in cirrhosis: It appears that the haemodynamic changes in 
cirrhosis begin in the splanchnic circulation, at some early stage in the natural history 
o f  patients with cirrhosis and portal hypertension. At some further stage, the 
hyperdynamic circulation becomes clinically evident. The Oxford Textbook o f  
Medicine describes the clinical features hyperdynamic circulation as flushed 
extremities, bounding pulses and capillary pulsations in cirrhosis which is associated 
with systemic hypotension, tachycardia, elevated cardiac output and reduced total 
systemic vascular resistance (Sherlock 1986). In 1988, Schrier and colleagues 
proposed the ‘peripheral arterial vasodilatation hypothesis ’ to account for this 
hyperdynamic circulation as well as the initiation o f  sodium and water retention in 
cirrhosis (Schrier et al. 1988). Thereafter, Vallance and Moncada (1991) suggested a 
mechanism by which enodtoxaemia induces NO over-production and peripheral 
vasodilatation in patients with liver disease. Their hypothesis was based on data 
provided by other experiments: (1) NO synthesis is induced in the endothelium and 
smooth muscle when vascular tissue is exposed to endotoxin or cytokines in vitro 
(Beasley 1990). (2) Infusion o f  endotoxin in humans leads to the gradual appearance 
o f  peripheral vasodilatation (Sufffedini et al. 1989). (3) Inhibitors o f NOS increase 
blood pressure o f patients with septic shock (Petros et al. 1991) and (4) High 
circulating levels o f endotoxin are found in cirrhotic patients with or without clinical 
evidence o f infection (Lumsden et al. 1988). Evidence supporting a role for NO has 
been obtained from various experimental models o f cirrhosis. For example, 
administration o f NOS inhibitors to cirrhotic rats increases systemic vascular 
resistance, thus modulating hyperdynamic circulation (Calver et al. 1994). Moreover, 
the production o f NO is observed to increase in cirrhotic patients by using various 
parameters including increased plasma nitrate + nitrite (NO end products) and urinary 
cGMP levels (Fernandez-Rodriguez et al. 1997). As mentioned above several other 
circulating vasodilators (e.g. endocannabinoids, glucagon and CGRP) may also be 
implicated in the peripheral vasodilatation observed in cirrhosis. Overall, peripheral 
vasodilatation in cirrhosis activates three major compensatory mechanisms (see 
Dagher and Moore 2001 for review):
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1. Renin-angiotensin-aldosterone system: This leads to water and salt retention and 
exacerbate accumulation o f  fluids in the peritoneum {Ascites).
2. Sympathetic nervous system. This impairs the renal auto-regulatory mechanism 
which regulates kidney perfusion.
3. Stimulation o f arginine vasopressin (AVP) release from the pituitary gland: This 
can lead to impaired so lute-free water excretion by the kidney and dilutional 
hyponatremia, a complication in patients with advance cirrhosis.
These compensatory mechanisms along with oxidative stress (see below) are major 
cause o f renal vasoconstriction in cirrhosis (Dagher and Moore 2001). Renal 
impairment in most patients with cirrhosis is secondary to functional abnormalities 
that occur in response to a severe systemic vasodilatation which triggers an intense 
compensatory neuro-hormonal response causing sodium retention, solute-free water 
retention and finally, severe renal vasoconstriction. Hepatorenal syndrome is the end 
o f the spectrum o f functional renal abnormalities by a severe vasoconstriction o f  the 
renal circulation. It seems that the pathogenesis o f hyperdynamic circulation is 
complex with several non-linear interactions between vascular and neural 
mechanisms.
Role o f  oxidative stress in the pathogenesis o f  hyperdynamic circulation:
Administration o f  low molecular weight thiols (e.g. N-acetylcysteine and lipoic acid) 
prevents the development o f hyperdynamic circulation in rat models o f  portal 
hypertension (Fernando et al. 1998; Marley et al. 1999). Since low molecular weight 
thiols have antioxidant properties, these observations suggest that oxidative stress may 
have a role in the pathogenesis o f  hyperdynamic circulation in cirrhosis. A marked 
overproduction o f F2 -isoprostanes has also been reported in experimental models as 
well as patients with cirrhosis (Fernando et al. 1998; Marley et al. 1999; Holt et al. 
1999). Isoprostanes are a group o f vaso-active compounds which derived from the 
free radical oxidation o f arachidonic acid (Morrow et al. 1992). In a landmark study 
Holt et al., (1999) observed that N-acetylcysteine ameliorates renal dysfunction and 
survival rate in patients with hepatorenal syndrome, suggesting a relationship between 
oxidative stress and pathogenesis o f hyperdynamic circulation. The mechanism o f  
how low molecular weight thiols such as N-acetylcysteine and lipoic acid improve the
18
haemodynamic abnormalities in cirrhosis is not well understood. However it was 
postulated that N-acetylcysteine might enhance cell redox status and cellular rodox 
signalling (see chapter 1 .8 ).
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1.3 Cardiac dysfunction in cirrhosis
Cirrhosis is known to be associated with numerous cardiac abnormalities, but only 
until relatively recently did the development o f  techniques for precisely measuring 
cardiovascular variables allow determination o f the extent o f these anomalies. 
Cardiac abnormalities in cirrhosis include:
1. Chronotropic incompetence
1. High cardiac output at rest but blunted contractile responsiveness to physical or 
pharmacological stimuli (this phenomenon has been controversially termed cirrhotic 
cardiomyopathy).
3. Prolongation o f QT interval
4. Decreased heart rate variability (HRV).
1.3.1 Chronotropic incompetence
Chronotropic incompetence in cirrhosis is defined as impaired acceleration o f  heart 
rate in response to physiological stimuli (see Zambruni et al. 2006 for review). 
Although resting tachycardia is a feature o f the hyperdynamic circulatory syndrome, 
maneuvers leading to either activation o f the sympathetic nervous system (or alter the 
sympathovagal balance in favour o f the sympathetic system) such as Valsalva 
maneuver, tilting, ice-cold skin stimulation and physical exercise, do not evoke an 
adequate acceleration o f heart rate (Bemardi et al. 1987; Lee et al. 1990; Bemardi et 
al 1991, Wong 2001). Impaired chronotropic responses can be observed in patients 
with cirrhosis regardless o f the aetiology o f cirrhosis, and its prevalence increases 
with the disease severity (Bemardi et al 1991). Accordingly, the dose o f 13-agonists 
(such as isoproterenol) required to increase heart rate by 25 beats/min increases by 
threefold with respect to healthy subjects (Ramond et al. 1986). Likewise, in rats with 
biliary cirrhosis, a four fold increase in the dose o f isoproterenol was needed to elicit a 
10% increase in basal heart rate compared with sham-operated animals (Lee et al. 
1990).
Whether and to what extent abnormal chronotropic responses have a clinical impact in 
patients with cirrhosis is unknown. Recent studies on the haemodynamic 
abnormalities associated with renal failure precipitated by spontaneous bacterial
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peritonitis (Ruiz-del-Arbol et al. 2003; Ruiz-del-Arbol et al. 2005) suggest that 
chronotropic incompetence may play an important role in the pathophysiology o f  such 
complications. Contrary to preconceived ideas, renal failure precipitated by 
spontaneous bacterial peritonitis is not associated with a significant drop in peripheral 
vascular resistance, but is associated with a reduction in cardiac output. Since cardiac 
output is the product o f heart rate and the stroke volume (cardiac output = heart rate x 
stroke volume), there may be two causes for this reduction o f  cardiac output, such as 
impaired heart contractility or impaired heart rate acceleration. What is certain is that 
heart rate failed to increase in these patients, even in the face o f  a dramatic activation 
o f sympathetic nervous system (Ruiz-del-Arbol et al. 2003; Ruiz-del-Arbol et al. 
2005). A similar haemodynamic abnormality has been reported in paracentesis- 
induced circulatory dysfunction. In fact, even though a further reduction in peripheral 
vascular resistance actually occurred, a striking feature was that cardiac index did not 
increase at all. Again, one possible reason for this was that heart rate did not show any 
significant acceleration (Ruiz-del-Arbol et al. 1997). Possibly, these reports are the 
first to demonstrate how chronotropic incompetence can assume clinical relevance in 
patients with cirrhosis.
The mechanism o f  chronotropic incompetence in cirrhosis is not well understood. 
Mani et al. (2002) have previously reported that, NO plays a dual role in the 
regulation o f the sino-atrial pacemaker cells and this may have a role in the 
pathophysiology o f  chronotrpic incompetence in rats with biliary cirrhosis. We have 
further investigated this which is presented in Chapter 4.
1.3.2 “Cirrhotic cardiomyopathy”
This syndrome was first described in the late 1960s, although for many years, it was 
mistakenly attributed to latent or sub-clinical alcoholic cardiomyopathy (see Lee et al. 
2007 for review). In 1953, Kowalski and Abelmann showed that an increased cardiac 
output, decreased blood pressure, and total peripheral resistance along with a 
prolonged QT interval were present in alcoholic cirrhosis. In another study, Regen et 
al. (1969) injected angiotensin (a potent vasoconstrictor) into ten alcoholic cirrhotic 
patients and noted a rise in cardiac output and stroke volume; however it was 
significantly less than the effect in healthy controls. Subsequent studies in human and 
animal models with non-alcoholic cirrhosis, dating from the mid-1980s showed a
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similar pattern o f increased baseline cardiac output with blunted response to physical 
or pharmacological stress (see Lee et al. 2007 for review). Although nowadays 
presence o f cardiac dysfunction in cirrhosis is considered to be a well-described 
clinical entity, however the term “cirrhotic cardiomyopathy” is still controversial.
Left ventricular hypertrophy has been reported in patients and rats with cirrhosis 
(Pozzi et al. 1997; Inserte et al. 2003). Histomorp ho metric analysis revealed a 
significant increase in cell volume o f  cardiomyocytes from the left ventricle o f  
cirrhotic rats, but no differences in myocardial collagen content (Inserte et al. 2003). 
Echocardiography data in patients has also shown an increase in left ventricle wall 
thickness in cirrhotic patients with ascites (Pozzi et al. 1997). Left ventricular wall 
thickness in this patient population probably reflects an adaptive change in response 
to hyperdynamic circulation and not necessarily the presence o f cardiomyopathy 
(Inserte et al. 2003). However, elevated circulating levels o f  brain natriuretic peptide 
(BNP; the gene o f  which is predominantly expressed in failing cardiomyocytes) has 
been reported in cirrhosis (Henriksen et al. 2003), which most likely reflects increased 
cardiac ventricular generation o f these peptides and thus indicates the presence o f  
myocardial dysfunction.
Studies on isolated papillary muscle from rats with cirrhosis have shown a blunted 
inotropic response upon stimulation with 6 -adrenergic agonists (Ma et al. 1996; Liu et 
al. 2000). In contrast, studies on isolated perfused hearts pereparations (at constant 
pressure), were unable to detect any contractility dysfunction in experimentally 
induced cirrhosis (Inserte et al. 2003; Mani and Moore, unpublished). The differences 
in the perfused heart and papillary muscle studies can be explained in part by the 
different influence o f left ventricular hypertrophy in both models. In the papillary 
muscle model, generated tension is calculated by dividing generated force by cross- 
sectional muscle area. In the presence o f  hypertrophy, cross-sectional area is greater, 
and, for the same contractile force, generated tension will be smaller. In contrast, in 
the isolated heart model generated pressure, instead o f tension, is analyzed. According 
to the Laplace law, wall tension in the intact heart is calculated as the product o f 
pressure by cavity radius divided by wall thickness. Because cavity radius in cirrhotic 
and control hearts are equal, by applying the Laplace formula, generated wall tension 
in cirrhotic model is reduced by ~ 20 % with respect to hearts from control rats. In
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other words, because, in cirrhotic rats, higher ventricular mass produces the same total 
work, work produced by unit o f myocardial mass is smaller (Inserte et al. 2003).
Lee and colleagues have extensively studied the mechanism o f  cardiac dysfunction in 
cirrhotic rats using isolated papillary muscle (Ma et al. 1996; Liu et al. 2000; Liu et al. 
2001; Gaskari et al. 2005). In their model, blunted inotropic response to adrenergic 
stimulation in cirrhotic rats has been shown to be a reversible phenomenon. Thus, pre­
incubation o f  the papillary muscle with NOS inhibitors, haem oxygenase inhibitors as 
well as CB1 receptor antagonists normalizes the inotropic responsiveness to 
adrenergic stimulation in bile duct ligated rats (Liu et al. 2000; Liu et al. 2001; 
Gaskari et al. 2005). Based on these studies it has been suggested that over-activity o f  
NO, carbon monoxide and endocannabinoid systems might have a role in the genesis 
o f  cardiac inotropic dysfunction in cirrhosis. Considering the undeniable interrelation 
o f  these systems, further studies are required to elucidate the complex mechanism o f  
the observed effects.
Overall, it seems that cirrhosis is associated with a decrease in responsiveness o f  both 
cardiomyocytes and sino-atrial pacemaker cells to adrenergic stimulation. However 
whilst, a moderate left ventricular hypertrophy compensates for the blunted inotropic 
response, there is no such compensatory mechanism in pacemaker cells. This makes 
chronotropic incompetence a prominent feature in cardiac abnormalities observed in 
cirrhosis.
1.3.3 Prolongation of QT interval
The electrocardiographic QT interval reflects ventricular repolarization. Several 
studies have reported a high prevalence o f  prolonged QT interval in patients with 
cirrhosis. Several investigations have shown that QT interval prolongation increases 
with the severity o f liver disease, but can also occur in patients with well- 
compensated cirrhosis (Bernardi et al. 1998; Bal and Thuluvath 2003). The 
mechanisms leading to QT interval prolongation in cirrhosis are unknown. The recent 
finding that QT interval prolongation correlates with circulating concentrations o f  
BNP suggests that a sub-clinical cardiomyopathy may be responsible for its 
development (Henriksen et al 2003). Over all, the QT interval is further prolonged by 
transjugular intrahepatic portosystemic shunt (TIPS) (Trevisani et al. 2003) and is
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shortened or normalized by acute administration o f  beta-blockers (Henriksen et al. 
2004), chronic NO synthesis blockade (Tavakoli et al. 2007) and liver transplantation 
(Garcia-Gonzalez et al. 1999; Bal and Thuluvath 2003). However, the clinical 
interpretation o f the QT interval prolongation in cirrhosis remains unclear.
1.3.4 Decreased heart rate variability
Spontaneous variations in heart rate have been known since the advent o f 
experimental physiology in the early 1700s however it is only since the development 
o f  modem computational methods that we have been able to study heart rate 
variability. Normally, heart rate varies beat to beat which reflects the complex 
interplay between the autonomic nervous system and the heart (Fig. 1.3A). Loss o f  
heart rate variability (HRV) and increased heart rate regularity is a common feature o f 
systemic inflammatory conditions such as endotoxaemia and liver failure (Mani et al. 
2006a; Fleisher et al. 2000). Previous studies have shown that indices o f depressed 
heart rate variability in patients with liver failure correlate not only with the extent o f  
disease progression, but also predict the adverse outcomes in this patient’s population 
(Fleisher et al. 2000). For instance Fleisher et al. (2000), have shown that heart rate 
variability was significantly lower in the non-survivor patients awaiting liver 
transplantation than the survivors. The mechanism o f  decreased heart rate variability 
in cirrhosis remains unclear. However in chronic liver disease there is an increased 
incidence o f autonomic neuropathy (Hendrickse et al, 1992) and increased circulary 
concentration o f  pro-inflammatory cytokines (Tilg et al. 1992; Genesca et al. 1999), 
both o f which may impact upon this dynamic relationship (Fig 1.3B). Chapter 5 and 6  
provide the background information and experimental set up to study the mechanism 
o f  decreased heart rate variability in patients and rats with cirrhosis.
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Figure 1.3. Basal heart rate shows fluctuations in healthy subjects due to a complex 
non-linear interaction between different physiological mechanisms which modulate 
cardiac cycle (A). Many o f these mechanisms can potentially be affected in cirrhosis 
directly or indirectly through endotoxaemia (B). Cirrhosis is associated with a 
significant decrease in heart rate variability. However it is unclear which component 
is responsible for loss o f heart rate variability in cirrhosis.
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1.4. Reactive nitrogen species
Since the first reports o f endogenous generation o f  nitric oxide (NO) in mammalian 
systems almost 20 years ago (Ignarro et a l, 1987, Palmer et al., 1987 and Furchgott, 
1988), the physiology, pathophysiology, biochemistry and pharmacology o f  NO and 
related or derived nitrogen oxides have received intense attention. Much o f  the 
research focus has been on nitrogen oxides that are oxidized relative to NO. Such 
species are generated in biological systems primarily via the reaction o f  NO with 
molecular oxygen or oxygen-derived species. For example, the reaction o f  NO with 
superoxide (O2 ) produces peroxynitrite (ONOO"), which is a strong oxidant and 
responsible for some o f  the toxicity associated with NO. Nitrogen dioxide (NO2 ) and 
dinitrogen trioxide (N2 O3 ), derived from the aerobic decomposition o f  NO, have also 
been reported to be relevant to biological signalling and macromolecule modification 
such as nitrosation o f thiol groups in proteins (S-nitrosation) (Williams 1999). More 
recently, nitrite (NO2 ), which is also derived from the aerobic or biological oxidation 
o f NO, has been postulated to be subject to reduction in mammalian systems and 
therefore may function as a storage pool o f NO (Gladwin et al., 2005).
1.5 Nitric Oxide (NO)
Nitric oxide is the first gaseous species unequivocally identified as an endogenously 
generated cell signalling agent (Ignarro et al., 1987, Palmer et al., 1987 and Furchgott, 
1988). The first established physiological role for NO was vasorelaxation. The ability 
o f NO to elicit vasorelaxation is due to its ability to increase intracellular levels o f  
cGMP secondary to activation o f soluble guanylate cyclase (sGC) in smooth muscle 
cells. However, it appears that the effects o f  NO go beyond its ability to activate sGC 
and other mechanisms such as modification o f  functional proteins by NO (or its 
reactive derivatives) can explain some physiological or pathological effects o f  NO. 
For example S-nitrosation o f proteins (addition o f -N O  to the protein’s sulfhydryl 
group) might have a significant role in cell signalling (Hess et al. 2005) and nitration 
o f  tyrosine residues (addition o f -N O 2 ) o f  critical proteins has been shown to be 
implicated in the pathophysiology o f  various diseases such as sepsis and allograft 
rejection (MacMillan-Crow et al. 1996; Fukuyama et al. 1997).
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1.6. Nitric Oxide synthesis in mammals
Nitric oxide is synthesized by the family o f  enzymes known as nitric oxide synthase 
(NOS) (see Alderton at al. 2001 for review). NOS enzymes are usually referred as 
dimeric in their active form and contain relatively tightly bound cofactors FAD, FMN, 
tertrahydrobiopterin and haem. They catalyse the reaction o f  L-arginine, NADPH and 
molecular oxygen to the free radical NO, citrulline and NADP:
L-Arginine + 2 0 2 + 2NADPH + 2H+ —> NO + Citrulline + 2NADP+ + 2H20
There are three primary iso forms o f NOS that originate from separate genes and differ 
in their sub-cellular localization and mode o f  regulation. They are typically designated 
as endothelial (eNOS), neuronal (nNOS), and inducible NOS (iNOS), although these 
designations do not strictly reflect their tissue expression or utility. eNOS and nNOS 
are constitutively expressed; nevertheless, their levels can change in response to a 
variety o f  physiological events (e.g., hormonal influences). As the name indicates, 
iNOS is highly induced in a variety o f  cells, often as a result o f  immune stimulation 
(e.g., lipopolysaccharide, cytokines). Both eNOS and nNOS are regulated primarily 
by Ca2+ via the actions o f  calmodulin. In contrast, iNOS is not regulated by Ca2+ (see 
Alderton at al. 2001 for review).
1.7. NOS regulation
NO is now known to be synthesized in a large number o f different tissues playing a 
wide variety o f physiological roles. The regulation o f NOS activity in order for NO to 
perform this variety o f  roles is complex. Cellular and tissue specific localization o f  the 
NOS isoforms can be regulated by transcriptional regulation. Furthermore NOS 
activity can be regulated by covalent modification (e.g. phosphorylation,), protein- 
protein interactions (interaction with Heat-shock protein 90) and modulation o f  its 
cellular localization (e.g. localization in caveolea).
Calcium-Calmodulin (CaM): CaM was the first protein shown to interact with NOS 
(Bredt and Snyder 1990) and is necessary for the enzymatic activity o f  all three 
iso forms. The Ca -dependence o f  NO synthesis distinguishes the NOS isoforms, with
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nNOS and eNOS having a much higher Ca2+ requirement than iNOS. CaM binding 
increases the rate o f electron transfer from NADPH to the reductase domain flavins 
(Gachhui et al. 1996; Gachhui et al. 1998).
Phosphorylation: Phosphorylation o f the nNOS and eNOS iso forms can decrease or 
increase NOS activity. Thus, fluid shear stress elicits phosphorylation o f  Ser11 7 9  
residue o f  eNOS through protein kinase Akt activation and increases NOS activity 
(Corson et al. 1996; Dimmeler et al. 1999; McCabe et al. 2000). In contrast, the 
phosphorylation o f  nNOS at Ser8 4 7  by CaM-dependent kinases leads to a decrease in 
NOS activity (Hayashi et al. 1999; Komeima et al. 2000).
Heat-shock protein 90 (Hsp90): The molecular chaperone Hsp90 has been identified 
as a regulator o f eNOS activity, possibly as an allosteric modulator (Garcia-Cardena
1998). Activation by vascular endothelial growth factor (VEGF), histamine or fluid 
shear stress in human endothelial cells increases the interaction between eNOS and 
Hsp90 and increases eNOS activity by approximately three folds (Mata-Greenwood et 
al. 2006). The activity o f  purified eNOS was also increased by purified Hsp90, 
suggesting a direct interaction, the details o f which are not yet clear.
Caveolin: eNOS is localized to the caveolae (Garcia-Cardena 1996) which are micro­
domains o f  the plasma membrane that are implicated in a variety o f  cellular functions 
including endocytosis o f plasma proteins and signal transduction events. The caveolin 
proteins are the major coat proteins o f caveolae and in endothelial cells eNOS binds to 
caveolin-1, while in cardiac myocytes eNOS is associated with caveolin-3 (Feron et 
al. 1996). Caveolin-1 directly inhibits eNOS activity and this interaction is regulated 
by CaM (Ju et al. 1997; Michel et al. 1997). Mice lacking the gene for caveolin-1 
(cav-1 knockout mice), exhibit a significant increase in eNOS activity (Drab et al. 
2001). Caveolin-3 also binds to nNOS in skeletal muscle, inhibiting NO synthesis, 
and this inhibition is reversed by CaM (Venema et al. 1997).
Protein inhibitor o f  N O S (PIN): The N-terminal extension o f  nNOS contains a 
binding site for the 89-amino-acid protein PIN (Jaffrey and Snyder 1996). However, 
the literature is contradictory on the ability o f  PIN to inhibit NOS activity. The 
identification o f PIN as a light chain o f myosin and dynein (King et al. 1996) has led 
to the suggestion o f an alternative role for PIN as an axonal transport protein for
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nNOS rather than a regulator o f nNOS (Hemmens et al., 1998)
1.8. Nitric Oxide reactions and modification of proteins by NO
Nitric oxide-mediated modifications o f proteins is rooted in its chemical structure as a 
free radical (see Eiserich et al. 1998 for review). These modifications include: (1) 
binding to metal centres (e.g. haem proteins) a process which is called nitrosylation;
(2) Nitrosation o f thiol and amine groups to form S-nitrosothiols and N-nitrosamines;
(3) Nitration o f tyrosine, tyrptophan and lipids. However, two particular modifications 
have recently received much attention, S-nitrosation o f thiols to form S-nitrosothiols 
and nitration o f tyrosine residues to produce nitrotyrosine (Fig. 1.4).
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Figure 1.4. Reactive nitrogen 
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proteins to form iron-nitrosyl 
{nitrosylation) and with 
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1.8.1 Metal centres:
The mechanism by which NO elicits vasorelaxation is known to occur via activation 
o f  the enzyme soluble guanylate cyclase (sGC) through nitrosylation o f  haem group 
(see Cooper 1999 for review). sGC is a haem-containing protein, which exists in the 
cytosolic fraction o f  virtually all mammalian cells and acts as a principal intracellular 
target for NO. Activation o f  sGC by NO results in an increased conversion o f GTP to 
the second messenger, cGMP, which governs many aspects o f  cellular function via 
interaction with cGMP-dependent protein kinases, cyclic nucleotide gated ion 
channels, or cyclic nucleotide phosphodiesterases (Hobbs 1997). As a consequence, 
sGC has become accepted as the primary NO receptor, and the NO-sGC-cGMP signal 
transduction pathway has been established as an important signal transduction system. 
In addition to sGC, it has been suggested that NO binding to ferrous haem in 
mitochondrial cytochrome oxidase occurs under physiological conditions which might 
have important implications in the regulation o f mitochondrial respiration, cell 
apoptosis and survival (Moncada and Erusalimsky 2002; Mason et al. 2006).
1.8.2 S-Nitrosation:
The modification o f thiol residues by NO to form S-nitrosothiols has been proposed to 
have a role in physiology o f NO signalling since this modification is reversible and 
might act as a on/off switch o f certain proteins. A wide variety o f proteins have been 
found to be susceptible to S-nitrosation. These proteins cover a wide range o f  
functions, including housekeeping enzymes (e.g. GAPDH), G-proteins (e.g. ras), 
transcription factors (e.g. NF-kB) and proteases such as caspases (Mohr et al. 1996; 
Jaffrey et al. 2001; Marshall and Stamler 2001; Mannick et al. 1999). Based on in 
vitro studies about one hundred proteins have been shown to undergo regulation by S- 
nitrosation but only a handful o f  proteins have been identified as targets for S- 
nitrosation in vivo (Jaffrey et al. 2001). As a signalling mechanism, S-nitrosation 
should show reversibility. Here we briefly discuss about formation and decomposition 
o f  S-nitrosothiols:
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A. S-nitrosothiol formation: The modification o f thiol proteins by NO typically occurs 
indirectly after the reaction o f  NO with oxygen (or oxygen-derived species), or 
oxidized metal (M1^ 1) to form more oxidized nitrogen oxides like N 2 O3 or the 
equivalent o f nitrosonium ion (NO+) in the case o f  a metal-mediated process (see Gow 
et al. 2004 for review).
(Formation o f S-nitrosothiol via NO auto-oxidation)
NO + 0 2 -> 2N 0 2 
N 0 2 + NO —> N2 O3 
N 2 O3 + RSH -> RSNO + N 0 2" + H+
(Metal-mediated formation o f S-nitrosothiols)
N O n-IvT 1 —> M ^'-N O  
M ^'-N O  + RSH -> M n + RSNO + H+
Classically, the formation o f S-nitrosothiols has been considered to occur via the 
formation o f a nitrosating intermediate such as N 2 O3 following the auto-oxidation o f 
NO (Wink et al. 1994; Kharitonov et al. 1995). Critically important to such a reaction 
pathway is the requirement for two NO molecules to generate the nitrosating 
intermediate. This requirement makes such a reaction highly dependent on the local 
concentration o f  NO within a system. As such it will occur more readily under 
inflammatory conditions where the flux o f NO is drastically increased and also under 
hydrophobic conditions where NO's lipophilicity causes it to accumulate in cell 
membranes (Gow et al. 1997). This is in contrast to metal-catalyzed synthesis o f  S- 
nitrosothiols which is first order with respect to NO and hence could potentially occur 
under physiological concentrations o f NO seen in hydrophilic areas.
B. Decomposition o f  S-nitrosothiols: Loss o f NO from S-nitrosothiols can occur 
photochemically (UV range) or by a Cu+-dependent reaction where Cu+ comes from 
reduction o f Cu2+ in presence o f ascorbate or a thiolate anion (RS')(Williams 1999). 
Moreover a number o f enzyme systems catabolize S-nitrosothiols in vitro. These 
include xanthine oxidase (Trujillo et al. 1998), thioredoxin reductase (Nikitovic et al.
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1996), glutathione peroxidise (Hou et al. 1996), copper zinc superoxide dismutase 
(Cu/Zn SOD) (Jourd'heuil et al. 1998) and glutathione-dependent formaldehyde 
dehydrogenase (which has been referred to as GSNO reductase) (Liu et al. 2001). It is 
not clear if these enzymes actually have role in S-nitrosothiol decomposition in vivo; 
however S-nitrosothiols can undergo trans-nitrosation reactions both in vitro and in 
vivo (Williams 1999; Orie 2005). Trans-nitrosation is the process by which an NO 
equivalent is transferred from one thiol molecule to another thiol
(Trans-nitrosation reaction)
RSNO + R’SH <-> RSH + R’SNO
This is particularly important as low molecular weight thiols (such as cysteine and 
glutathione), will readily undergo trans-nitrosation reactions with high molecular 
weight S-nitrosothiols to form less stable intermediates such as S-nitrosocysteine 
(CysNO) or S-nitrosogluathione (GSNO), which readily decompose and release NO 
(Orie et al. 2005). Mechanistically this may lead to compartmentalization o f  S- 
nitrosated proteins. For example, the cytosol is perhaps the least conducive cellular 
environment for protein-S-NO  stability because protein S-nitrosothiols can be readily 
reduced by glutathione (~ 5mM in cytosol) or thioredoxin, each o f which, once S- 
nitrosated through trans-nitrosation, can be enzymatically de-nitrosated (Liu et al. 
2001). To protect S-nitrosothiols from reductive or trans-nitrosative degradation, they 
may be stored or protected in membranes, in lipophilic protein folds, in vesicles, and 
in interstitial spaces (Mannick et al. 2001). Caspase activation during apoptosis 
provides an example o f how this type o f  sequestration is used in the process o f  cell 
signalling. These enzymes are ordinarily sequestered in an S-nitrosated (inactive) state 
in the mitochondrial inter-membrane space. When a cell receives an apoptotic signal, 
these caspases are released into the cytosol where they rapidly become de-nitrosated. 
De-nitrosation leads to caspase activation and initiation o f apoptosis (Mannick et al. 
1999).
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1.8.3 Nitration:
Nitrated biological molecules, such as nitrated proteins and nitrolipids, are widely
distributed in many organisms, and nitrogen dioxide radical ( NO 2 ) is the most likely
nitrogen species to cause their formation (O'Donnell and Freeman 2001; Lim et al.
2002; Radi 2004). NO2 is formed from the decomposition o f  peroxynitrite (or
reaction with CO2 , see below). In addition, peroxidases such as myeloperoxidase can
generate NO2 or nitryl chloride from the reaction o f  nitrite with hypochlorous acid
(Baldus et al. 2001). The discovery in 1995-1996 that CO2 reacts rapidly with 
peroxynitrite and alters its reactivity was vital in understanding its reactions (Lymar 
and Hurst 1995; Denicola et al. 1996, Uppu et al. 1996). The modulation o f  
peroxynitrite reactivity by CO2 described above is shown below:
(In absence o f  C 0 2) H+ + 'OONO HOONO-> HO* + *N02
(In presence o f CO2 ) CO2 + OONO —» ONOOCO2 —> CO 3 + NO 2
In the absence o f  CO2 , peroxynitrite decomposes slowly to form the free radicals HO
and NO 2 . However in mammals, biological fluids and tissues contain 1-2 mM CO2 , 
and the reaction o f peroxynitrite with CO2 is 50 to 1 0 0  times faster than its rate o f  
decomposition to form HO and NO2 . Furthermore, other biological molecules, such
as haem proteins, also react with peroxynitrite at considerable rates. Thus, in vivo, it
seems unlikely that peroxynitrite decomposes to form HO and NO2 , because this
reaction is too slow. In the presence o f CO2 , peroxynitrite generates CO3 and NO 2 
radicals in a fast reaction.
HO is extremely reactive and reacts with virtually all biomolecules as fast as they 
collide and consequently live only microseconds. For this reason, biological damage
by the HO radical is random, inefficient, and widespread, and generally does not
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affect critical cellular targets. In contrast, other radicals, such as CO3 and NO 2 ,
display various degrees o f  selectivity for biological molecules (Augusto et al. 2002). 
The HO radical reacts at or near the rate limit for diffusion with most bio molecules,
whereas the CO3 and NO 2 radicals react more slowly and consequently have longer
diffusion distances. The order o f  reactivity is HO > CO3 > NO2 , and unlike the HO
radical, CO3 and NO2 can be quite selective for certain biomolecules. For example,
the CO3 radical reacts at least 100,000 times faster with tyrosine, tryptophan, or
cysteine than it does with alanine or glycine, effectively targeting only some o f  the
amino acids in a protein. NO 2 , also has been found to react selectively with the amino
acid residues tyrosine, tryptophan, and cysteine in proteins (see Pryor et al. for 
review).
Tyrosine nitration is becoming increasingly recognised as a prevalent, functionally 
significant post-translational protein modification that serves as an indicator o f RNS- 
mediated oxidative inflammatory reactions. It is widely accepted that formation o f 
nitrotyrosine residues in proteins takes place in a two-step reaction in which free
radical, such a CO3 ' (carbonyl radical), abstracts a H atom form tyrosine residue,
generating a tyrosyl radical which then reacts with a NO 2 in a radical-radical 
recombination reaction (Fig. 1.5).
OH
x*
R
O* O
A |
R R
*NO,
Figure 1.5. Nitration o f tyrosine residues in proteins. X’ represent any free radical 
(e.g. carbonyl radical) with ability to convert tyrosine to tyrosyl radical.
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The formation o f  nitrotyrosine not only provides a footprint o f oxidative injury by 
reactive nitrogen species but is critically linked to altered protein structure and 
function during inflammation. Thus nitration o f  the o-position o f tyrosine decreases 
the p/G o f the tyrosine hydroxyl group from 10.1 to 7.2 (Schopfer et al. 2003). This 
introduces a net negative charge to approximately half o f  nitrated tyrosine residues at 
physiological pH. This bulky, anionic substituent can induce changes in protein 
conformation, resulting in altered enzyme catalytic activity. Some enzymes contain 
tyrosyl radicals in their active sites, and these radical centres are targets for reaction
with NO: since the reaction o f  these two radicals occurs near the diffusion limit.
Thus, preferential nitration o f  active-site tyrosyl radicals in prostaglandin H2 synthase- 
1 (PGSH-1) has been suggested, since the degree o f nitration is found to correlate with 
the loss o f  enzyme activity (Goodwin et al. 1998). Other important proteins are 
affected by nitrotyrosine formation. For example, the selective cellular incorporation 
o f  nitrotyrosine into the extreme carboxyl terminus o f  the cytoskeletal protein a- 
tubulin impaires tubulin function (Eiserich et al. 1999). Also, nitration o f  a critical 
tyrosine residue (Tyr 67) in cytochrome c profoundly affects its redox-related 
properties (Cassina et al. 2 0 0 0 ); nitration o f sarcoplasmic reticulum calcium pump at 
Tyr 294 and Tyr 295 inhibits the enzyme (Viner et al. 1999) and finally nitration o f  
Tyr 34 accounts for inactivation o f human Mn superoxide dismutase in rejecting 
transplanted kidneys (MacMillan-Crow et al. 1996). If protein nitration is to be 
considered a cell signalling mechanism, four basic criteria should be met. First, the 
precursors for protein nitration should have controlled rates o f formation. Second, 
protein nitration should be specific (i.e. nitration should occur on specific tyrosine 
residues o f particular proteins). Third, nitration should modify target protein activity 
and cell function. Fourth, nitration must be reversible. Partial fulfilment o f these 
criteria has been convincingly demonstrated for several proteins, but no single protein 
has successfully met all four o f these crucial definitions o f a cell signalling molecule 
(Schopfer et al. 2003).
Degradation o f  nitrated proteins. Little is known about the fate o f nitrated proteins in 
vivo. It has been postulated that there is increased proteolytic degradation o f  nitrated 
proteins. For example, Souza et al. (2000) have shown that nitration o f tyrosine 
residue(s) in proteins is sufficient to induce an accelerated degradation o f  the 
modified proteins by the proteasome to release free amino acids as well as free
35
nitrotyrosine. The urinary elimination o f  free nitrotyrosine is minimal, and it rapidly 
undergoes metabolism to form 3-nitro-4-hydroxyphenylacetic acid (NHPA) which is 
excreted as the major urinary metabolite o f nitrotyrosine (Fig. 1.6) (Ohshima et al. 
1990).
Protein 0N00‘ >. Nitrated Protein
De-nitrase (?).OH
Thiols
ProteinFree Nitrotyrosine Protein-bound 
Ami notyrosine 
NO, ->  NH,OH
1Metabolism
OH
N 0 2
OH
(3-Nitro-4-Hydroxyphenylacetic acid)
Figure 1.6. Degradation o f nitrated proteins: Three distinct pathways have been 
postulated for degradation o f nitrated proteins, i. Proteolysis o f nitrated proteins 
releases free nitrotyrosine which undergoes metabolism to form a de-aminated and de- 
carboxylated product, NHPA (3-nitro-4-hydroxyphenylacetic acid), ii. Non-enzymatic 
reduction o f nitrotyrosine to aminotyrosine has been shown in vitro (Balabanli et al.
1999). This reaction depends on the presence o f haem and thiols and occurs within the 
physiological pH. Protein-bound nitrotyrosine can potentially undergo reduction to 
form aminotyrosine in vitro. Hi. A putative de-nitrase activity has been reported in 
rats which removes nitro group form protein-bound nitrotyrosine (nitrotyrosine 
denitrase).
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Apart from proteolytic degradation o f  protein-bound nitrotyrosine, two other 
pathways have been postulated which potentially affect nitrated proteins. Murad and 
colleague reported a putative “de-nitrase” activity in tissues obtained from 
endotoxaemic rats (Kamisaki et al. 1998; Irie et al. 2003). This activity was monitored 
by the decreased intensity o f  nitrotyrosine immunoreactive bands in Western blots and 
increased nitrate levels in reaction mixtures (Kamisaki et al. 1998). However, neither 
an enzyme catalyzing this reaction nor a product o f this reaction was identified. A 
thiol-dependent non-enzymatic pathway which reduces nitrotyrosine to aminotyrosine 
(-NO 2 —► -NH2 ) has also been demonstrated recently (Balabanli et al. 1999). However 
it is not clear whether or not this reaction occurs in vivo. Figure 1.6 summarises 
different suggested mechanism involved in degradation o f nitrated proteins.
1.9. Measurement of S-nitrosothiol formation and protein nitration and
1.9.1 Measurement of S-nitrosothiols:
S-nitrosothiols are unstable under certain conditions. In buffer solution they can be 
broken down by ultraviolet (UV) light or by trace amounts o f  copper ions. Therefore 
solutions should be kept in the dark, and trace metal ions chelated by 
diethylenetriaminepentaacetic acid (DTPA). They are most stable under acidic 
conditions. The second important thing to understand is that thiols in biological 
samples, particularly low molecular weight thiols, will readily undergo trans- 
nitrosation reactions with S-nitrosothiols to form less stable intermediates such as S- 
nitrosocysteine (CysNO) or S-nitrosogluathione (GSNO), which readily decompose. 
This can be prevented by adding N-ethylmaleimide (NEM) to samples during 
collection. For example, previous studies in our lab showed that whereas 40% o f 
added S-nitrosoalbumin (1 pM) decomposes within 2 hours, it was stable for up to 24 
hours at room temperature when NEM was present (Marley et al. 2000). NEM 
alkylates thiol groups rapidly, and prevents thiol-dependent decomposition o f  S- 
nitrosothiols.
Many methods have been described for the measurement o f  S-nitrosothiols in the 
literature, but only a few have been validated and successfully applied to their 
quantitative measurement in biological samples. To validate a method one should be
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able to add the analyte to the biological fluid in question, and demonstrate that the 
assay quantitatively measures an increment o f  the analyte concentration equal to the 
amount added. This validation still does not exclude the possibility that other 
compounds endogenously present in biological samples may cause overestimation. 
This is a significant problem in the measurement o f S-nitrosothiols, since nitrite, 
present in all biological samples is usually detected by the methods used to measure 
S-nitrosothiols. Since background nitrite concentrations are -200  nM in plasma, it is 
necessary to remove nitrite. Some groups have used a gel filtration methods (Gladwin 
et al. 2 0 0 0 ), but these are time consuming and do not remove nitrite completely. 
Moore and colleagues have shown that nitrite ions can effectively be removed by 
reaction with acidified sulfanilamide, and this has no impact on the nitric oxide (NO) 
signal released by authentic S-nitrosothiols added to plasma (Marley et al. 2000).
The method that has been developed in our laboratory was based on the release o f  NO 
by reaction by a mixture o f copper sulphate, iodide in acid and release o f  free iodine, 
and quantification o f released NO by ozone-dependent chemiluminescence (Marley et 
al. 2 0 0 0 ).
2Cu2+ + 41' -► 2CuI2 -► 2 Cu(,)I + I2 
I2 + r  -> I3'
I3' + 2RS-NO -> 3T + 2RS* + 2NO+
2RS* -> RSSR
2NO+ + 21' -> 2NO + I2
Chemiluminescence-based assays can detect plasma concentrations o f  S-nitrosothiols 
as low as -5  nM (Marley et al. 2000, 2001) This method is similar to, and gives 
identical results to that developed by Gladwin et al. (2000) With this method the 
concentration o f  S-nitrosothiols in venous plasma o f healthy human volunteers was 
estimated as -  10 nM which is considerably lower than previous reports (0.2-7 pM) 
(Goldman et al. 1998; Stamler et al. 1992). Many investigators were initially confused 
by their own findings, since it was originally reported by Stamler et al. (1992) that 
plasma S-nitrosothiols (predominantly S-nitrosoalbumin) was present at a
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concentration o f  7 pM. This measurement was based on photolytic cleavage o f  the S- 
NO bond. These levels are now widely acknowledged to be too high, with most recent 
estimates o f plasma S-nitrosothiol concentrations as being in the low nano-molar 
range (Marley et al. 2000 and 2001; Akaike2000; Rosso et al. 2001). The specificity 
o f  chemiluminescence-based analysis o f  NO-related compounds is high because the 
majority o f  other molecules potentially able to give chemiluminescence with ozone 
are not volatile, or do not occur in biological systems. We have also recently 
developed a method to stabilise and measure total S-nitrosothiol content in solid tissue 
homogenates which is discussed in chapter 3.
To detect specific S-nitrosothiols such as GSNO or S-nitro so albumin requires a 
separation system such as high performance liquid chromatography (HPLC). Akaike 
et al. (1997) developed a sophisticated HPLC method to separate nitrite, and S- 
nitrosothiols with post-column copper based decomposition o f  S-nitrosothiols and 
derivatization by the Griess reaction. However, this method was not sensitive enough 
to detect basal concentrations o f S-nitrosothiols in plasma.
1.9.2 Measurement of protein nitration:
The measurement o f protein nitration presents several problems. Most investigators 
have used immunoassays. Whilst immunoassays imply specificity by using specific 
antibodies it should be realized that it is easy to generate non-specific staining. The 
ideal method should be sensitive, specific and quantitative. Therefore mass- 
spectrometric assays are the most reliable methods for assessment o f nitration 
reaction. A second approach is to measure the urinary excretion o f  3-nitro-4- 
hydroxyphenylacetic, the major urinary metabolite o f nitrotyrosine and this method is 
discussed in chapter 2 .
The main problem with measuring nitrotyrosine again is nitrite, which causes 
artifactual nitration o f  tyrosine if acidic conditions (pH<3) are employed during 
sample preparation (Knowles et al. 1974, Frost et al. 2000). To measure protein- 
bound nitrotyrosine by gas chromatography mass spectrometry (GC/MS) or HPLC, 
investigators have usually employed acid hydrolysis, which causes artifactual 
nitration o f tyrosine or enzymatic hydrolysis, which may be incomplete or release 
nitrotyrosine from auto-hydrolysis o f  the enzymes employed. To circumvent these
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problems Moore and colleagues have developed a method in which alkaline 
hydrolysis o f proteins is used to release nitrotyrosine and tyrosine followed by 
GC/MS analysis (Frost et al. 2000). By using deuterated tyrosine ([2 H4 ] tyrosine) as 
an internal standard, one can assess artifactual nitration by measuring the formation o f  
[2 H3 ] nitrotyrosine (Frost et al. 2000).
1.9.3 Identification of protein targets to nitration or nitrosation:
Based on in vitro studies about one hundred proteins have been shown to undergo 
regulation by S-nitrosation but only a handful o f proteins have been identified as 
targets for S-nitrosation in vivo (Jaffrey et al. 2001). Loss or rearrangement o f S-NO 
group during sample preparation has been the most important technical limitation but 
recent advances, using thiol blocking agents to stabilize S-nitrosothiols, and the use o f  
the biotin switch method, have provided new tools for identifying S-NO-modified 
proteins formed in vivo (Jaffrey et al. 2001). With the exception o f  S-nitrosoalbumin, 
which represents < 0.01% o f total albumin (Marley et al. 2001), we do not know what 
proportion o f  proteins regulated in this way are S-nitrosated at any one time, and this 
is similar to that observed for nitrotyrosine which is also present at <0 .0 1 % o f total 
tyrosine residues in tissue proteins. The nitrosation and nitration o f proteins is a 
relatively selective process since specific cysteine or tyrosine residues in proteins 
undergo modification by reactive nitrogen species. Site directed mutagenesis methods 
have been used to determine the specific residue responsible for altered protein 
function nitration or nitrosation (Shimokawa et al. 1990; Perez-Mato et al. Sun et al. 
2001). Liquid chromatography linked to tandem mass spectrometry (LC/MS/MS) is a 
commonly used method for identification o f selective site(s) o f nitration or nitrosation 
in relatively pure proteins (Ducrocq et al. 1998; Petersson et al. 2001). More recently 
the combination o f 2  dimensional gel electrophoresis and matrix-assisted laser 
desorption ionization/time-of-flight (MALDI-TOF) mass spectrometric analysis has 
identified several liver proteins nitrated during endotoxaemia (Aulak et al 2001).
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1.10. Aims and hypothesis
Cirrhosis is associated with increased production o f  reactive oxygen species (e.g. 
super oxide O2 ) which react with NO to form reactive nitrogen species. Reactive 
nitrogen species (e.g. peroxynitrite) readily react with amino acid residues o f  proteins 
to form nitrosated or nitrated adducts. Although cirrhosis is well recognized as being 
associated with increased NO synthesis, the role o f nitration or nitrosation o f  proteins 
in the genesis o f  cardiac dysfunction in cirrhosis has not previously been investigated. 
Here we hypothesised that increased formation o f reactive nitrogen species in 
cirrhosis causes nitration/nitrosation o f cardiac proteins and leads to impaired cardiac 
chronotropic function.
The aims o f the work described in this thesis were:
1. To develop a method for dynamic assessment o f nitration reactions in vivo.
2. To develop a method for stabilization and measurement o f S-nitrosothiols in tissues
3. To test the hypothesis that increased formation o f reactive nitrogen species in 
cirrhosis causes nitration/nitrosation o f cardiac proteins and leads to impaired cardiac 
chronographic function.
4. To investigate the underlying mechanism o f  decreased heart rate variability in 
cirrhosis.
1.11 Overview of this thesis
Chapter 2 discusses the biochemical pathway in which circulating para- 
hydroxyphenylacetic acid (PHPA) undergoes nitration to form 3-nitro-4- 
hydroxyphenylacetic acid (NHPA). The chapter proposes that measurement o f urinary 
NHPA can be used to assess the formation o f reactive nitrogen species in vivo.
Chapter 3 deals with our investigations on the stability o f S-nitrosothiols in tissue 
homogenates and our studies on the nature o f the tissue factor which accelerates the 
decomposition o f  S-nitrosothiols.
Chapter 4 describes the main experimental work presented to assess the role o f  
nitration/nitrosation reactions in the genesis o f impaired heart rate variability and 
cardiac chronotropic function in rats with biliary cirrhosis.
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Chapter 5 provides the background information and experimental set up to study the 
mechanism o f  decreased heart rate variability in in 75 patients with cirrhosis.
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Chapter 2: Dynamic assessment of nitration reaction in vivo
2.1 Introduction
Assessment o f protein nitration is commonly used as a footprint for the formation o f  
reactive nitrogen species in vivo. However, one o f the major disadvantages o f  
measuring nitrotyrosine in proteins is that nitrated proteins are broken down at 
variable rates, and the resulting free nitrotyrosine is taken up by cells, metabolized, 
and excreted. For example, Souza et al. (2000) have shown that nitration o f  tyrosine 
residue(s) in proteins is sufficient to induce an accelerated degradation o f  the 
modified proteins to release free amino acids as well as free nitrotyrosine (Souza et al.
2000). The urinary elimination o f free nitrotyrosine is minimal, but its secondary 
metabolites can potentially serve as biomarkers o f  overall nitrotyrosine formation in 
vivo. Since the pioneering work o f Ohshima et al. (1990), it is known that 
nitrotyrosine is metabolized to 3-nitro-4-hydroxyphenylacetic acid (NHPA), which is 
excreted in the urine as the major urinary metabolite. This suggests that measurement 
o f  urinary NHPA could be used as a marker o f  systemic nitrotyrosine formation in 
vivo. It is not known, however, whether urinary NHPA is derived solely from 
metabolism o f  nitrotyrosine or whether it can also be formed by nitration o f  
endogenous /?«ra-hydroxyphenylacetic acid (PHPA), a metabolite o f  tyrosine (Fell et 
al. 1978). PHPA readily undergoes nitration in vitro (Takahama et al. 2002), and has 
been used as a chemical probe to monitor nitration reactions in vitro (van der Vliet et 
al. 1997; Eiserich et al. 1998). However, it is not known whether or not this reaction 
occurs endogenously, and whether or not measurement o f the formation o f NHPA can 
be used as an index o f nitration reactions in vivo. The aims o f  the present study were 
thus to determine whether or not NHPA can be formed endogenously from nitration 
o f  circulating PHPA, and whether or not measurement o f urinary NHPA can be used 
to monitor systemic nitration reactions in vivo.
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2.2 Materials and Methods I
Chemicals
All chemicals were purchased from Sigma Aldrich (Poole, Dorset, U.K.) unless stated 
otherwise. [ 13Cq] Tyrosine, [2 H4 ] acetic acid, 2 H2 0  and 2 HC1 were purchased from 
Cambridge Isotope Laboratories (Andover, MA, U.S.A.).
Synthesis o f  internal standards, [ !3Cs]PHPA and [ ISCsJNHPA
[1 3Cg]PHPA was synthesized following the de-amination and de-carboxylation o f  
[ l3 C9 ] tyrosine using Taiwan cobra (Naja naja atra) venom as a catalysing enzyme
1 T(Nucaro et al. 1998). In brief, [ C9 ] tyrosine was added to 50 mM ammonium formate 
buffer (pH 7.4) at a concentration o f 0.2 mg/ml, and venom was added at a 
concentration o f 1 mg/ml, before incubation at 37 °C for approx. 2 h. [ l3 Cs]PHPA was 
extracted into ethyl acetate, dried under nitrogen, and was then further purified by 
HPLC on a Techsphere C i8 column (25 mMx4 . 6  mM). This employs a gradient o f 
water containing 0.1% (v/v) TFA (trifluoroacetic acid) (solution A) and 0.1% (v/v) 
TFA/acetonitrile (solution B). Initial conditions were 100% solution A, changing to 
9:1 solution A/solution B over 15 min, then to 1:1 solution A/solution B from 15 to 30 
min. The fractions containing [13Cs]PHPA were identified by their retention times and 
characteristic UV spectra with a photodiode array system. Fractions containing 
[ 1 3Cs]PHPA were pooled and freeze-dried under vacuum. [l3 Cs]NHPA was 
synthesized after exposure o f [13C8 ]PHPA to acidified nitrite (1 M hydrochloric acid 
and sodium nitrite, 200 mM) followed by ethyl acetate extraction, and drying under 
nitrogen.
Synthesis o f  deuterium-labelled PHPA
[2 H6 ]PHPA was synthesized by deuterium exchange (Shimamura et al. 1986). In brief, 
50 mg o f PHPA was dissolved in a mixture o f [2 H4 ]acetic acid (0.4 ml) and 2 H2 0  (0.5 
ml) and the solvent was evaporated in a stream o f  nitrogen at 90 °C. This procedure
was repeated twice to remove active protons as completely as possible. The resulting
2 2 residue was dissolved in a mixture o f  [ H4 ]acetic acid (0.3 ml), H2 O (0.3 ml) and
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2 HC1 (37% in 2 H2 0 , 0.8 ml). The solution was sealed in an acid-digestion bomb and 
heated in an autoclave at 190 °C for 8  h. The product was extracted with ethyl acetate 
and washed with water. After drying o f  the organic phase, the resulting materials were 
dissolved in 0.1% (v/v) TFA/water (adjusted to pH 5.0 with ammonia solution) and 
were then applied to an LCig reverse-phase columns (Supelclean SPE tubes; Sigma) 
that had been pre-washed with 2 ml o f methanol and 5 ml o f 0.1% (v/v) TFA/water 
(pH 5.0). The column was washed with 2 ml o f  water and [ H6 ]PHPA was eluted with 
4 ml o f  25% (v/v) methanol in water.
The concentrations o f 13C-labelled and deuterated standards were determined against 
known amounts o f unlabelled standards using the method described below.
Sample purification and derivatization fo r  urinary NHPA and PHPA
[ 13Cs]NHPA (10 ng) or [ 13Cg]PHPA (100 ng) was added to 100 pi o f human urine, or 
20 pi o f  rat urine, and was diluted to 1 ml with de-ionized water. Following the 
addition o f 1 ml o f  ethyl acetate and vortex mixing, the organic phase was removed, 
and the sample was evaporated under a stream o f nitrogen. The residue was 
reconstituted in 30 pi o f acetonitrile, applied to a silica TLC plate (LK6  60 A, 250 pm  
layer thickness, 5 cm x 2 0  cm; Whatman, Clifton, NJ, U.S.A.), and was run to the top 
o f the plate in chloroform/methanol (80:20, v/v). Compounds migrating in the region 
o f Rf.~0.22 for NHPA and at 0.20 for PHPA, and 1 cm above and below, were scraped 
from the plate and extracted in 1 ml o f  ethyl acetate/ethanol (50:50, v/v), dried under 
nitrogen, and derivatized to the pentafluorobenzyl ester, by the addition o f 2 0  pi o f  
10% (v/v) di-isopropyl ethylamine in acetonitrile and 40 pi o f  10% (v/v) 
pentafluorobenzyl bromide in acetonitrile for 1 h at room temperature (21-23 °C), 
dried under nitrogen and re-dissolved in 20 pi o f «-undecane for analysis o f  NHPA or 
50 pi o f >?-undecane for analysis o f  PHPA.
Measurement ofplasm a concentrations o f  NHPA and PHPA
To measure plasma levels o f NHPA and PHPA, blood was taken from three male 
Sprague-Dawley rats into tubes containing EDTA, which were centrifuged at 2300 g  
for 30 min at 4 °C. The internal standards (10 ng o f [ 1 3Cs]NHPA or 100 ng o f  
[ 1 3C8 ]PHPA) were added to 1 ml o f  plasma, which was immediately filtered by
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centrifugation at 9000 g  in a microfiige through a 30 kDa molecular-mass cut-off 
centrifugal membrane (Ultrafree; Millipore, Bedford, MA, U.S.A.) to remove high- 
molecular-mass proteins. The filtrate was applied to an LCig reverse-phase column 
that had been pre-washed with 2 ml o f methanol and 5 ml o f 0.1% (v/v) TFA/water 
(pH 5.0). The column was washed with 2 ml o f water. Then NHPA and PHPA were 
eluted with 4 ml o f  25% (v/v) methanol in water and dried under vacuum before TLC 
extraction as described above. The samples were derivatized to the pentafluorobenzyl 
ester by the addition o f  2 0  pi o f  1 0 % (v/v) di-isopropyl ethylamine in acetonitrile and 
40 pi o f 10% (v/v) pentafluorobenzyl bromide in acetonitrile for 1 h at room 
temperature, dried under nitrogen and re-dissolved in 20 pi o f «-undecane before GC 
(gas chromatography)/MS analysis.
GC/MS analysis o f  derivatized samples
Samples were analysed on a GC equipped with a 15 m DB-1701 (J&W Scientific, 
Folsom, CA, U.S.A.) capillary column (0.25 mm internal diameter, 0.25 pm film 
thickness) interfaced with a mass spectrometer (Trio 1000; Fisons Instruments, 
Beverly, MA, U.S.A.). The ion source and interface temperature were set at 200 °C 
and 300 °C respectively. Samples were analysed in negative-ion chemical ionization 
(NICI) mode with ammonia as the reagent gas, using 1 pi o f each sample for 
injection. The initial column temperature was maintained at 150 °C for 1 min 
increasing to 300 °C at 20 °C/min. Samples were quantified by isotope-dilution 
GC/MS and ions were monitored at 376 and 384 mass units for NHPA and at 311 and 
319 mass units for PHPA with single-ion monitoring. The concentrations were 
calculated from the known l3 C8 -labelled internal standards, which are 8  mass units 
heavier than the authentic NHPA and PHPA.
Exclusion o f  artifactual nitration o f  PHPA during analysis
Initial studies using buffers at pH 4.0 showed that there was significant artifactual 
nitration o f  PHPA during the preparation o f samples (results not shown). Therefore, to 
ensure that there was no artifactual nitration o f  PHPA during the preparation o f  urine 
samples, the formation o f  [2 Hs]NHPA from 100 ng o f [2 H6 ]PHPA added to 100 pi o f  
human urine was monitored in a separate series o f experiments.
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Standard curves fo r  evaluation o f the assays
To determine the accuracy o f the assay, known amounts (0-20 ng o f NHPA or 0-10 
fig o f  PHPA) were added to 100 pi o f  human urine and the samples were analysed as 
unknowns. For measurement o f intra-assay variability, six aliquots from a urine 
sample o f  one volunteer were analysed as described above and the intra-assay 
variability was calculated as percentage coefficients o f variation (100xS.D./mean).
Nitrotyrosine measurement in biological samples
1 ^Nitrotyrosine in biological samples was measured by GC/MS. 10 ng [ C9 ] labelled 
nitrotyrosine was used as stable isotopic internal standards. [ l3 C9 ] Nitrotyrosine was
1
synthesized by nitration o f [ C9 ] tyrosine as described (Frost et al. 2000). Following 
two steps solid phase extraction using LCig and ENV+ (Isolute, UK) columns, 
nitrotyrosine was converted into the respective amides by the addition o f 1 0 0  pi o f  
anhydrous dimethylformamide and 20 pi o f  di-isopropyl ethylamine. Samples were 
left for at least 5 min on ice, after which 40 pi o f  ethyl heptafluorobutyrate was added. 
After being left for a further 30 min, samples were sonicated for 2 h. Un-reacted and 
excess reagents were evaporated under nitrogen. The amino acid amides were 
converted into the /-butyl(dimethyl)silyl ester or ether by the addition o f 30 pi o f  
TBDMS containing 1% (v/v) N-(/-butyldimethylsilyl)-N-methyltrifluoroacetamide 
chlorosilane at room temperature for 30 min. Derivatized samples were dried under 
nitrogen and re-dissolved in 20 pi o f  undecane. Samples were analysed on a GC 
equipped with a 15 m capillary column (0.25 mm internal diam., 0.2 pm film 
thickness) interfaced with a Trio 1000 mass spectrometer. The ion source and 
interface were set at 200 and 300 °C respectively. Samples were analysed in NICI 
mode with ammonia as the reagent gas. All samples were injected with the on-column 
injection technique. On-column injection is the method by which a sample is directly 
injected manually into the analytical column from a fine-bore microlitre syringe. This 
technique avoids problems that can arise from the interactions between the analyte 
and the glass injection liner. The initial column temperature was maintained at 150 °C 
for 1 min and then increased to 300 °C at 20 °C/min for nitrotyrosine analysis.
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Animal studies
Male Sprague Dawley rats (body mass 270-300 g) were obtained from the 
Comparative Biology Unit at the Royal Free and University College Medical School 
(Hampstead Campus, UCL, London, U.K.)* All animal procedures were in accordance 
with Home Office recommendations. The animals were anaesthetized with an 
intraperitoneal injection o f sodium pentobarbital (60 mg/kg). The jugular vein and the 
urinary bladder were cannulated with polyethylene cannulae. Physiological saline 
solution was infused into the animals at 25 ml/kg per h through the jugular vein and 
urine samples were collected every 30 min as described below.
Metabolism o f  nitrotyrosine to NHPA
To determine the metabolism o f  nitrotyrosine to NHPA, 250 nmol o f  nitrotyrosine 
was dissolved in 1 ml o f  sterile PBS and was injected intravenously into three rats as a 
bolus. Urine samples were collected every 30 min for 5 h, with a single 30 min 
collection (basal) immediately before injection o f  nitrotyrosine. The urinary 
concentration o f  NHPA and PHPA was determined as described above. Urinary 
content o f un-metabolized nitrotyrosine was also measured in each sample using GC 
with NICI MS, as previously described above (Frost et al. 2000).
Nitration o f  PHPA in vivo
[ H6]PHPA was injected intravenously as a bolus (250 nmol, dissolved in 1 ml o f  
PBS) after the initial basal urine collection (t= 30 min) into three rats, and urine 
samples were collected every 30 min for 4.5 h. Nitration o f [2 H6 ]PHPA produces 
[2 H 5 ]NHPA as a result o f replacement o f a single deuterium o f the aromatic ring by 
the NO: group.
Effect o f  endotoxaemia on the formation o f  NHPA
LPS (lipopolysaccharide) from Salmonella typhimurium was injected intravenously 
into three rats as a bolus (5 mg/kg in 1 ml o f  PBS). Urine samples were collected 
every 30 min for 4.5 h, with a single 30 min collection (basal) immediately before the 
injection o f LPS. The urinary content o f NHPA, PHPA and nitrotyrosine was 
determined as above. In a further study, 250 nmol o f  [2 H6 ]PHPA was injected
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intravenously into three rats 2 h after administration o f LPS (5 mg/kg). The urinary 
content o f NHPA, PHPA, [2 Hs]NHPA and [2 H6 ]PHPA were then quantified by 
GC/MS using l3 C8 -labelled internal standards. For measurement o f  the deuterium- 
labelled compounds, ion masses (m/z) o f  381 and 337 were selected in selective-ion 
monitoring, which are 5 and 6  mass units heavier respectively than the authentic 
NHPA and PHPA.
Statistical analysis
All data are presented as means ± SEM. Statistical evaluation o f  the data was carried 
out with the analysis o f variance (ANOVA) followed by the Newman-Keuls test for 
multiple comparisons, and P<0.05 was considered statistically significant.
2.3. Results I
To investigate the formation o f  NHPA in vivo, it was necessary to develop a method 
that can accurately measure this metabolite, and avoid the problems that are 
encountered during the assay o f  other nitrated products, such as nitrotyrosine [3,17]. 
Thus the method needs to be reproducible with biological samples and free o f  
artifactual nitration o f  its precursor (PHPA).
Characterization o f  the derivatives o f  NHPA and PHPA
The structures o f the pentafluorobenzyl ester derivatives o f  NHPA and PHPA are 
shown in Fig 2.1. The molecular mass o f  derivatized NHPA is 557 Da, which is 45 
mass units heavier than derivatized PHPA (512 Da). The de-protonated molecular ion 
for the NHPA derivative is evident at m/z 556 [A/-H]' and for PHPA at 511 [A/-H]', 
which are visible on the NICI spectra shown in Fig 2.1. Analysis o f  the 
pentafluorobenzyl ester derivatives o f  NHPA and PHPA by full-scan mode (Fig 2.1) 
showed that NHPA has a dominant ion at m/z 376 ([M -181], loss o f  one 
pentafluorobenzyl ester group). PHPA has a dominant ion at m/z 331 [M-181], which 
is also compatible with the loss o f  a pentafluorobenzyl ester group. On the basis o f  
these results, all further work was focused on developing the analytical method for 
NHPA and PHPA as the pentafluorobenzyl ester derivative with selective-ion 
monitoring at 376 and 331 mass units for NHPA and PHPA respectively. The 
detection limit was approx. 1 pg on column injection (for both NHPA and PHPA). 
After GC/MS analysis o f  urine samples, a single peak was eluted with the respective 
1 3C-labelled internal standards, which were 8  mass units heavier than the authentic 
NHPA and PHPA (Fig. 2.2). As shown in Fig. 2.3, full scan analysis o f  derivatized 
deuterium-labelled PHPA showed that the synthesized compound had a dominant ion 
at m/z 337 which is 6  mass units heavier than the authentic PHPA and corresponds to 
[2 H6]PHPA (Fig. 2.3).
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Figure 2.1. Structures and spectra from NICI scans o f the pentafluorobenzyl 
derivative o f NHPA (upper panel) and PHPA (lower panel). The molecular mass o f  
derivatized NHPA is 557 Da, which is 45 mass units heavier than derivatized PHPA 
(512 Da). The de-protonated molecular ion for the NHPA derivative is evident at m/z 
556 [M-H]- and for PHPA at 511 [M-H]-. NHPA has a dominant ion at m/z 376 ([M- 
181], loss o f one pentafluorobenzyl ester group). PHPA has a dominant ion at m/z 331 
[M-181], which is also compatible with the loss o f a pentafluorobenzyl ester group.
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Figure 2.2. Typical chromatogram showing peak shape and resolution for both NHPA 
(A) and PHPA (B) in a urine sample. The 1 Cg-labelled NHPA and PHPA resulted in 
derivatives that were 8  mass units heavier than the parent compound. NHPA (A) was 
quantified by monitoring ions o f  m/z 376 and 384, and PHPA (B) by monitoring ions 
o f m/z 331 and 339. The x-axis represents the retention time (rt).
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Figure 2.3. Spectra from NICI scan o f the pentafluorobenzyl derivative o f  authentic 
PHPA (lower panel) and deuterium-labelled PHPA (upper panel). The molecular mass 
o f deuterium lablled PHPA is 6  mass unit heavier than authentic PHPA, showing a 
successful synthesis o f [2 H6 ]PHPA using deuterium exchange.
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Standard curves o f  NHPA and PHPA
There was a good correlation between the added and measured amounts o f NHPA 
(^=0.998) and PHPA (^=0.995) in urine, with a linear standard curve superimposed 
on the basal concentrations o f  these analytes (Fig 2.4). The intra-assay variation on a 
single urine sample was 7.4% and 6.1% for NHPA and PHPA respectively (n=6 ).
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Figure 2.4. Standard curves for NHPA (upper panel) and PHPA (lower panel) in 
human urine. Known amounts o f NHPA and PHPA were added to urine. Following 
analysis as unknowns, the expected amount o f added NHPA or PHPA was recovered 
with a good correlation when analysed by GC/MS.
Nitration o f  PHPA as an artifact
Artifactual nitration o f PHPA during sample preparation was investigated after the 
addition o f [2H6]PHPA to 100 pi o f urine. Based on the evaluation o f m/z 381 and 
retention time, no [2H5 ]NHPA was detected after extraction and derivatization o f  
samples using the method described. However, if  buffers o f  pH 4.0 or below were 
used, there was significant artifactual nitration (results not shown).
Effect o f  nitrotyrosine infusion on urinary NHPA and nitrotyrosine levels
The basal excretion rate o f urinary NHPA in this group o f rats was 8.1 ±0.5 pmol/min 
(Fig 2.5). Following the bolus injection o f nitrotyrosine (250 nmol), the urinary 
excretion rate o f NHPA increased to a peak o f 84.8±6.6 pmol/min within 30 min o f  
injection. The urinary excretion o f  NHPA remained at 81.7±12.2 pmol/min until 60 
min, and thereafter decreased back towards baseline levels o f  9.1 ±1.5 pmol/min by 5 
h (Fig 2.5). These results indicate that only 4.3±0.2% o f the injected nitrotyrosine is 
excreted as urinary NHPA. Free nitrotyrosine was undetectable in the urine under 
basal conditions. However, following the intravenous injection o f  250 nmol o f  
nitrotyrosine, urinary nitrotyrosine became detectable with an excretion rate o f  
peaking at 16.8±5.3 pmol/min at 30 min post-injection, but was undetectable by 4 h 
(Fig 2.5). Only 0.49±0.16% o f the injected nitrotyrosine was excreted unchanged into 
the urine.
Effect o f LPS administration on urinary NHPA and nitrotyrosine levels
Injection o f LPS into rats decreased the urine output from 26.5±5.2 to 16.6±7.1 
pl/min. As shown in Fig 2.6, there was initially no change in the urinary excretion o f  
NHPA, but 2 h after the injection o f LPS, there was a sustained increase in the urinary 
excretion o f NHPA from 7.61±1.3 to 15.7±2.1 pmol/min (P<0.01). Urinary 
nitrotyrosine was undetectable until 90 min after bolus injection o f  LPS, but, 
thereafter, small amounts o f free nitrotyrosine were detectable (P<0.01) (Fig 2.6).
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Figure 2.5. Urinary excretion o f  NHPA and nitrotyrosine (NT) after intravenous 
injection o f nitrotyrosine. Urinary excretion rate o f NHPA and free nitrotyrosine 
increased by 30 min following the intravenous bolus injection o f 250 nmol o f 
nitrotyrosine into anaesthetized rats. Results are means ± SEM. (n=3).
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Figure 2.6. Urinary excretion o f NHPA and nitrotyrosine (NT) after intravenous 
injection o f LPS. Urinary excretion rate o f NHPA and free nitrotyrosine both 
increased following the injection o f LPS (5 mg/kg) into anaesthetized rats at 30 min. 
Results are means ± SEM. (n=3). ANOVA shows a significant increase in NHPA and 
PHPA excretion after LPS administration (P<0.01).
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Nitration o f  infused f  H^JPHPA
In order to determine the extent o f endogenous nitration o f circulating PHPA in vivo, 
the formation o f  [2H5 ]NHPA was investigated in rats injected with [2H6]PHPA. A 
GC/MS chromatogram revealed a peak with an m/z o f 381, consistent with the 
nitration o f [2H6]PHPA to [2H5 ]NHPA (Fig 2.7). The urinary excretion rate o f 
[2Hs]NHPA was 12.6±3.0 and 5.1±1.8 pmol/min at 30 and 60 min after the bolus 
injection o f  [2H6]PHPA respectively (Fig 2.8). The urinary excretion o f  
unmetabolized [2H6]PHPA peaked within 30 min after the bolus injection, and total 
recovery o f  [2H6]PHPA was 78±2% within the initial 4 h o f urine collection. This 
suggests that there is relatively little metabolism, if any o f  PHPA in vivo. At 60 min 
after [2H6]PHPA injection, the urinary excretion rate o f [2H6]PHPA was very close to 
the normal range o f authentic PHPA excretion (2.3±0.7 nmol/min) (Fig 2.8), and this 
time interval was selected for comparison o f  the endogenous NHPA/PHPA ratio with 
the [2H5]NHPA/[2H6]PHPA ratio. At 60 min, the ratio o f [2H5]NHPA/[2H6]PHPA was
6.1 ±1.0 (pmo 1/nmol), and the ratio o f endogenous NHPA/PHPA was 7.0±0.9 
(pmol/nmol). Assuming that endogenous PHPA is handled in the same way as infused 
PHPA, there is approx. 0.9 pmol/nmol o f NHPA unaccounted for, and which is 
assumed to be derived from metabolism o f  nitrotyrosine. Injection o f  LPS resulted in 
a significant increase (P<0.05) in the NHPA/PHPA ratio as well as the 
[2H 5 ]NHPA/[2H6]PHPA ratio (Fig 2.9). Meanwhile, the total recovery o f  [2H6]PHPA 
was significantly decreased after LPS administration (39.2±4% compared with 
78±2%; F*<0.05) during 4 h o f urine collection. We attribute this to the marked 
decrease in urine volume post-LPS.
Plasma concentrations o f  PHPA and NHPA
The plasma concentration o f PHPA was 2.7±1.1 pmol/1 (410±171 ng/ml) in rats. In 
contrast, the plasma concentrations o f  NHPA were undetectable.
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Figure 2.7. Chromatogram o f a urine sample obtained from a rat injected with 
[2H6]PHPA. In vivo formation o f [2Hs]NHPA, represented as a distinguished peak, 
was detected with m/z 381. The values o f  m/z 376 and m/z 384 represent authentic 
NHPA and ,3Cg-labelled internal standard respectively.
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Figure 2.8. Urinary excretion o f  [ ~ H s ] N H P A  and [ ~ H 6 ] P H P A  after intravenous 
injection o f [ 2 H 6 ] P H P A .  The urinary excretion rate o f [ ‘ H s ] N H P A  (upper panel) and 
[ 2 H ( , ] P H P A  (lower panel) both increased following the intravenous bolus injection o f  
[ 2 H 6 ] P H P A  (250 nmol) into anaesthetized rats. As shown in the upper panel, there 
was a marked increase in the formation o f ["PUjNHPA, which can only arise from 
nitration o f  infused [ ~ H 6 ] P H P A .  The total recovery o f  injected [ ‘ P f r J P H P A  was 
78±2% during the first 4 h o f urine collection. Results are means ± SEM. (n=3). The 
mean urinary excretion rate o f endogenous P H P A  was 2.3±0.7 nmol/min, and the 
range o f  excretion rate observed in normal rats is shown by the dotted lines (a).
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Figure 2.9. NHPA/PHPA ratio as an index o f RNS formation. Under basal 
conditions, the ratio o f NHPA/PHPA gives an index o f the rate o f nitration o f PHPA, 
and the metabolism o f  nitrotyrosine. ["HftjPHPA was used as a probe to assess the 
nitration o f  PHPA to NHPA in vivo. Injection o f LPS increases the ratio o f 
endogenous NHPA/PHPA as well as that o f [2H5 ]NHPA/[2H6]PHPA, suggesting that 
much o f  the NHPA that is excreted in urine during endotoxaemia is derived from the 
nitration o f  circulating PHPA. Results are means ± SEM. *P<0.05 compared with the 
saline-treated group.
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2.4. Discussion I
One o f  the major disadvantages o f measuring nitrotyrosine in tissues or biological 
fluids is that nitrated proteins are broken down at variable rates, and nitrotyrosine is 
metabolized and excreted (Souza et al. 2000, Tabrizi-Fard et al. 1999). Thus the 
concept that measurement o f NHPA, as the major urinary metabolite o f nitrotyrosine, 
is attractive, since it can provide a time-integrated index o f nitrotyrosine formation in 
vivo. However, it is important to know whether this metabolite is formed exclusively 
from nitrotyrosine, or whether it can be formed via nitration o f PHPA, which is 
present at high concentrations in plasma.
Since the identification o f  NHPA as the major metabolite o f  nitrotyrosine, there have 
been no reliable assays for the measurement o f NHPA in biological fluids. For 
instance, an electrochemical-based HPLC method has been described for the 
measurement o f NHPA (Crow 1999), but the specificity and reproducibility o f  this 
method have not been evaluated so far. Beal et al. (1997) have also reported an assay 
for measurement o f  NHPA in spinal tissue, but their method has the disadvantage that 
extractions are performed in extremely acidic conditions in which nitrite, always 
present in biological samples, can cause artifactual nitration o f  PHPA. In the present 
study, we have described a novel assay for the measurement o f  urinary NHPA, which 
has the advantage o f being highly sensitive, specific and reproducible.
The major finding o f  this study is that urinary NHPA is not derived solely from 
nitrotyrosine metabolism and at least one other pathway is responsible for its 
formation in vivo (Fig. 2.10). The nitration o f [2H6]PHPA to [2Hs]NHPA provides 
unequivocal proof that nitration o f circulating PHPA can occur. Indeed, based on our 
animal studies, we estimate that most o f the urinary NHPA (approx. 85%) is formed 
by nitration o f  PHPA in vivo in the rat, despite the fact that only a relatively small 
fraction o f  the infused PHPA is nitrated in vivo. This occurs because PHPA is present 
in plasma at a concentration o f  approx. 2.7 pmol/1, whereas free nitrotyrosine is only 
present at approx. 4.2 nmol/1 (Moore and Mani 2002).
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Figure 2.10 Two identified pathways, which can produce NHPA in vivo. NHPA can 
be formed by either nitration o f  PHPA or catabolism o f free nitrotyrosine. Tyrosine 
decarboxylase and tyramine oxidase are two identified metabolic enzymes that are 
responsible for conversion o f  tyrosine and nitrotyrosine into PHPA and NHPA. RNS: 
Reactive nitrogen species.
Although the major source o f urinary NHPA is formed by nitration o f endogenous 
PHPA, we also demonstrate that NHPA excretion increased after intravenous 
nitrotyrosine injection. Less than 5% o f injected nitrotyrosine was excreted in the 
urine as NHPA over 5 h, which is consistent with the observations o f  Tabrizi-Fard et 
al. (1999), who also observed that only 5-6%  o f  infused nitrotyrosine was
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metabolized to NHPA. The large volume o f  distribution o f free nitrotyrosine and the 
absence o f detectable nitrotyrosine in normal urine suggest that there is cellular 
uptake as well as tubular re-absorption o f free nitrotyrosine by various amino-acid 
transporters in the cell membrane. In contrast, 78 ± 2% o f injected ["H6]PHPA was 
rapidly excreted into the urine unchanged, demonstrating that there is little, if any 
metabolism o f  this compound. Based on a plasma concentration o f PHPA o f 2.7±1.1 
pmol/1, and a urinary excretion rate o f PHPA at 2.3 ± 0.7 nmol/min in rats, the renal 
clearance o f PHPA is estimated to be approx. 0.85 ml/min. This value is very close to 
the glomerular filtration rate o f our laboratory rats (1.02±0.1 ml/min) (Anand et al. 
2002), and suggests that PHPA is simply filtered and not re-absorbed by the kidneys.
We have also shown that measurement o f ["Hs]NHPA after infusing ["H6]PHPA may 
be used as an index o f reactive nitrogen species formation in vivo. Our observation 
that endotoxaemia causes a significant increase in [ HsJNHPA excretion (Fig 2.9) 
supports the validity o f  this novel approach. Moreover our observation that the ratio
") 9o f  nitration o f [‘H.sJNHPA from infused ["H6]PHPA was almost identical with that o f  
endogenous NHPA to PHPA suggests that measurement o f the NHPA/PHPA ratio 
may be useful to assess nitration reactions in vivo (Fig 2.9).
The present study has shown for the first time that endogenous PHPA can be nitrated 
to NHPA in vivo, which, until the present study, has been regarded as the major 
metabolite o f  nitrotyrosine. On a practical level, we have also shown that 
measurement o f urinary NHPA can be used to monitor nitration reactions in vivo, 
although its sensitivity and specificity at this stage o f these studies are unknown. We 
conclude that the measurement o f urinary NHPA excretion provides a time-integrated 
index o f  reactive nitrogen species formation in vivo, although it is not exclusively 
related to nitrotyrosine metabolism.
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Chapter 3: Stabilization and measurement of S-nitrosothiols in tissues
3.1 Introduction
S-Nitrosothiols are formed by the reaction o f reactive nitrogen species (e.g., N 2 O 3 ) 
with a sulfhydryl group, either with a low-molecular-weight species such as 
glutathione or within a protein such as albumin. The control o f  protein function by S- 
nitrosation is counter-regulated by de-nitrosation, a process which may involve low- 
molecular-weight thiols such as glutathione or cysteine, which can undergo trans- 
nitrosation reactions to form S-nitrosoglutathione (GSNO) and S-nitrosocysteine 
(CysNO), respectively (Williams 1999). Both GSNO and CysNO are inherently 
unstable in a biological milieu such as plasma or tissues and may release NO or react 
with other thiols to form thiolated adducts together with the secondary release o f  NO 
(Williams 1999). Therefore, methods which measure the tissue concentrations o f  S- 
nitrosothiols should ensure that all tissue S-nitrosothiols, including low-molecular- 
weight species, are stable under the conditions employed.
Various methods have been developed to measure the tissue levels o f  S-nitrosothiols 
and, more specifically, identify S-nitrosated proteins. These include 
chemiluminescence-based assays o f total tissue S-nitrosothiol concentration, and the 
biotin-switch assay (Jaftfey et al. 2001). While many advances have been made in the 
detection o f  either total cellular S-nitrosation or individual S-nitrosothiols, proteomic 
methods tor the detection o f S-nitrosation are in relative infancy due to the rapid 
decomposition o f  S-nitrosothiols both in vivo and in vitro.
The decomposition o f  S-nitrosothiols is accelerated in plasma by free thiols and 
transition metals (Williams 1999). Thus, both low- and high-molecular-weight S- 
nitrosothiols can be stabilized in plasma by reaction o f  the free thiol group with N- 
ethylmaleimide (NEM) and chelation o f  metal ions by DTPA (diethylenetriamine 
pentaacetic acid) (Moore and Mani 2002). As part o f  our program to develop assays 
for tissue S-nitrosothiols based on the chemiluminescence method, we initially wished 
to confirm that tissue S-nitrosothiols are stabilized in tissue homogenates by perfusing 
tissues with buffer containing NEM and DTPA. In our laboratory we had previously 
shown that both S-nitro so albumin and GSNO are stable in plasma under these 
conditions (Marley et al 2001), which enable sampling and subsequent measurement
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by reductive chemiluminescence assays. However, it rapidly became apparent to us 
that, low-molecular-weight S-nitrosothiols decompose in liver and kidney tissue 
homogenates, even in the presence o f  NEM and DTPA. Studies in cell culture by 
Zhang and Hogg (2004) have also indicated that spiking cells with GSNO or S- 
nitrosoalbumin before homogenization with NEM/DTPA results in incomplete 
recovery o f  GSNO, whereas S-nitrosoalbumin is fully recovered. The present study 
reports our investigations on the stability o f  S-nitrosothiols in tissue homogenates and 
our studies on the nature o f the tissue factor which accelerates the decomposition o f  S- 
nitrosothiols.
3.1 Materials and methods II
Chemicals
All S-nitrosothiols used in this study were synthesized in our laboratory and stored at 
-80°C  in the presence o f NEM (10 mM) and DTPA (2 mM). All chemicals were 
purchased from Sigma (Poole, UK).
Synthesis o f  S-nitrosothiols
S-Nitroso-L-cysteine (L-CysNO), S-nitroso-D-cysteine (D-CysNO), and S- 
nitrosoglutathione (GSNO) were prepared by reacting equal volumes o f  sodium nitrite 
(10 mM) with the corresponding reduced thiols (10 mM) at pH 2 as described 
previously (Moore and Mani 2002). Stocks o f S-nitrosoalbumin were prepared by 
incubation o f  reduced human serum albumin with L-CysNO (prepared as above) at 
room temperature for 30 min in the dark. Any remaining un-reacted thiol groups were 
then alkylated with NEM (1 mM) at room temperature, followed by dialysis at 4°C 
against 4 x 3 litres o f PBS supplemented with DTPA (100 mM) for 72 h (Marley et al. 
2000).
Preparation o f  tissue homogenates
Male Sprague-Dawley rats (280-300 g) were housed in a standard caging system and 
kept on a reversed 12/12 light/dark cycle. Animals were fed a standard chow diet and
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allowed access to food and water ad libitum. All animal procedures were in 
accordance with Home Office (UK) recommendations. On the day o f  the experiment, 
animals were anesthetized by intraperitoneal injection o f  sodium pentobarbital (60 
mg/kg). After thoracotomy, organs were flushed free o f blood and perfused through 
the left ventricle with NEM/DTPA (10/2 mM) freshly prepared in PBS, which leads 
to efficient in situ alkylation o f thiols and complexation o f  free transition metals. 
Organs (liver, kidney, heart, and brain) were cut into small pieces and homogenized in 
ice-cold NEM/DTPA phosphate buffer (10/2 mM, pH 7.4; 5/1 vol/wet wt) using a 
Potter-Elvehjem homogenizer. Homogenates were kept on ice in the dark and used 
within 30 min o f  preparation. The protein content o f the homogenates was assessed by 
the Biuret method and the final concentration o f  tissue homogenates as set at 5 mg 
protein/ml using NEM/DTPA in PBS. Blood was also collected from the aorta into 
tubes containing EDTA (final concentration 2 mM) and centrifuged for 10 min at 
1300g. After addition o f  NEM (final concentration 10 mM), the plasma samples were 
kept at 4°C and used on the day o f collection.
Measurement o f  S-nitrosothiols
S-Nitrosothiols were quantified, as previously described (Marley et al. 2000; 2001), 
by a copper/iodide-mediated cleavage o f  S-nitrosothiols to release NO, which was 
quantified by its gas phase chemiluminescence reaction with ozone (NO analyzer; 
Sievers, Boulder, CO, USA). Immediately before analysis o f  the samples, nitrite was 
removed by reacting with acidified sulfanilamide as described (Marley et al. 2000). 
The reaction mixture, consisting o f  potassium iodide and iodine in glacial acetic acid, 
was kept at constant temperature in a septum-sealed, water-jacketed reaction vessel, 
continuously bubbled with nitrogen (Scheme 3.1). The purge vessel we use is 
approximately eight times as large as the conventional Sievers purge vessel. It 
contains 8 ml glacial acetic acid and 2 ml potassium iodide (50 mg/ml) and 400 /zl 
copper sulfate (50 mg/ml). Addition o f copper sulfate makes the solution brown due 
to the release o f  iodine. In this regard this method is similar to the triiodide method 
described by Gladwin and colleagues (Gladwin et al. 2000). The outlet o f the gas 
stream was passed through a scrubbing bottle containing sodium hydroxide (1 M) in 
order to trap traces o f acid and iodine before transfer into the detector. Standards and 
sample aliquots (500 fi\) were injected into the reaction mixture by gas-tight Hamilton
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syringes. Nitric oxide signal output was sampled at 2 Hz. Peak integration was 
performed after signal smoothing to eliminate high-frequency noise and baseline 
correction. To confirm that the species is an S-nitrosothiol rather than an N- 
nitrosamine or an iron-nitrosyl, samples were run before and after the addition o f  
H gC f (final cone 2%) (Feelisch et al. 2002). Calculated NO amounts were validated 
by injection o f  freshly prepared nitrite standards into the same reaction chamber 
(without acid sulfanilamide). We have previously shown that S-nitrosothiols give the 
same signal as nitrite.
Injection
Port With From Inert 
Septa G as Supply
C ondenser
Reducing 
Agent
Drain Stopcock
Scheme 3.1. Reaction chamber set up for reduction o f  nitros(yl)ated compounds. The 
reaction chamber is attached to a nitric oxide analyse (NOA). This figure is adapted 
from Siever’s NO analyzer catalogue (NOAIM 280, Revision C, 1997).
68
The decomposition o f  S-nitrosothiols in homogenates o f  rat liver
Various S-nitrosothiols (L-CysNO, D-CysNO, GSNO, S-nitro so albumin) were 
incubated to give a final concentration o f  250 nM with aliquots o f  rat liver 
homogenates (5 mg/ml protein concentration, volume 500 p\). This low concentration 
o f  added S-nitrosothiols was used (rN>50 pmol/mg protein) because this is most likely 
to represent what may be observed in vivo. The presence o f  NEM, which alkylates 
free thiol groups, blocks all rra/7.s-nitrosation reactions with proteins or other thiols. A 
vertical rota shaker was employed for continuous stirring during the incubation. The 
aliquots were incubated with the S-nitrosothiol at either 37 or 4°C and kept in the 
dark. The levels o f  S-nitrosothiols were measured at different time intervals (1, 15, 60, 
and 120 min) using the chemiluminescence-based assay. In a separate experiment, 
aliquots o f liver homogenate were heated at 80°C for 30 min to denature the proteins. 
After the samples were cooled to 4°C, L-CysNO was added to give a final 
concentration o f  250 nM and the levels o f  S-nitrosothiol were then measured at 
different time points as above. The reason for carrying out most measurements at 4°C 
was to slow decomposition down to a rate that could be easily followed. In a separate 
experiment, liver tissues were homogenized in PBS and were incubated with 0.1 
mg/ml proteinase K. at 37°C in the presence o f  1 mM CaCb. Thirty minutes after 
incubation with proteinase K, NEM and DTPA were added to liver homogenate (final 
concentration o f  10 and 2 mM, respectively). After the samples were cooled to 4°C, 
L-CysNO was added to give a final concentration o f  250 nM and the levels o f  S- 
nitrosothiol were then measured at different time points as above. Each experiment 
was repeated at least five times (in tissue homogenates obtained from different rats).
The decomposition o f L-CysNO in homogenates o f  different tissue
Different tissue homogenates (kidney, heart, and brain) were also prepared as above 
(5 mg/ml protein concentration, aliquots o f 500 p\) and incubated with L-CysNO 
(final concentration o f 250 nM) at 4°C in the dark. The levels o f S-nitrosothiol were 
then measured at 1, 15, 60, and 120 min by chemiluminescence. Acceleration o f  
CysNO decay was also tested after supplementation o f liver and heart homogenates 
with either NADH or NADPH (1 mM final concentration).
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Effects o f  different enzyme inhibitors on CysNO decomposition
In some experiments, allopurinol (500 /zM; xanthine oxidase inhibitor), iodoacetate (1 
mM; inhibitor o f  thioredoxin reductase and glutathione peroxidase, an alkylating 
agent) (Jourd'Heuil et al. 2000), or oxamic acid/propargylglycine (2 mM; inhibitors o f  
H:S-producing enzymes cystathionine B-synthase and cystathionine y-lyase, 
respectively) (Stipanuk et al. 1982) were incubated with liver tissue homogenates for 
30 min at 4°C before addition o f  L-CysNO (final concentration 250 nM). Based on 
published studies one would expect that y-glutamyl transpeptidase (y-GT) would 
decay GSNO to S-nitroso-cysteinylglycine, which then may get hydrolyzed to CysNO 
(Hogg et al. 1997). To test this, liver homogenates were incubated with acivicin (2 
mM; a y-GT inhibitor) for 30 min at 4°C before addition o f  GSNO or L-CysNO (final 
concentration 250 nM). The level o f  S-nitrosothiols was then measured at different 
time points (1, 15, 60, and 120 min).
Effects o f  specific transition metal chelators on CysNO decomposition
Diethyl dithiocarbamate (1 mM) and histidine (10 mM), which are reported to remove 
copper from copper-containing proteins (such as Cu/Zn superoxide dismutase) (Misra 
et al. 1979), were incubated with rat liver homogenates for 30 min (4°C) before 
addition o f  L-CysNO (final concentration 250 nM). The levels o f  CysNO were then 
measured at different time points (1, 15, 60, and 120 min). The effects o f a selective 
Cu^ chelator (neocuproine; 1 mM) and a free iron chelator (deferoxamine; 1 mM) on 
L-CysNO decomposition were also examined as described above.
Effects o f  oxygen depletion on the decomposition o f  L-CysNO in liver
Liver homogenates were deoxygenated by sparging with helium for 10 min and kept 
in a gas-tight chamber filled with argon (4°C). L-CysNO was added with a gas-tight 
syringe and the levels o f  S-nitrosothiols were measured 30 min after addition o f  
CysNO.
Stabilization o f  L-CysNO in liver homogenate by potassium ferr icy anide
S-N O  bonds can be reduced by ferrous proteins such as ferrous deoxyhemoglobin and 
deoxymyoglobin (Gladwin et al. 2000). Gladwin and colleagues has previously
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reported that potassium ferricyanide [K3 Fen,(CN)6 ] can stabilize S-nitrosohemoglobin 
in red blood cells (Gladwin et al. 2000). Thus, in a separate set o f  experiments 
potassium ferricyanide was used to oxidize ferrous proteins (Fe2+—>Fe3+) in rat liver 
homogenates containing NEM and DTPA. In brief, liver homogenates were incubated 
in potassium ferricyanide (4 mM final concentration) 10 min before the addition o f  
CysNO (final concentration 250 nM) at 4°C. The levels o f CysNO were then 
measured at different time points (1, 15, 60, and 120 min).
Preparation o f  cellular fractions and ultra-filtration o f  cytoplasmic proteins
Mitochondrial, microsomal, and cytoplasmic fractions o f  rat liver homogenates were 
isolated using differential centrifugation as described (Evans 1992). The 
mitochondrial and microsomal fractions were re-suspended in NEM/DTPA buffer (2 
mg protein/ml). In some experiments the cytoplasmic fraction was subjected to 
centrifugal filtration to remove high-molecular-weight proteins (Microcon YC-10 
centrifugal filter units, cut-off 10, 50, and 100 kDa; Millipore, Bedford, MA, USA). 
The effects o f cellular fractions on CysNO decomposition were then examined as 
above.
Measurement o f  nitrite + nitrate after incubation o f  CysNO with liver homogenate
Important elements o f S-nitrosothiol decomposition are reductive pathways that form 
NO. The released NO might undergo oxidation to form nitrite and nitrate in the 
presence o f molecular oxygen. To address the role o f such reactions in contributing to 
the metabolism o f  CysNO in liver homogenate, nitrite + nitrate levels were measured 
after incubation o f liver homogenates with CysNO. Liver tissue homogenate was 
prepared as described above in NEM/DTPA PBS buffer (5 mg/ml protein 
concentration, 0.5 ml aliquots) and incubated with L-CysNO (4°C, final concentration 
o f  2.5 gM) for 2 h. A higher concentration o f CysNO was employed in these 
experiments because at low concentrations (250 nM) changes in nitrite + nitrate could 
not be detected due to high level o f  background nitrite + nitrate in tissue homogenates 
(4.13 ± 0.53 pM). Nitrite + nitrate levels were determined by chemiluminescence as 
described (Harry et al. 1999). In brief, samples were centrifuged for 10 min (10,000g) 
and 100 p\ o f supernatant was incubated with nitrate reductase, FAD, and NADPH to 
convert nitrate to nitrite (1 h, room temperature). Nitrite then was reduced to NO by
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refluxing with acetic acid and potassium iodide and measured by chemiluminescence. 
Standard curves o f sodium nitrite and nitrate were used for calibration. Preliminary 
data showed that NEM (which is present in liver homogenate; 10 mM) did not 
interfere with nitrate conversion to nitrite under the conditions employed.
Is there inducihility o f  the protein causing decomposition o f S-nitrosothiols?
During preliminary experiments it became apparent that liver tissue homogenates 
from rats with biliary cirrhosis caused an accelerated decomposition o f  S- 
nitrosothiols, compared to normal liver tissue. Because biliary cirrhosis is associated 
with endotoxaemia (Harry et al. 1999), we tested whether injection o f  
lipopolysaccharide (LPS) could induce up-regulation o f the tissue factor responsible 
for the decomposition o f  L-CysNO in vitro and formally measured its activity in 
cirrhotic liver tissue. Thus two models were employed:
(A) Endotoxaemia: Endotoxaemia was induced by intraperitoneal injection o f  LPS (5 
mg/kg from Salmonella typhimurium) to male Sprague-Dawley rats (280-300 g, 
n = 4). Animals were killed under pentobarbital anaesthesia 6 h after LPS injection 
and organs were perfused with NEM/DTPA PBS buffer as described above. Liver 
tissue homogenate was homogenized (5 mg/ml protein concentration, 0.5-ml aliquots) 
and incubated with CysNO (4°C, final concentration 2.5 pM ) for different time 
intervals (0, 15, 60, and 120 min). A higher concentration o f CysNO was employed in 
this experiment because at low concentrations, changes in S-nitrosothiols could not be 
detected due to the high concentration o f background S-nitrosothiols in liver 
homogenates.
(B) Biliary' cirrhosis: Biliary cirrhosis is associated with chronic endotoxemia and a 
systemic inflammatory response (Harry et al. 1999). Biliary cirrhosis was induced in 
male rats by ligation o f the bile duct under general anaesthesia as described elsewhere 
(Harry et al. 1999). Cirrhotic animals (n = 6) were killed under pentobarbital 
anaesthesia 4 weeks after the operation. The liver was perfused in NEM/DTPA PBS 
buffer. Liver tissue homogenates (5 mg/ml protein concentration, 0.5 ml aliquots) 
were incubated with L-CysNO (4°C, final concentration 250 nM) for different time 
intervals (0, 15, 60, and 120 min) and assessed using chemiluminescence.
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Time-dependent decay o f  endogenously formed S-nitrosothiols in endotoxemic liver
Liver tissues from endotoxemic rats (see above, n = 4) were perfused and 
homogenized in ice-cold NEM/DTPA PBS buffer (^5 0 0  mg tissue in 5 ml buffer). 
Some liver tissues were homogenized separately in NEM/DTPA PBS buffer 
supplemented with potassium ferricyanide (4 mM; ^500  mg tissue in 5 ml buffer). 
Homogenates were kept on ice in the dark and were analyzed 1, 5, and 15 min after 
tissue homogenization. In order to measure low-molecular-weight S-nitrosothiols the 
liver homogenates were subjected to centrifugal filtration to remove high-molecular- 
weight proteins using Millipore YC-10 centrifugal filters (cut-off 30 kDa). All 
samples were run before and after the addition o f  HgCb (final concentration 2%).
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3.2 Results II
Incubation o f CysNO with rat liver homogenates resulted in a time-dependent 
decrease in CysNO concentration in the presence o f  NEM and DTPA at 37°C, which 
was slowed on cooling, with a half-life o f  3 and 31 min at 37 and 4°C, respectively 
(Fig. 3.1). In contrast, CysNO was stable in PBS containing NEM/DTPA at both 4 
and 37°C as shown in Fig. 3.1. Because o f the very rapid decomposition at 37°C, all 
subsequent experiments were carried out at 4°C. To determine whether this rapid 
decomposition o f  L-CysNO was a generalized phenomenon o f low-molecular-weight 
S-nitrosothiols, the effects o f liver homogenate on the decomposition o f  D-CysNO, 
GSNO, and S-nitrosoalbumin were also assessed. The rate o f decomposition o f  D- 
CysNO was identical with that o f L-CysNO as shown in Fig. 3.2. GSNO also 
undergoes rapid decomposition in liver homogenates, with a half-life o f 16 min at 
4°C. By contrast, the high-molecular-weight S-nitrosothiol S-nitrosoalbumin was 
stable under these conditions, with no significant loss over 2 h.
To determine whether the decomposition o f low-molecular-weight S-nitrosothiols by 
tissue was liver-specific we next incubated CysNO with kidney, heart, and brain 
homogenates as well as plasma. As shown in Fig. 3.3, there was a time-dependent 
decomposition o f  CysNO in kidney homogenates and, to a lesser extent, in heart 
homogenates in the presence o f NEM/DTPA. This activity was minimal in brain 
tissue homogenates as well as plasma. The order o f  L-CysNO degradation activity 
was liver > kidney > heart > brain > plasma. The data in Fig. 3.3 seem to indicate that 
although an activity is present in other organs, the activity is lost very rapidly (except 
for liver and kidney). This raised the question o f whether the factor is unstable in 
these tissues or whether an important cofactor is being consumed. As the mechanism 
is likely to be reductive, we examined if the addition o f NADH or NADPH could 
accelerate CysNO decay in these and other tissues. The results showed that 
supplementation with NAD(P)H had no significant effect on CysNO decomposition in 
liver or heart homogenates (data not shown).
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Figure 3.1. CysNO decomposition by liver homogenate incubated with N- 
ethylmaleimide/DTPA PBS at different temperatures (37°C vs 4°C). Liver tissue was 
perfused with jV-ethylmaleimide/DTPA (10/2 mM) containing PBS and homogenized. 
CysNO was then added (final concentration 250 nM) to the liver homogenates (5 
mg/ml) or buffer and measured at the different time points shown. Data are expressed 
as means ± SEM. The right side represents a typical detector response after addition 
o f CysNO to rat liver homogenates at 4°C and its measurement at the different time 
points by chemiluminescence.
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Figure 3.2. S-Nitrosothiol decomposition in presence o f liver homogenate at 4°C. 
Liver tissue was perfused with jV-ethylmaleimide/DTPA (10/2 mM) in PBS and 
homogenized. L-CysNO, D-CysNO, GSNO, or .S-nitrosoalbumin was added (final 
concentration 250 nM) to the liver homogenates (5 mg/ml) and measured at different 
time points. Each experiment was repeated at least five times and data are expressed 
as means ± SEM.
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Figure 3.3. CysNO decomposition in presence o f plasma, liver, kidney, heart, and 
brain homogenates (4°C). All organs were perfused with A-ethylmaleimide and 
DTPA (10 and 2 mM respectively) in phosphate buffer and homogenized. L-CysNO 
was added (final concentration 250 nM) to the homogenates (5 mg/ml) and measured 
at different time points. Each experiment was repeated at least five times and data are 
expressed as means ± SEM.
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The marked temperature dependency o f  L-CysNO decomposition, as well the tissue 
heterogeneity, suggested to us that a protein/enzyme might be responsible for the 
rapid decomposition o f CysNO. Therefore, we initially tried heating the liver 
homogenate (80°C for 30 min), and secondly we added proteinase K, a proteolytic 
enzyme, to the liver homogenate for 30 min before adding CysNO. Either proteolysis 
o f  proteins or their denaturation by heating inhibited the ability to catalyse CysNO 
decomposition by ^>90% in liver tissue (Fig. 3.4).
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Figure 3.4. CysNO decomposition by fresh, heat-denatured liver homogenates or 
after proteolysis by proteinase K. After the samples were cooled down (4°C), L- 
CysNO was added to give a final concentration o f  250 nM in either freshly prepared, 
proteolyzed, or denatured liver homogenates followed by measurement o f  CysNO at 
different time points. Data are expressed as means ± SEM.
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To determine which cellular fraction was responsible for the decomposition o f  
CysNO, mitochondrial, cytoplasmic, and microsomal preparations were prepared 
from liver homogenates. CysNO was stable in both the microsomal and the 
mitochondrial fractions, and the decomposition o f CysNO was observed only in the 
cytoplasmic fraction o f rat liver homogenates (Fig. 3.5).
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Figure 3.5. CysNO decomposition in the presence o f whole liver homogenate and 
mitochondrial, microsomal, cytoplasmic, and low-molecular-weight (LMW) fractions 
o f  rat liver at 4°C. Each fraction was resuspended in jV-ethylmaleimide/DTPA (10/2 
mM) containing PBS. Each experiment was repeated at least five times and data are 
expressed as means ± SEM.
To determine whether the factor causing CysNO degradation activity resided in a 
high- or low-molecular-weight species, the cytoplasmic fraction was subjected to 
centrifugal filtration at different molecular weight cut-offs. Ultrafiltration o f  the
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cytoplasmic fraction resulted in no detectable CysNO decomposition activity in 
filtrates obtained through 10-, 50-, and 100-kDa cut o ff filters, suggesting that activity 
resides in a high-molecular-weight fraction. Re-suspension o f  the retained 
cytoplasmic fraction (e.g., in the sludge that remains above the filter) in buffer 
showed >90% o f  CysNO degradation activity compared with liver homogenates. 
Thus, in liver homogenates, there is a factor which is (a) heat labile, (b) resides in the 
cytoplasm, and (c) has a high molecular weight (i.e., cannot be filtered through the 
Millipore centrifuged filters).
These data suggested that a protein might be responsible for catalyzing the 
decomposition o f CysNO. Many proteins have been described as affecting the 
stability o f  S-nitrosothiols. Fig. 3.6 shows that neither selective metal chelators 
(neocuproine and deferoxamine) nor iodoacetate (an inhibitor o f thioredoxin reductase 
and glutathione peroxidase), acivicin (y-glutamyl transpeptidase inhibitor), allopurinol 
(xanthine oxidase inhibitor), or oxamic acid/propargylglycine (inhibitors o f  H2 S- 
producing enzymes) had any effect on the decomposition o f  CysNO. We also tested 
the effect o f acivicin on GSNO decay in liver homogenate; however, we were unable 
to show any significant effect (data not shown). Diethyl dithiocarbamate, which 
removes copper from copper-containing proteins, did not block the CysNO 
decomposition activity o f  liver homogenates (Fig. 3.6). One possible candidate to 
cause decomposition o f  L-CysNO and other low-molecular-weight S-nitrosothiols is a 
redox-sensitive metalloprotein. To test this we initially tested the effect o f potassium 
ferricyanide, which can oxidize ferrous iron proteins to ferric iron proteins. Incubation 
o f  normal liver homogenate with potassium ferricyanide significantly inhibited L- 
CysNO decay as shown in Fig. 3.6 (P<0.001, ANOVA). The effect o f hypoxia on the 
stability o f  L-CysNO in liver tissue was also assessed. Sparging o f  liver homogenates 
with helium to cause oxygen depletion led to a significant stabilization o f  L-CysNO, 
with the decomposition decreasing from 46 ± 4 to 24 ± 7% (P<0.025, n = 4, /-test) 30 
min after addition o f CysNO in control and hypoxic homogenates, respectively.
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Figure 3.6. CysNO decomposition by liver homogenate after 30 min incubation with 
acivicin (2 mM), allopurinol (500 /xM), iodoacetate (1 mM), oxamic
acid/propargylglycine (2 mM), diethyl dithiocarbamate (1 mM), neocuproine (1 mM), 
deferoxamine (1 mM), and potassium ferricyanide [K3 Fem(CN)6 ; 4 mM]. Liver was 
homogenized in /V-ethylmaleimide/DTPA containing PBS (4°C). Each experiment 
was repeated at least five times and data are expressed as means ± SEM.
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Because iron proteins can reduce reactive nitrogen species to nitrate, we determined 
whether the major product o f CysNO decomposition was either nitrite or nitrate. We 
observed a significant increase in both nitrite and nitrate concentrations in liver 
homogenate (P< 0.05, paired t-test), with nitrate contributing more than 95% o f  
detected nitrite + nitrate (Fig. 3.7). Thus, incubation with CysNO (2.5 /zM final 
concentration) led to an increase in nitrite + nitrate concentration by 2.2 ± 0.3 /zM in 
liver homogenates.
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Figure 3.7. Formation o f  nitrite + nitrate (NOx) in liver homogenate after 2 h 
incubation with CysNO in A-ethylmaleimide/DTPA buffer. Incubation with CysNO 
(2.5 fiM final concentration) led to a 2.17 ±0.25 /zM increase in NOx levels. * 
P < 0.05 in comparison with nitrite + nitrate levels before addition o f  CysNO (paired 
t- test).
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To determine whether liver disease or endotoxaemia could induce an increase in the 
level or activity o f the putative iron protein, the decomposition o f  L-CysNO was 
measured in liver homogenates from rats with endotoxaemia or cirrhosis (Fig. 3.8). 
Both endotoxaemia and biliary cirrhosis significantly increased the rate o f  
decomposition o f L-CysNO, even in the presence o f NEM and DTPA (P<0.02, 
ANOVA). We also looked at the basal level o f  hepatic nitroso compounds in septic 
rats. Homogenization o f septic liver in NEM/DTPA phosphate-buffered saline was 
associated with a time-dependent decay o f  the signal as shown in Fig. 3.9A. Under 
these experimental conditions, the mercury-resistant signal was stable over a 30-min 
period. Homogenization o f the endotoxaemic livers in ferricyanide-containing buffer 
stabilized the hepatic levels o f  nitrosated compounds and gave a series o f  stable peaks 
as shown in Fig. 3.9B.
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Figure 3.8. CysNO decomposition in the presence o f liver homogenates o f rats with
(A) acute sepsis or (B) biliary cirrhosis. Each experiment was repeated at least four 
times and data are expressed as means ± SEM.
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Figure 3.9. (A) Decomposition o f endogenously formed nitroso compounds in liver 
obtained from a rat with acute endotoxaemia. Liver was homogenized in NEM/DTPA 
phosphate-buffered saline and kept on ice before analysis at different time intervals 
(1, 15, 30 min). Addition o f mercury (Hg2+) selectively cleaves S-NO bonds and the 
mercury-resistant nitroso compounds contain both A-nitrosamines and iron-nitrosyl.
(B) Ferricyanide stabilizes S-nitrosothiols and selectively cleaves iron-nitrosyl 
complexes. Homogenization o f septic liver in ferricyanide containing buffer stabilizes 
the hepatic levels o f S-nitrosothiols over 30-min periods.
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3.3 Discussion II
This study shows that low-molecular-weight 5-nitrosothioIs are inherently unstable in 
tissue homogenates and that assays which measure tissue S-nitrosothiol concentration 
probably simply measure the levels o f  relatively stable 5-nitroso proteins. More 
importantly we have shown that the decomposition o f CysNO is catalyzed by a 
factors) which has the characteristics o f  a cytoplasmic ferrous protein, based on its 
sensitivity to proteolysis, thermal instability, high molecular weight, and sensitivity to 
potassium ferricyanide.
It has been shown that degradation o f  CysNO in the presence o f vascular tissue 
homogenate can be completely eliminated by the alkylation o f thiol groups with NEM 
(Kostka et al. 1999). Here we have shown that unlike vascular tissue, liver and kidney 
homogenates decompose CysNO in a thiol-independent manner. This CysNO 
degradation activity was negligible in brain and heart homogenates and was almost 
absent from plasma. We used a high concentration o f a potent thiol-blocking agent 
(NEM; 10 mM) to ensure that the maximum yield o f alkylation was achieved (i.e., 2 
//mol/mg protein, which is ~ ^ 2 0  times more than the expected amount o f cysteine 
residues in proteins). In a separate set o f experiments NEM concentration was 
increased to 50 mM and almost identical results were achieved (data not shown). 
Apart from non-enzymatic degradation, several enzymatic mechanisms, including 
glutathione peroxidise (Hou et al. 1996), thioredoxin reductase (Nikitovic et al. 1996), 
xanthine oxidase (Trujillo et al. 1998), Cu/Zn superoxide dismutase (Jourd’heuil et al. 
1998), glutathione-dependent formaldehyde dehydrogenase (Liu et al. 2001), and 
H:S-producing enzymes (Giles et al. 2004), are able to decompose 5-nitrosothiols in 
vitro, but their physiological relevance is not well understood. In our study 
pharmacological tests were negative for several candidate enzymes, namely 
glutathione peroxidase, thioredoxin reductase, xanthine oxidase, superoxide 
dismutase, y-GT, cystathionine /5-synthase, and cystathionine y-lyase. Recently Liu et 
al. have shown that glutathione-dependent formaldehyde dehydrogenase (GSNO 
reductase) reduces GSNO to disulfide and ammonia (Liu et al. 2001). However, this 
44-kDa GSNO reductase is highly specific for GSNO and no activity has been 
observed for CysNO and 5-nitro so homo cysteine (Liu et al. 2001). Although we have 
not directly investigated whether the protein responsible for CysNO decomposition is
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the same as the recently identified enzyme, GSNO reductase, the GSNO selectivity o f  
GSNO reductase over other low-molecular-weight S-nitrosothiols makes this unlikely.
To determine whether the observed activity was stereoselective, we carried out studies 
comparing D-CysNO and L-CysNO decomposition and observed that liver 
homogenates are equally active at decomposing both isomers (Fig. 3.2). This 
observation is not in favour o f  a direct enzymatic pathway by which CysNO is being 
consumed as a substrate. Furthermore the ability o f potassium ferricyanide to stabilize 
CysNO decay in tissue homogenates shows that a cytoplasmic ferrous protein (or a 
group o f ferrous proteins) might be involved in this process. NEM cannot prevent the 
formation o f A-nitrosation and iron-nitrosyl products. According to studies by 
Feelisch and colleagues, the formation o f N-nitrosation and iron-nitrosyl products is 
as ubiquitous as that o f S-nitrosation products (Feelisch et al. 2002). Spencer et al. 
(2000) have already shown that GSNO can be reduced by ferrous deoxyhaeme 
proteins such as haemoglobin and myoglobin. Gladwin et al. (2000) have also used 
ferricyanide/cyanide to selectively cleave NO from nitrosyl haemoglobin before 
analysis by a methodology similar to the one presented here. This approach relies on 
the classical Evelyn and Malloy technique o f  haemoglobin quantification in blood 
based on the oxidation o f oxyhaemoglobin to methaemoglobin (Evelyn and Malloy 
1938). Here we have shown that incubation with potassium ferricyanide inhibits the 
decomposition o f  both added CysNO (Fig. 3.6) and endogenously formed S~ 
nitrosothiols in rat liver homogenates (Fig. 3.9). As shown in Fig. 3.9, the signal 
detected from endogenously formed nitroso compounds in an endotoxaemic rat was 
subjected to a time-dependent decay in liver tissue homogenates in the presence o f  
NEM and DTP A. Under these experimental conditions, the mercury-resistant signal 
was stable over a 30-min period. Addition o f mercury selectively cleaves S-NO bonds 
and the mercury-resistant peak which remain, contains both A-nitrosamines and iron- 
nitrosyl complexes. On the other hand, homogenization o f the endotoxaemic liver in 
ferricyanide-containing buffer was associated with detection o f a series o f  stable 
peaks (Fig. 3.9B). Ferricyanide oxidizes the ferrous proteins, which leads to 
decomposition o f  iron-nitrosyls and stabilization o f S-nitrosothiols. Thus the 
mercury-resistant fraction under this condition contains just A-nitrosamines because 
the iron-nitrosyl complexes are unstable in the presence o f  ferricyanide. Based on this 
chemistry a method for stabilization and measurement o f tissue S-nitrosothiols, A-
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nitrosothiols, and iron-nitrosyl complexes is proposed in Fig. 3.10. This method has 
the advantage that it can potentially measure both high-molecular-weight and low- 
molecular-weight nitroso species using centrifugal filtration (Fig. 3.10). The currently 
most used method for separation o f  low- and high-molecular-weight nitroso 
compounds is based on trichloroacetic acid (TCA) precipitation o f tissue proteins. 
However, TCA precipitation may be associated with artifactual formation o f nitroso 
compounds due to acidification o f  nitrite and formation o f  reactive nitrogen species. 
Our unpublished data have also shown that homogenization o f tissues in TCA- 
containing medium is subject to a time-dependent decomposition o f  S-nitrosothiol 
levels, which might be due to formation o f  hydrogen sulfide from sulfide in acidified 
tissue homogenates (unpublished observation). Incubation with CysNO led to an 
increase in nitrite + nitrate concentration in liver homogenates in which nitrate 
contributed more than 95% o f detected nitrite + nitrate. This mechanism is oxygen 
dependent and ferricyanide sensitive. It has been theorized that iron-nitrosyl 
complexes (such as HbFenNO) react with oxygen; forming a haem-peroxynitrite 
adduct and finally liberating nitrate (Cooper 1999). However, the elucidation o f  the 
nature o f the tissue factor involved in the catabolism o f  CysNO requires further study. 
Most importantly, we have described the decomposition o f  low-molecular-weight S- 
nitrosothiols by a metalloprotein and described a simple method to stabilize these 
compounds until analysis. Thus, homogenization o f tissues in ferricyanide-containing 
buffers in the presence o f  NEM and DTP A can stabilize S-nitrosothiols in tissues 
before the measurement o f their levels.
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Tissue perfused with NEM/DTPA
Homogenization in NEM/DTPA solution Homogenization in K3Fe"'(CN)e/NEM/DTPA solution
Centrifugal filtration (30 kDa cut off)
+ Hgd2 
(2% final concentration)
+ HgCI2 
(2% final concentration)
+ Hgd2 
(2% final concentration)
+ acid sulfinalamide 
(0.5% final concentration)
+ acid sulfinalamide 
(0.5% final concentration)
+ acid sulfinalamide 
(0.5% final concentration)
+ acid sulfinalamide 
(0.5% final concentration)
+ add sulfinalamide 
(0.5% final concentration)
Cu*7l'3 reagent Cu*7l3 reagentCu*7l'3 reagent Cu‘71-3 reagentCu‘71-3 reagent
LMW N-nitrosamlnes LMW N-nitrosamines + LMW RSNON-nitrosamines N-nitrosamines + RSNON-nitrosamines + Iron-nitrosyl
Figure 3.10. Flow diagram for the measurement o f S-nitrosothiols, N-nitrosamines and iron-nitrosyl complexes in tissues. The method is 
based on detection o f  NO released form nitos(yl)ated compounds in presence o f Cu2+/I 3, Hg2+ (which selectively cleaves S-NO) and 
ferricyanide (which stabilizes S-nitrosothiols and cleaves iron-nitrosyl complexes).
Chapter 4: Role of nitration and/or S-nitrosation of cardiac proteins in the 
pathogenesis of cardiac chronotropic dysfunction in rats with biliary cirrhosis 
4.1 Introduction
The cardiac cycle undergoes a natural variation due to respiratory cycle, baroreflex 
activation, the intrinsic variability o f cardiac pacemaker activity, circadian rhythms 
and other physiological mechanisms (see for Altimiras 1999 for review). Loss o f  
heart rate variability (HRV) and increased heart rate regularity is a common feature o f 
systemic inflammatory conditions such as endotoxaemia and liver failure (Mani et al. 
2006a; Fleisher et al. 2000). Previous studies have shown that indices o f depressed 
heart rate variability in patients with liver failure correlate not only with the extent o f  
disease progression, but also predict survival in these patients (Fleisher et al. 2000). 
Thus, Fleisher et al. (2000), have shown that heart rate variability was significantly 
lower in the non-survivor patients awaiting liver transplantation compared with 
survivors.
The mechanism o f  decreased heart rate variability in cirrhosis remains unclear 
however it shares some basic characteristics with other systemic illnesses such as 
congestive heart failure and sepsis. Malave et al., (2003) have shown that circulating 
levels o f tumour necrosis factor-alpha (TNF-a) correlate with indices o f  depressed 
heart rate variability in patients with congestive heart failure. TN F-ahas a crucial role 
in pathogenesis o f  inflammatory conditions such as endotoxaemia as well as the 
progression o f heart failure. Since TN F-acan blunt 13-adrenergic signalling (Chung et 
al., 1990), Malave et al. (2003) suggested that T N F-ais a major circulating mediator 
which decreases 6 -adrenergic responsiveness and leads to a decrease in heart rate 
variability observed in heart failure and systemic inflammatory conditions.
Abnormalities in both cardiac muscle physiology and cardiac neural autonomic 
regulation have been documented in patients with cirrhosis (Hendrickse et al. 1992; 
Lee et al. 2007). Cardiac function is abnormal in cirrhosis, with subnormal cardiac 
responses to pharmacological and physiological stimuli. Manoeuvres leading to 
sympathetic nervous system activation by different means, such as tilting, physical 
exercise and pharmacological stimulation, do not evoke an adequate acceleration o f  
heart rate in cirrhotic patients compared with normal subjects (Bemardi et al. 1987;
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Bemardi et al 1991, Wong 2001). Despite the fact that down regulation o f  B- 
adrenergic signalling is well documented in cirrhosis, its role in the loss o f  heart rate 
variability in cirrhosis is unknown.
Recent studies proposed a pathophysiologic role for increased cardiac nitric oxide 
(NO) and endocannabinoid formation in the development o f cardiac abnormalities in 
experimental cirrhosis (Liu et al. 2000; Gaskari et al. 2005). Inhibition o f  either NO 
synthase (NOS) or endocannabinoid receptors improves the blunted responsiveness o f  
isolated papillary muscle to adrenergic stimulation in vitro (Liu et al. 2000; Gaskari et 
al. 2005). The reason for increased cardiac NO and endocannabinoid formation is not 
precisely understood, however it is proposed that endotoxaemia, possibly from gut- 
derived bacterial translocation, causes induction o f NO as well as endocannabinoid 
formation leading to cardiovascular dysfunction in cirrhosis (Rasaratnam et al. 2004). 
Endotoxaemia is a common feature o f cirrhosis and high concentrations o f circulating 
endotoxins are found in cirrhotic patients with no clinical evidence o f  infection due to 
impaired clearance o f  gut bacterial endotoxin in diseased liver (Wiest and Garcia- 
Tsao 2005). Since endotoxin can induce the synthesis o f  both NO (Petros et al. 1991) 
and anandamide (Varga et al. 1998), here we have hypothesised that this may have 
two consequences. Firstly there may be increased NO and endocannabinoid 
formation leading to altered cardiac responsiveness to B-adrenergic stimulation and 
secondly the subsequent loss o f cardiac responsiveness to autonomic modulation 
contributes to the decrease in heart rate variability (Fig. 4.1).
The contribution o f nitric oxide (NO) to the pathophysiology o f cardiac dysfunction in 
cirrhosis is well documented (Van Obbergh et al. 1996; Liu et al. 2000; Mani et al. 
2002). Nitric oxide is involved in the modulation o f cardiac function in the normal 
heart, as well as in various cardiac diseases via mechanisms involving NO that are 
both dependent on and independent o f guanylate cyclase (Balligand et al. 1997; 
Paolocci et al. 2000). For example, evidence suggests NO attenuates cardiac 
pacemaker activity, mediated by cGMP (Herring et al. 2002), However, NO may also 
modify cardiac function through nitration or S-nitrosation o f  cardiac proteins 
(Paolocci et al. 2000; Gow et al. 2004). Tyrosine residues in proteins are targets for 
nitration by reactive nitrogen species such as peroxynitrite and may lead to loss o f
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function. One example o f  this is actin, which when nitrated loses its ability to contract 
effectively (Aslan et al. 2003). Likewise, cell signalling via phosphorylation o f  
tyrosine residues also may become impaired after nitration o f  critical regulatory 
proteins (Gow et al. 2004). Moreover, the concept that protein function may be 
controlled by S-nitrosation o f a critical cysteine residue has emerged in biology as a 
potentially important mechanism or pathway to control cellular function (Hare and 
Stamler 2005). Although cirrhosis is well recognized as being associated with 
increased NO synthesis, the role o f nitration or nitrosation o f cardiac proteins in 
cardiac function in cirrhosis has not previously been investigated.
The aims o f  the work described in this chapter were:
1. Evaluate the relationship between heart rate variability and the degree o f  atrial 
chronotropic responsiveness to adrenergic stimulation.
2. To test the hypothesis that increased formation o f reactive nitrogen species in 
cirrhosis causes nitration/nitrosation o f cardiac proteins and leads to impaired cardiac 
chronographic function. Therefore, we have investigated the effects o f  two 
independent treatments (a low-molecular-weight thiol and an NO synthase inhibitor), 
both o f which can decrease nitration/nitrosation o f proteins, on cardiac chronotropic 
responses in a rat model o f biliary cirrhosis.
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Clearance of LPS
Nitrosativt 
iw stress
Neomycin + Polymixin
AM 251
TNF-alpha
Pentoxifylline■
Anandamide
Nitric Oxide ■ N-acetylcysteine
LPS l-n a m e  Blunted beta-adrenergic signalling 
Decreased heart rate variability
Cirrhosis
Fig. 4.1. A schematic representation o f the working hypothesis on the mechanism o f  
decreased heart rate variability in cirrhosis. Cirrhosis leads to impaired clearance o f  
endotoxins derived from gut bacterial flora. Since endotoxaemia enhances the 
formation o f  both NO and anandamide, it is hypothesised that this may lead to cardiac 
dysfunction through induction o f nitrative/nitrosative stress and a subsequent decrease 
in heart rate variability. These hypothetical pathways can be inhibited by various 
pharmacological interventions (red arrows).
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4.2 Material and Methods
Chemicals
All materials were purchased from Sigma (Pool, UK), otherwise specified in the text. 
Animals
Male Sprague-Daw ley rats (250-280 g) were obtained from the Comparative Biology 
Unit (Royal Free and University College Medical School, London). All animal 
procedures were in accordance with Home Office (UK) recommendations. Bile duct 
ligated (BDL) rats were used as an experimental model o f  biliarty cirrhosis. Animals 
were given free access to normal rodent chow and water up until the time o f  bile duct 
ligation or subsequent study. A midline abdominal incision was made under general 
anaesthesia induced by intra-peritoneal injection o f  diazepam (5 mg/kg) after intra­
muscular administration o f  Hypnorm (fentanyl/fluanisone; 0.4 mg/kg). For those 
undergoing bile duct ligation, the common bile duct was isolated, triply ligated, and 
cut between the ligatures (Harry et al. 1999). Sham procedure involved a similar 
operation, but without ligation or cutting o f the bile duct.
Time dependent effect o f  bile duct ligation o fH R V
Bile duct ligation was induced as described above. Bile duct ligated and sham 
operated rats were anaesthetized 1,2,3,4 and 5 weeks post operation using isoflurane 
(n=8-12 each group). A 20-min single channel (lead II) electrocardiogram (ECG) was 
recorded. We used low concentration o f  isoflurane (1.5 %) for smooth recording o f  
ECG as isoflurane has the minimal systemic homodynamic effects in rats compared 
with other volatile or non-volatile anaesthetics (Janssen et al. 2004). The ECG signal 
was amplified using a Powerlab system (ADInstrument, Australia) and was digitized 
at a sampling rate o f 1 kHz. The R-R interval time series was first generated using the 
automatic scheme in order to detect the R peak in the ECG. To exclude the influence 
o f  diurnal variations, the ECG recordings were begun between 2 p.m. and 5 p.m.
Heart rate variability analysis using Poincare plot
The Poincare plot was used for HRV analysis. The Poincare plot is a graphical 
presentation o f  the correlation between the consecutive R-R intervals (Fig. 4.2). If  the 
heart rate rhythm is regular then the points in Poincare plot are located closely around
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the line o f  identity (axis o f  the first quadrant). The standard deviation o f the points 
perpendicular to the line-of-identity denoted by SD1 describes short-term variability, 
which is mainly caused by the respiratory sinus arrhythmia (vagal modulation). The 
standard deviation along the line-of-identity denoted by SD2 describes long-term 
variability. Quantitative analysis o f the Poincare plot was performed using software 
developed by Niskanen et al (2004).
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Figure 4.2. The Poincare plot is a graphical presentation o f  the correlation between 
the consecutive R-R intervals. A common way to analyse heart rate dynamics using 
the Poincare plot is to fit an ellipse to the graph. The ellipse is fitted onto the line-of- 
identity at 45° to the normal axis. The standard deviation o f the points perpendicular 
to the line-of-identity denoted by SD1 describes short-term variability, which is 
mainly caused by the effect o f respiration on vagal drive. The standard deviation 
along the line-of-identity denoted by SD2 describes long-term variability.
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Pharmacological manipulation
All subsequent studies were performed at day 28 post-bile duct ligation or sham 
operation, when biliary cirrhosis had developed. Histological examination was 
performed on formalin-fixed liver stained with haematoxylin and eosin to confirm the 
development o f biliary cirrhosis. At 24 days after the operation, the animals (BDL and 
control) were divided into six experimental groups, which received one o f  the 
following treatments for 4 days:
1) Sub-cutaneous injection o f  A^-L-nitro-arginine methyl ester (L-NAME, a non- 
selective NOS inhibitor), 0.5 mg/kg/twice a day (n=8 ).
2) Sub-cutaneous injection o f  N-acetylcysteine (130 mg/kg/twice a day; infusible 
solution, Celltech, UK; n=8-12).
3) Sub-cutaneous injection o f an endocannabinoid receptor 1 (CB1) antagonist, 
AM251 (Tocris, UK), 3.0 mg/kg/twice a day (n=8 ).
4) Sub-cutaneous injection o f pentoxifylline 10 mg/kg/twice a day to inhibit 
TNF-Of formation (n=6 ).
5) Oral neomycin (5 g/1 drinking water) and Polymixin B (1.3 g/1 drinking water) 
in combination with sub-cutaneous injection o f physiological saline solution to 
remove the bacterial flora (n=8 ).
6 ) Sub-cutaneous injection o f physiological saline solution (1 ml/kg; n=12).
On day 28 the rats were anaesthetized with isoflurane (1.5 %) and a lead II ECG was 
recorded (20 min) for the analysis o f  HRV as described above. The heart o f  each 
animal was then removed and the auricles were dissected out from isolated hearts in 
cold oxygenated physiological solution. Blood was also collected in nitrate-free 
ethylendiamine-tetraacetic acid (EDTA) containing tubes for measurement o f  plasma 
nitrate + nitrite levels in the experimental groups.
Preparation o f  isolated atria (in vitro study)
Isolated rat atria were used as a model system in this investigation because it is 
amenable to direct measurements o f cardiac chronotropic response without being 
encumbered by confounding physiological mechanisms operative in more complex 
systems. In brief, the left and right atria were isolated in cold oxygenated
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physiological solution and suspended under isometric tension o f 1 , 0 0 0  mg force in a 
25 mL organ bath glass chamber (Mani et al. 2002). The temperature o f  the bathing 
solution was 37.0 ± 0.1 °C, and pH was 7.4. The composition o f physiological solution 
in mM was as follows: NaCl, 112; KC1, 5; CaCh, 1.8; MgCh, 1; NaHzPCU, 0.5; 
KH2 PO4 , 0.5; NaHCC>3 , 25; glucose, 10; and EDTA, 0.004. The solution was 
oxygenated with a gas mixture o f 95% O2 and 5% CO2 . The right atrium, which 
contains the sino-atrial node, was used for recording the spontaneous atrial beating, 
and was stimulated by increasing concentrations o f isoproterenol from 1 0 ' 10 to lO' 6  
mol/L (chronotropic study).
Western blotting
Snap frozen cardiac tissues were homogenized in ice-cold RIPA buffer containing 
protease inhibitors (protease inhibitor mixture from Roche, Mannheim, Germany), 50 
mM Tris (pH 8 ), 150 mM NaCl, 1% NP-40, 0.5% Sodium Deoxycholate and 0.1% 
SDS. Homogenates were then sonicated followed by centrifugation at 10,000 xg for 5 
min at 4 °C. After determining the protein concentrations o f the supernatants 
(Bradford assay with bovine serum albumin as standard), 10 fig protein o f  each 
sample was fractionated by SDS-PAGE and transferred to a polyvinylidene fluoride 
(PVDF) membrane. After blocking with Tris buffered saline (10 mM Tris, 100 mM 
NaCl) containing 0.1% Tween-20 for 1 h, the membranes were incubated overnight 
with rabbit anti-eNOS, iNOS or CB1 antibody (1:2000, 1:1000 and 1:100 dilutions 
respectively, rabbit polyclonal antibody from Sigma, Upstate and Santa Cruz 
Biotechnology respectively). After rigorous washing, the membranes were incubated 
with anti-rabbit IgG alkaline phosphatase-linked antibody (1:5000 dilution, Perbio 
Science, UK). Alkaline phosphatase was detected using a BCIP/NBT developing kit 
(Promega, Madison, USA). Proteins extracted from rat endothelium, stimulated 
macrophages and rat brain were used as the positive control for eNOS, iNOS and CB1 
immunoreactivity respectively. Cardiac myosin (heavy chain) was used as the 
housekeeping protein. Developed immunoblot membranes were digitized and band 
optical densities were quantified using a computerized imaging system (Imaging 
densitometer model GS-670, Bio-Rad, Hercules, CA, USA). Densitometry data are 
expressed as relative optical densities (ROD) in arbitrary units.
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Plasma nitrite+ nitrate concentrations
Plasma nitrite and nitrate was measured by a chemiluminescence-based assay as 
described chapter 3. In brief, nitrate was converted to nitrite using nitrate reductase. 
Samples were then injected into a reaction chamber containing acetic acid and 
potassium iodide (50 mg/mL) at a ratio o f 4:1. This reduces nitrite to NO, which is 
purged from the refluxing solution by nitrogen and reacts with ozone before analysis 
by chemiluminescence (NOA). Measurements were calibrated against standard curves 
o f  sodium nitrate.
Tissue nitrotyrosine levels
Protein-bound nitrotyrosine levels were measured in the cardiac atrium, ventricle, 
liver and brain obtained from controls and rats with biliary cirrhosis using an isotope- 
dilution mass spectrometric method developed in our laboratory (Frost et al. 2000, 
Moore and Mani 2002). The effect o f L-NAME and N-acetylcysteine on the levels o f  
free nitrotyrosine was also measured in ventricular tissue, but not in the atria, since 
insufficient tissue was obtained. In brief, tissue was homogenized in a mixture o f  ice- 
cold saline (2 mL) and chloroform/methanol (2:1) containing 10 ng 13C9 -nitrotyrosine, 
and the protein precipitate (middle layer) was isolated by centrifugation at 2 0 0 0  * g  
for 30 minutes at 4°C. The supernatant was used for measuring free nitrotyrosine (in 
ventricles) and the protein precipitates were lyophilized under vacuum for assessment 
o f protein-bound nitrotyrosine. 1-1.5 mg o f lyophilized protein was hydrolyzed for 15 
hours at 120°C in 1 mL 4 M sodium hydroxide following the addition o f  10 ng
13 2 • • . •[ C^nitrotyrosine and 10 Pg o f [ FL^tyrosine as stable isotopic internal standards. 
These conditions prevent the artifactual nitration o f tyrosine that occurs during acidic 
hydrolysis conditions. Following two steps o f solid phase extraction, nitrotyrosine and 
tyrosine were quantitated by stable isotope dilution gas chromatography/negative ion 
chemical ionization mass spectrometry (Frost et al. 2000, Moore and Mani 2002). 
Results o f protein bound nitrotyrosine are expressed as a ratio o f  nitrotyrosine to 
tyrosine (pg/pg).
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Assessment o f  nitration reactions in vivo using deuterated PHPA as a probe 
To determine whether N-acetylcysteine inhibits the formation o f reactive nitrogen 
species in vivo, or inhibits the nitration o f  circulating phenolic compounds, a novel 
method was employed based on infusion o f deuterated /?ara-hydroxyphenylacetic acid 
([2 H6 ]PHPA) followed by measurement o f  the urinary excretion o f  it's nitrated 
product using mass spectrometry (see chapter 2). This experimental approach allows 
us to assess the formation o f  reactive nitrogen species dynamically, since the 
formation o f  nitrated deuterated pflra-hydroxyphenylacetic acid (PHPA) can only 
occur through direct attack o f its phenolic ring by reactive nitrogen species in vivo. 
Therefore, in a separate set o f experiments, BDL or sham-operated rats were 
anesthetized with isoflurane (1.5%) and the external jugular vein and the urinary 
bladder were cannulated with PE-10 and PE-50 tubes respectively. [2 H6 ]PHPA (250 
nmol) was infused intravenously by bolus injection, and the level o f urinary deutrated
3-nitro-/?«ra-hydroxy-phenylacetic acid (["HsJNHPA) was measured sequentially
2 2 during a 4-hour urine collection (nitration o f [ H&JPHPA produces [ HsJNHPA as a
result o f replacement o f a single deuterium o f  the aromatic ring by the -NO2 group)
using mass spectrometry (chapter 2; Mani and Moore 2005). The basis for this
method is illustrated in Scheme 4 .1 .
COO-
RNS
OH
COO-
NO
OH
2H6-PHPA 2H5-NHPA
Scheme 4.1. Nitration o f deuterium-labelled PHPA by reactive nitrogen species 
(RNS)
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Cardiac concentrations o f  S-nitrosothiols.
A reductive chemiluminescense-based assay was used for measuring cardiac levels o f  
S-nitrosothiols as described in chapter 3. In a separate set o f experiments, the left 
ventricle was perfused with ice-cold perfusion buffer (phosphate saline buffer, pH 7.4 
containing a thiol blocking agent NEM and DTPA o f 5 and 1 mmol/L respectively). 
After homogenization o f -5 0 0  mg o f  the snapped-frozen tissue in ice-cold perfusion 
buffer, S-nitrosothiols were determined by a copper (II)/iodine/iodine-mediated 
cleavage o f S-nitrosothiols to NO, which was then quantified by its gas phase 
chemiluminescent reaction with ozone in a NO analyzer (NOA, Sievers, Boulder, CO) 
by a method developed in our laboratory (chapter 3)
Measurement o f  cardiac F2 -isoprostanes and arachidonic acid.
Since many reactive nitrogen species also initiate lipid peroxidation reactions in vivo 
we also measured the concentration o f  esterified F2 -isoprostanes in cardiac tissue 
(Moore et al. 1995). In short, -2 5 0  mg whole cardiac tissue was homogenized in a 
mixture o f saline and chloroform/methanol solution containing butylated 
hydroxytoluene (5%) (to inhibit ex vivo lipid peroxidation), and centrifuged at 3,000g 
for 10 minutes. This process results in three phases, an upper aqueous phase, 
separated from the lower lipid containing phase by a ring o f protein precipitate. The 
lower lipid layer was aspirated and, following the addition o f 500 pg o f  [2 H4 ]iso- 
PGFa and 50ng o f [^Hgjarachidonic acid (Cayman Co., Ann Arbor, MI) as internal 
standards, was dried down under nitrogen, and hydrolyzed in methanolic 15% 
potassium hydroxide solution (1 hour, 37°C). To extract the F2 -isoprostanes, the pH 
was adjusted to 3.0, and the samples were extracted on a Cis solid-phase extraction 
cartridge (Elstree, Hertsfordshire, Waters, UK) as described, (Moore et al. 1995) 
converted to the pentaflurobenzyl ester, purified by thin-layer chromatography and 
analyzed as the tri-methysilyl ether. Detection was performed by selected ion 
monitoring gas chromatography negative ion chemical ionization/mass spectrometry 
with monitoring o f  ions at m/z 569 and 573 (Moore et al. 1995). To control for the 
hydrolysis step, the levels o f free (i.e., hydrolyzed) arachidonic acid were also 
measured by a mass spectrometric method developed in our laboratory (Mani and 
Moore, unpublished). In brief, arachidonic acid was extracted on a Cig solid-phase 
extraction cartridge (Waters), converted to the pentaflurobenzyl ester, purified by
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thin-layer chromatography and analyzed by stable isotope dilution negative ion 
chemical ionization mass spectrometry by monitoring ions at m/z 303 and 311. The 
levels o f  F2 -isoprostanes were expressed as the ratio o f  F2 -isoprostanes to arachidonic 
acid in cardiac tissue homogenates.
Immunogold electron microscopy
In a separate set o f experiments freshly-isolated atria from controls and rats with 
cirrhosis were excised and immersed in isotonic fixative (4% paraformaldhyde, 0.5% 
glutaraldehyde, in 0.1 mol/L phosphate buffer, pH 7.4, with 0.1 mol/L sucrose) for 
electron microscopic immunocytochemistry as has previously described (n = 2 ) 
(Mihm et al. 2002). Tissues were then infiltrated and embedded m LR white resin. 
Thin sections (70-90 nm) were cut and mounted on coated nickel grids. The grids 
were then blocked (0.1% bovine serum antigen, 0.1 mol/L glycine in PBS) for 30 
minutes and incubated for 2  hours with rabbit polyclonal antibody raised against 
nitrotyrosine (anti-nitrotyrosine, 1:500, a kind gift o f Dr. Joseph Beckman, University 
o f Alabama at Birmingham, Alabama). Following a series o f washes, grids were 
incubated for 1 hour with 10 nm Immunogold-linked, EM grade, goat anti-rabbit IgG 
(1:50 dilution). Following another series o f  washes, grids were successively stained 
with uranyl acetate and Reynold's lead citrate before visualization with a transmission 
electron microscope. Electron micrographs (31,000 x original magnification) were 
scanned using a digital imaging system.
Statistical analysis
The results are presented as mean ± SEM. ANOVA was applied with Newman-Keuls 
test and P values less than 0.05 were considered statistically significant. In conditions 
where the parametric test was not permitted (owing to heterogeneity o f variances) a 
non-parametric Kruskal-Wallis test followed by Dunn's multiple comparison test were 
used for statistical analysis.
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4.3. Results III
Time dependent effect o f  bile duct ligation on basal heart rate and HRV  
Time-dependent effect o f bile duct ligation on basal heart rate and HRV parameters is 
shown in Figure 4.3. Four and five weeks after bile duct ligation rats showed a 
significant bradycardia compared with sham-operated animals (Fig 4.3A). Bile duct 
ligation did not have any significant effect on short-term HRV (SD1), however long­
term HRV (SD2) was significantly affected by the ligation o f  bile duct, 4 and 5 weeks 
post operation (Fig 4.3).
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In vivo study: heart rate and HRV in cirrhotic rats (4 weeks BDL rats)
The heart rate o f cirrhotic rats was significantly (P<0.01) lower than control rats. 
Administration o f L-NAME, N-acetylcysteine or AM251 led to normalization o f the 
basal heart rate in BDL rats. Neither pentoxifylline nor oral neomycin/polymixin B 
administration was able to normalize bradycardia in BDL cirrhotic rats (Fig 4.4).
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Figure 4.4. Basal heart rate (beat/min) in control or cirrhotic rats given saline, L- 
NAME (A), N-acetylcystemine (B: NAC), AM251 (C), pentoxifylline (D: PTXF) or 
neomycin/polymixin B (E: NEO + POLY B). Data are shown as Mean ± SEM. * 
P<0.05 compared controls. + P<0.05 compared with Saline treated BDL rats. 6 - 8  rats 
were used in each group.
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The Poincare plot in two representative rats is shown in Fig 4.5. In healthy rats the 
Poincare plot is scattered along the line o f identity while this scattering is significantly 
less in cirrhotic rats. There was a marked decrease in long-term HRV (SD2) in rats 
with cirrhosis in comparison with sham-operated animals (4.2 ± 0.4ms vs 11.2 ± 
0.9ms to P<0.01). No significant difference was found between control and cirrhotic 
rats in short-term HRV as assessed by measuring SD1 (Fig 4.6). Decontamination o f  
gut bacterial flora using neomycin/polymixin B significantly normalised decreased 
long-term HRV (SD2) in BDL rats (4.2 ± 0.4 versus 10.9 ± 1.2), whereas none o f the 
pharmacological manipulations (L-NAME, N-acetylcysteine, AM251 or 
pentoxifylline) had a significant impact on long-term HRV (SD2) in cirrhosis (Fig 
4.7).
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Figure 4.5. Poincare plots in two representative control and cirrhotic rats.
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Figure 4.6. Short-term heart rate variability (SD1) in control or cirrhotic rats given 
saline, L-NAME (A), N-acetylcysteine (B: NAC), AM251 (C), pentoxifylline (D: 
PTXF) or neomycin/polymixin B (E: NEO + POLY B). Data are shown as Mean ± 
SEM. No statistically significant difference was found between the groups.
104
SD
2(
m
s)
 
SD
2(
m
s)
 
SD
2(
m
s)
□ Saline□ Saline 
L-NAME
□ Saline 
NEO + POLYB
□ Saline
CTR BDL CTR BDL
18
16
14
12
10
8
6
4
2
0
□ Saline 
■ AM251
CTR BDL
Figure 4.7. Long-term heart rate variability (SD2) in control or cirrhotic rats given 
Saline, L-NAME (A), N-acetylcysteine (B: NAC), AM251 (C), pentoxifylline (D: 
PTXF) or neomycin/polymixin B (E: NEO + POLY B). Data are shown as Mean ± 
SEM. * P<0.05 compared with controls.
+ P<0.05 compared with Saline treated BDL rats. 6 - 8  rats were used in each group.
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In vitro study
Initial studies confirmed that chronotropic responses to isoproterenol were impaired 
in isolated atria (Fig 4.8). Thus, there was a 1.8-fold increase in the EC 5 0  o f  
isoproterenol necessary to evoke the same response as normal rat atria in the 
spontaneously beating right atria isolated from cirrhotic rats (P<0.02). This confirms 
the observation that there are impaired cardiac responses to adrenergic stimulation in 
cirrhotic rats. The maximum response (/?max) to isoproterenol was not statistically 
different between controls and animals with cirrhosis (477 ± 10 beats/minutes vs. 466 
± 3 beats/minutes in control and animals with cirrhosis, respectively). The maximum 
response (Rmax) to the chronotropic effect o f B-adrenergic stimulation was similar in 
all experimental groups. As shown in Fig. 4.8, administration o f L-NAME, N- 
acetylcysteine or AM251 for four days normalized the chronotropic responsiveness o f  
isoproterenol in cirrhotic rats (P<0.05). Neither pentoxifylline nor oral 
neomycin/polymixin B administration could normalize the impaired responsiveness to 
adrenergic stimulation in isolated atria (Fig. 4.8).
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Figure 4.8. Chronotropic response o f spontaneous beating isolated atria to 
cumulative concentrations o f isoproterenol (10"10- 10"7). Atria are obtained from sham- 
operate (CTR) and bile duct ligated (BDL) cirrhotic rats given Saline, L-NAME (A), 
N-acetylcysteine (B: NAC), AM251 (C), pentoxifylline (D: PTXF) or
neomycin/polymixin B (E: NEO + POLY B). n=6 - 8  in each group. Data are expressed 
as mean ± SEM.
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Western blotting
As shown in Fig. 4.9, there was no significant alteration in eNOS band density in 
cardiac tissues obtained from cirrhotic and control rats (3.1 ±1.2 versus 2.7±0.9; 
ROD). We were not able to demonstrate iNOS expression in cardiac tissue obtained 
from controls or cirrhotic rats. Cirrhosis was associated with a significant (P<0.05) 
increase in the relative density o f  CB1 receptor compared with sham-operated rats 
(14.65±2.2 versus 23.2±3.2 ROD in sham-operated and cirrhotic rats respectively).
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Figure 4.9. Western blot analysis o f  eNOS and iNOS and cannabinoid CB1 receptor 
in cardiac tissue obtained from control (C l, C2, C3) and bile-duct ligated (B l, B2, 
B3) rats. Proteins extracted from endothelial monolayer, activated macrophages and 
rat cerebrum were used as the positive control (+ve) for eNOS, iNOS and CB1 
receptor immunoreactivity respectively. Myosin (heavy chain) was used as the 
housekeeping protein.
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Plasma nitrite + nitrate concentrations
As shown in Table 4.1, there was a significant increase in plasma concentrations o f  
NO end products (nitrite + nitrate) in rats with biliary cirrhosis (13.9 ± 1.7 to 21.7 ± 
1.8 fiM, P<0.01), which decreased following inhibition o f  NO synthase by L-NAME 
(13.0 ± 0.6 fiM, P<0.01 compared with BDL rats given saline). Pre-treatment with N- 
acetylcysteine, AM251 or pentoxifylline did not affect the plasma concentrations o f  
nitrite + nitrate levels in rats with biliary cirrhosis (Table 4.1). Decontamination o f  gut 
bacterial flora using neomycin/polymixin B increased plasma levels o f nitrite + nitrate 
in BDL rats (P<0.05 in cirrhotic groups).
Table 4.1. Plasma nitrate + nitrite (/-imol/L) in control or cirrhotic rats given Saline, 
L-NAME, N-acetylcysteine, AM251, pentoxifylline or neomycin + polymixin B.
Treatm e n
CTR BDL
Saline 13.9 ±1.7 22.1 ± 1.8 “
L-NAME 11.7 ± 0.9 13.0 ± 0.6 +
N-acetylcysteine 14.3 ±1.1 27.4 ±2.1 **
AM251 14.5 ±2.0 19.1 ± 1.3 *
Pentoxifylline 11.9 ±0.6 18.6 ± 3.3 +
Neomycin + 
Polymixin
19..0 ± 3.2 42.1 ±5.9  “ ++
Data are shown as Mean ± SEM. * P<0.05 compared controls. + P<0.05 compared 
with Saline treated BDL rats. 6 - 8  rats were used in each group.
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Nitrotyrosine concentrations in cardiac tissue and nitration o f  deuterated PHPA
As shown in Table 4.2, protein-bound nitrotyrosine levels increased significantly in 
atrial tissue, ventricle and liver but not in the brain o f  rats with biliary cirrhosis 
compared with controls. The administration o f L-NAME or N-acetylcysteine 
decreased atrial nitrotyrosine concentrations from 23 ± 3 pg/^g o f tyrosine to 15 ± 1 
and 17 ± 1 pg/^g respectively (Fig. 4.10). The same pattern o f  changes was observed 
in the ventricles as shown in Fig. 4.11. L-NAME decreases nitration o f  cardiac 
proteins by decreasing synthesis o f  nitric oxide, and the secondary formation o f  
reactive nitrogen species which cause nitration o f cardiac proteins. However, the 
mechanism by which N-acetylcysteine decreases nitration o f  proteins is unknown. 
One potential mechanism could be scavenging o f  reactive nitrogen species in vivo. To 
determine whether N-acetylcysteine scavenged and reduced the nitration potential o f  
reactive nitrogen species, rats were infused with [ H6 ]PHPA, and the formation o f  
[2 H 5]NHPA was measured by mass spectrometry. Biliary cirrhosis was associated 
with increased formation o f [ HsJNHPA following intravenous infusion o f  
[2 H6 ]PHPA (P<0.01; Fig. 4.12) consistent with increased formation o f reactive 
nitrogen species in rats with cirrhosis and nitration o f the phenolic ring o f  PHPA. 
However, administration o f N-acetylcysteine did not decrease the nitration o f  
[2 H6 ]PHPA in vivo (Fig. 4.12). An alternative potential mechanism ofN-acetylcystene 
could involve increased clearance and proteolysis o f nitrated proteins in vivo, since 
others have shown that nitration o f  proteins is associated with increased proteolysis o f  
the “abnormal" protein (Souza 2000). To test this, we hypothesized that increased 
proteolysis would increase levels o f  free nitrotyrosine in cardiac tissue. Therefore free 
nitrotyrosine levels were measured in cardiac ventricular tissue o f  normal rats as well 
those with cirrhosis ± treatment with N-acetylcysteine. We measured free 
nitrotyrosine in ventricular tissue, since the tissue concentration o f  free nitrotyrosine 
is very low ( < 2  pg/mg wet tissue), making it undetectable in small tissues such as rat 
atrium. However, free nitrotyrosine was easily measured in ventricular tissues and the 
levels were not significantly different in controls and rats with cirrhosis. However, the 
administration o f N-acetylcysteine led to a marked increase in the concentration o f  
free nitrotyrosine in the ventricular tissue in rats with cirrhosis (P<0.05; Fig. 4.11). 
Thus, whereas these data suggest N-acetylcysteine leads to increased proteolysis o f 
nitrated proteins, the mechanism remains unclear.
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Table 4.2. Comparison o f protein-bound nitrotyrosine levels between controls
Protein-Bound Nitrotyrosine (pg/pg tyrosine)
T issue C TR BDL P ( t - test)
Liver 63 ± 10 178 ± 4 0 <0.02
Atrium 16 ± 1 23 ±  3 <0.05
Ventricle 22 ±  9 57 ± 8 <0.05
Brain 9 ±  1 12 ± 3 ns
NOTE. Proteins were extracted from different tissues (liver, atrium, ventricle and 
brain) obtained from sham operated (control) or bile duct ligated (BDL) rats and 
analyzed by mass spectrometry. Levels are corrected for tyrosine. Data are Mean ± 
SEM. *P < 0.05, compared with control. 6 - 8  rats were used in each group, ns: non 
statistically significant.
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Figure 4.10. Protein-bound nitrotyrosine content o f atrial tissue obtained from control 
and rats with cirrhosis given saline, N-acetylcysteine (NAC; A), or L-NAME (B). (a) 
P < 0.05 compared with control, (b) P < 0.05 compared with saline-treated BDL rats.
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F igure 4.11. Protein-bound (upper panel, A-B) and free (lower panel, C-D) 
nitrotyrosine content o f ventricular tissue obtained from control and rats with cirrhosis 
treated with saline, N-acetylcysteine (NAC; A,C) or L-NAME (B,D). (a) P<0.05 
compared with controls, (b) P<0.05. (c) P<0.01 compared with saline-treated BDL 
rats. Protein-bound nitrotyrosine levels are expressed as a ratio to tyrosine (pg/pg).
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Figure 4.12. Assessment o f nitration reactions in vivo using deuterated PHPA 
([2 H6 ]PHPA) as probe. Injection o f  [2 H6 ]PHPA into rats with biliary cirrhosis leads to 
increased nitration o f PHPA and formation o f [2 H5]NHPA, which is excreted in urine. 
Pre-treatment o f animals with cirrhosis with N-acetylcysteine (NAC) did not decrease 
[2 H?]NHPA formation in vivo (A), and indicates that NAC does not work by 
scavenging reactive nitrogen species. However, L-NAME, which inhibits nitric oxide 
synthase, significantly reduced [2 Hs]NHPA formation in rats with cirrhosis (B). Data 
are expressed as mean ± SEM. 6 - 8  rats were used in each group. *P<0.01 compared 
with control groups. #P<0.05 in comparison with BDL (L-NAME) and control 
groups.
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Cardiac S-nitrosothiols.
To determine whether there was an increase in S-nitrosation o f cardiac proteins we 
measured the concentration o f S-nitrosothiols in cardiac tissue from control rats with 
cirrhosis with treatment with L-NAME or N-acteylcysteine, and rats with cirrhosis but 
without treatment. There was no difference in cardiac S-nitrosothiols following 
induction o f  cirrhosis, and neither N-acetylcysteine nor L-NAME had any effect on 
the cardiac levels o f  S-nitrosothiols (Table 4.3).
Cardiac F2 -isoprostanes.
The ratio o f esterified F2 -isoprostanes to arachidonic acid was significantly increased 
in cardiac tissue from rats with cirrhosis at 2.9 ± 0.5 ng/H-g AA (arachidonic acid) 
compared to controls (1.8 ± 0.2 ngMg AA, P<0.05), consistent with oxidative stress 
and increased lipid peroxidation in cardiac tissue. Treatment with either N- 
acetylcysteine or L-NAME had no significant effect on the tissue levels o f  F2 - 
isoprostanes (Table 4.3).
Table 4.3. Cardiac S-nitrosothiol and F2 -isoprostanes concentrations in control and 
cirrhotic rats treated with saline, N-acetylcysteine (NAC) or L-NAME.
C TR  BDL
Saline NAC L -N A M E Saline NAC L -N A M E
S-nitrosothiol (pmol/g) 5 6  ± 9 50 ± 9 49 ± 1 1  61 ± 7 53 ± 10 55 i 9
F;-isoprostanes ( n g p g  AA) : ()-2 1.6 t 0.2 l.x - 0.1 2.9 : 0.5 2.4 : 0.4 2.2 : 0.4
NOTE. F2 -isoprostanes are expressed as a ratio o f 8 -iso-PGF2 a to arachidonic acid 
(AA). S-Nitrosothiols are expressed as pmol/g o f  wet tissue. Data are Mean ± SEM.
* P <0 .05, compared with control (saline) group. 6 - 8  rats were used in each group.
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Immunogold electron microscopy studies
Representative electron micrographs from the atria o f controls and rats with cirrhosis 
are shown in Fig. 4.13. Myofibrillar and mitochondrial organelles are clearly visible. 
Black electron dense circles (5 nm gold particles) represent positively stained tissue 
for nitrotyrosine. In control images, relatively sparse immunostaining was observed, 
with roughly equal staining density between myofibrillar and mitochondrial 
compartments. However, an increase in staining o f myofibrillar and mitochondrial 
proteins in the atria o f rats with biliary cirrhosis was noted (Fig. 4.13).
B
Figure 4.13. Immunogold electron microscopy for nitrotyrosine in atria from control 
(A) and bile duct ligated (B) rats. Electron-dense circles indicate positive staining for 
nitrotyrosine.
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4.4 Discussion III
Recent studies have shown that indices o f depressed heart rate variability appear to 
predict adverse outcomes in patients with cirrhosis (Fleisher et al. 2000). The 
mechanisms that have been proposed for decreased heart rate variability include an 
imbalance in sympatho-vagal activation, abnormal baroreflex function and cirrhotic 
cardiomyopathy (Fig. 1.3), however the precise mechanism by which liver disease 
induces “regularisation” o f  heart rate variability in unclear.
In BDL rats, liver injury and the elevation o f serum transaminases peak at day 3 
following bile duct ligation. However portal hypertension and cirrhosis does not 
develop unitil weeks 3-4 (Bomzon et al. 1985). Most investigators use rats 4 to 6  
weeks after bile-duct ligation when portal hypertension is well established (Lee et al. 
1986). Animals usually die from sepsis or unexplained sudden death 6  weeks after 
bile dut ligation (unpublished observation). The present study showed that biliary 
obstruction in rats leads to a significant reduction in heart rate variations 4 and 5 
weeks after bile duct ligation. This shows that the decreased HRV and the 
development o f  liver cirrhosis are two parallel phenomena. In addition, three 
independent treatments (NOS inhibition, CB1 blockade and N-acetylcysteine) which 
lead to normalization o f cardiac chronotropic function were unable to restore the loss 
o f heart rate variability in cirrhotic rats. Likewise, decontamination o f  gut bacterial 
flora which normalizes heart rate variability in cirrhotic rats did not have a significant 
effect on impaired acceleration o f heart rate in response to 6 -adrenergic stimulation. 
These data demonstrate that decreased end-organ responsiveness to the B-adrenergic 
system does not play a role in the alteration o f HRV parameters following liver 
cirrhosis.
Bacterial translocation o f  gut flora into the portal circulation is well recognized in 
liver cirrhosis (see Wiest and Garcia-Tsao 2005 for review) and, in the presence o f  
both porto-systemic shunting and impaired clearance by the liver, has been implicated 
in the delivery o f endotoxins to the systemic circulation resulting in high local 
concentrations o f biologically active endotoxins capable o f activating the cytokine 
cascade. Loss o f HRV and increased heart rate regularity is a common feature o f 
systemic inflammatory conditions such as endotoxaemia (Mani et al. 2006a). In the 
present study decontamination o f gut bacterial flora normalized loss o f  HRV in
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cirrhotic rats which suggests that bacterial translocation o f  gut flora might have a role 
in decreased heart rate variability in biliary cirrhosis. We unexpectedly observed an 
increase in plasma nitrite + nitrate levels in cirrhotic rats treated with oral 
neomycin/polymixin B. This is in contrast with the traditional proposal that 
endotoxins from gut-derived bacterial translocation, causes induction o f iNOS leading 
to increased vascular NO production. In fact, we were unable to show a detectable 
induction o f iNOS in cardiac tissues obtained from BDL rats using conventional 
western blotting. To have a better picture o f the consequences o f intestinal 
decontamination in experimental cirrhosis, further studies are required using real time 
PCR to detect the expression o f NOS iso forms in different tissues as well as bacterial 
DNA (16S) in plasma and mesenteric lymph nodes.
Pentoxifylline, a xanthine derivative, is a known inhibitor o f TN F-a production 
(Strieter et al. 1988). Circulatory concentration o f  TNF-a is shown to be elevated in 
patients with cirrhosis (Yoshioka et al. 1989). Since TN F-a can blunt cardiac 13- 
adrenergic signalling we used pentoxifylline to test the hypothesis that elevation o f  
TN F-a decreases 13-adrenergic responsiveness and leads to a decrease in heart rate 
variability in cirrhotic rats. However, five days administration o f pentoxifylline to 
cirrhotic rats did not show any significant effect on HRV or impaired cardiac 
responsiveness to a 13-agonist. This suggests that TN F-a per se is not the ultimate 
mediator in the pathogenesis o f  cardiac dysfunction in BDL rats. We did not measure 
plasma TNF-a levels in control and BDL rats following pentoxifylline administration, 
thus further studies are required to rule out a role o f TN F-a in the genesis o f  cardiac 
dysfunction in cirrhosis. Although great strides in the last decade have helped to 
elucidate the pathways to systemic inflammation, single immunomodulatory therapies 
(e.g. anti-TNF-a antibodies) have failed to make a significant impact on the treatment 
o f circulatory dysfunction during inflammation (Abraham et al. 1998). Systemic 
inflammatory repsonse is an example o f a self-regulating complex system, with 
multiple cascading non-linear interactions and feedbacks. Alteration o f  heart rate 
dynamics in cirrhosis can be considered to be a reflection o f these non-linear 
interactions in the cardiovascular regulatory system.
Acceleration o f  the heart rate in response to catecholamines is impaired in cirrhosis. 
The endogenous ligand for the endocannabinoid CB1 receptor is anandamide which
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has a negative chronotropic effect on cardiac pacemaker cells via activation o f  CB1 
receptors (Krylatov et al. 2006). Although recent studies have shown that the 
endocannabinoid system is involved in the pathogenesis o f  cardiovascular dysfunction 
in liver disease (Batkai et al. 2001; Gaskari et al. 2005; Moezi et al. 2006), the 
possibility that impaired chronotropic response to catecholamines might relate to 
endocannabinoid signalling does not seem to have been considered in the studies 
undertaken to date. The present study showed that the impaired responsiveness o f  
isolated atrium was normalized by treatment o f cirrhotic animals with AM251 for four 
days (3 mg/kg). There was a significant up-regulation o f  CB1 receptors in atria 
obtained form cirrhotic rats compared with controls as assessed by immuoblotting. 
The effects o f  AM251 is not attributable to down-regulation o f  NO synthesis because 
the plasma concentrations o f nitrite + nitrate (NO end-products) were still 
significantly elevated in rats with cirrhosis treated with AM251 whereas L-NAME 
significantly decreased nitrate/nitrite concentrations in both groups. It seems that CB1 
receptors might have a role in the pathogenesis o f cirrhosis-associated cardiac 
chronotropic incompetence in cirrhosis and this effect appeared to be independent o f 
nitric oxide signalling and changes in autonomic nervous system as determined by 
analysis o f heart rate variability
This study confirms the observation that cardiac chronotropic function is abnormal in 
rats with biliary cirrhosis. More importantly, it demonstrates that this abnormality is 
associated with increased levels o f  protein-bound nitrotyrosine in cardiac tissue. The 
administration o f  either L-NAME or N-acetylcysteine, both o f which decrease the 
tissue levels o f  nitrotyrosine, led to normalization o f heart rate as well as cardiac 
responsiveness to adrenergic stimulation in rats with biliary cirrhosis. In patients with 
cirrhosis, although resting tachycardia is part o f the feature o f the hyperdynamic 
circulation, manoeuvres leading to sympathetic activation (e.g., ice-cold skin 
stimulation, mental stress, tilting and physical exercise), do not evoke an adequate 
acceleration o f heart rate compared with healthy subjects (Bemardi et al. 1987; 
Bemardi et al 1991, Wong 2001). Conversely, when the sympathetic responses to 
tilting or exercise are assessed by the plasma concentrations o f norepinephrine, the 
sympathetic response is enhanced (Bemardi et al. 1987; Bemardi et al 1991). This 
finding suggests the defect in cardiac responsiveness is located at the receptor and/or 
post receptor level. This notion is supported by the findings o f several studies
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assessing the effects o f  13-adrenergic agents. For example, in patients with cirrhosis, 
the ED25 o f isoproterenol is reported to be threefold higher than healthy controls 
(Ramond et al. 1986). Rats with biliary cirrhosis are bradycardic, and this condition is 
owing to a significant hypo-responsiveness to the chronotropic effect o f 
catecholamines (Nahavandi et al. 1999; Mani et al. 2002). In the present study, we 
showed that two independent treatments (N-acetylcysteine and L-NAME), both o f 
which can normalize chronotropic responses to adrenergic stimulation in vitro, also 
led to normalization o f heart rate in vivo (Fig. 4.4). Moreover spectral analysis o f  
HRV showed increased cardiac sympathetic activity in rats with cirrhosis, which was 
unchanged following either L-NAME or N-acetylcysteine treatment in rats with 
cirrhosis (Mani et al. 2006b). These data suggest impaired end-organ responsiveness 
to adrenergic stimulation may have a role in pathogenesis o f cardiac chronotropic 
dysfunction in cirrhosis and the effects o f L-NAME and N-acetylcysteine are 
independent o f changes in autonomic nervous system activity.
The mechanism o f tyrosine nitration in proteins under pathological conditions is an 
area o f active investigation. It can occur through the formation o f peroxynitrite or 
nitryl chloride, formed by the reaction o f nitric oxide and hypochlorous acid, both o f 
which can react with tyrosine in proteins to form nitrotyrosine (Baldus et al. 2001). 
Biliary cirrhosis is associated with enhanced nitric oxide production (Liu et al. 2000). 
Nitric oxide reacts rapidly with superoxide anion (O2 ") to form peroxynitrite which 
can nitrate tyrosine residues in proteins. There is now good evidence that liver disease 
is associated with oxidative stress and increased formation o f  reactive oxygen species 
(Marley et al. 1999; Ljubuncic 2000). Ljubuncic et al. (2000) reported an increased 
formation o f  lipid peroxidation products in the cardiac tissue o f rats with biliary 
cirrhosis compared with controls. This finding may be partly owing to enhanced 
generation o f superoxide by NADPH oxidase in response to angiotensin II (Pagano et 
al. 1997), endothelin (Barton et al. 1997), or bile acids (Bomzon et al. 1997). The 
observation that there is increased tyrosine nitration in cirrhosis in liver as well as 
cardiac tissue, but not in brain suggests that nitrative stress is a generalized 
phenomenon in cirrhosis, which can involve different organs including liver and 
cardiovascular system. In the liver, for instance, it has recently been shown that
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tyrosine nitration contributes to inactivation o f  hepatic glutamine synthetase which in 
turn leads to the development o f hyperammonemia in rats with cirrhosis and sepsis 
(Gorg et al. 2005).
Fernando et al. (1998) have previously observed that administration o f  N- 
acetylcysteine normalizes the systemic haemodynamic abnormalities in rats with 
portal hypertension, and lipoic acid (another low molecular weight thiol antioxidant) 
had a similar effect in rats with chronic bile duct ligation (Marley et al. 1999). 
Therefore, we investigated whether N-acetylcysteine could improve cardiac function 
in rats with biliary cirrhosis, and made the critical observation that administration o f  
N-acetylcysteine led to normalization o f  bradycardia in vivo, as well as improved 
cardiac responses to adrenergic stimulation in vitro (Figs. 4.4 and 4.8). These data are 
o f interest, because they have therapeutic implications, even though the mechanisms 
involved remain poorly understood. We observed that both N-acetylcysteine and L- 
NAME can each markedly decrease the levels o f tissue nitrotyrosine. Because 
nitration o f tyrosine can alter the protein's function, these data suggest nitration o f  
cardiac proteins may lead to abnormal cardiac responses in cirrhosis. Reactive 
nitrogen species can also react with cysteine residues in proteins to form S-nitrosated 
proteins. Therefore, we also measured the levels o f S-nitrosothiols in cardiac tissue o f  
rats with biliary cirrhosis; however there were no significant differences in cardiac 
levels o f  S-nitrosothiols between controls and rats with cirrhosis.
Both L-NAME and N-acetylcysteine can modulate the cardiac function and decrease 
cardiac nitrotyrosine levels in biliary cirrhosis. However, the effects o f  N- 
acetylcysteine is not attributable to downregulation o f NO synthesis because the 
plasma concentrations o f nitrite + nitrate (NO end-products) were still significantly 
elevated in rats with cirrhosis treated with N-acetylcysteine whereas L-NAME 
significantly decreased nitrate/nitrite concentrations in both groups (Fig. 4.6). The 
decrease o f protein-bound nitrotyrosine after N-acetylcysteine treatment may be 
related to the ability o f  N-acetylcysteine, to either inhibit the formation o f  reactive 
nitrogen species or to increase the proteolytic degradation o f  the nitrated proteins. 
Using [2 H6]PHPA as a probe to study formation o f reactive nitrogen species in vivo, 
we could initially show enhanced nitration reactions in vivo and a corresponding 
increased formation o f its nitrated product [2 H5]NHPA in rats with cirrhosis.
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However, based on this approach, we were unable to show decreased reactive 
nitrogen species formation following N-acetylcysteine administration as the urinary 
levels o f [ 2 H5]NHPA were un-changed in N-acetylcysteine treated animals (Fig. 4.12). 
Because these data suggest N-acetylcysteine does not scavenge reactive nitrogen 
species in our model, the effect o f N-acetylcysteine on nitrotyrosine levels could be 
explained if it enhances the degradation o f  nitrated proteins. Souza et al. have shown 
that nitration o f  tyrosine residue(s) in proteins is sufficient to induce an accelerated 
degradation o f the modified proteins to release free amino acids as well as free 
nitrotyrosine (Souza et al. 2000). This study suggested that if N-acetylcysteine 
increased proteolysis o f  nitrated proteins then free nitrotyrosine levels may be 
increased in animals treated with N-acetylcysteine. This finding was confirmed when 
the levels o f  free nitrotyrosine were measured in cardiac ventricular tissue and found 
to be increased (Fig. 4.11). This outcome suggests that N-acetylcysteine may 
upregulate proteolytic degradation o f  proteins containing nitrotyrosine leading to a 
decrease in protein-bound nitrotyrosine content and corresponding to an increase in 
free nitrotyrosine levels, and is consistent with reports that cellular redox state is a 
major modulator o f proteosme activity both in vivo and in vitro (Jahngen-Hodge et al. 
1997; Obin et al. 1998).
The mechanism by which protein nitration leads to abnormal cardiac function in 
cirrhosis is not clear, however a very similar mechanism has been recently postulated 
in cardiac dysfunction associated with high aldosterone levels (Sun et al. 2002). Sun 
et al. (2 0 0 2 ) have recently shown that chronic aldosterone/salt treatment is associated 
with a time-dependent generation o f nitrotyrosine in cardiomyocytes, which was 
attenuated by the administration o f  N-acetylcysteine. The concept that nitration o f  
cardiac proteins leads to cardiac dysfunction has also been described in AIDS-related 
cardomyopathy (Chaves et al. 2003), and diabetes-associated cardiac dysfunction 
(Turko et al. 2003). Therefore, the development o f new therapies, which prevent or 
modify nitration o f cardiac proteins in cirrhosis, may have important implications in 
other types o f cardiac dysfunction associated with systemic inflammation such as 
sepsis. Whereas the observation that increased nitration o f cardiac proteins in cirrhosis 
is o f  interest, the question arises which proteins are nitrated and are they functionally 
important? In a recent report, Kanski et al. (2005) employed a proteomic approach to 
identify the cardiac proteins that undergo age-dependent protein tyrosine nitration.
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Among the identified proteins are important mitochondrial enzymes responsible for 
ATP production and metabolism; desmin, which is involved in sliding o f  myocardial 
filaments and cardiac contraction, is also included (Kanski et al. 2005). Although we 
have tried to identify which proteins are nitrated in the current study (data not shown), 
we have not been able to obtain reproducible data, and at present the identity o f  the 
nitrated proteins remains unknown. However, the immunogold studies also suggest 
that cytoskeletal and mitochondrial proteins are targets for nitration in the atria o f  rats 
with cirrhosis. We conclude that cirrhosis leads to increased nitration o f  cardiac 
proteins, oxidation o f  cardiac lipids, and abnormal cardiac function. The observation 
that two independent treatments, which decrease cardiac nitrotyrosine levels, also lead 
to normalization o f cardiac function, suggests nitration o f cardiac proteins may lead to 
abnormal cardiac function.
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Chapter 5. Decreased heart rate variability in patients with cirrhosis
5.1 Introduction
Decreased heart rate variability (HRV), or increased regularity o f  the cardiac rhythm, 
has been reported in number o f clinical settings associated with increased production 
o f inflammatory cytokines, for example sepsis, systemic inflammation and ischaemic 
heart disease, (Aronson et al. 2001; Griffin et al. 2005; Hamaad et al. 2005; Lanza et 
al. 2006) and in several neuropsychiatric conditions, for example, depression (Kim et 
al. 2005; Vigo et al. 2004) dementia (Kim et al. 2006; Zulli et al. 2005) and 
symptomatic relapse in major psychoses (Kim et al. 2004).
HRV is also decreased in patients with chronic liver disease (Hendrickse et al. 1992; 
Lazzeri et al. 1997; Fleisher et al. 2000; Coelho et al. 2001; Ates et al. 2006) and is a 
negative predictor o f outcome in this patient population (Hendrickse et al. 1992; Ates 
et al. 2006). Plasma concentrations o f inflammatory cytokines are increased in 
patients with cirrhosis, even in the absence o f  active infection (Tilg et al. 1992; 
Genesca et al. 1999) and this activation o f inflammatory mediators might explain the 
decrease in HRV observed in these patients. However, while there is a clear positive 
correlation between plasma levels o f the inflammatory cytokines and the degree o f 
hepatic dysfunction (Tilg et al. 1992; Genesca et al. 1999) the relationship between 
HRV and the degree o f hepatic decompensation is much less robust.
The possibility that the changes in HRV observed in patients with cirrhosis might 
relate to the presence and degree o f  hepatic encephalopathy does not seem to have 
been considered in the studies undertaken to date. The pathogenesis o f hepatic 
encephalopathy remains unknown but recent interest has focused on the potential role 
o f inflammatory mediators (Blei 2004; Shawcross et al. 2004; Jover et al. 2006; 
O'Beirne et al. 2006). Indeed serum levels o f  inflammatory cytokines have been 
shown to positively correlate with the severity o f hepatic encephalopathy in this 
patient population (Genesca et al. 1999; Odeh et al. 2004; Odeh et al. 2005).
In this chapter, the relationship between HRV, assessed using both linear and non­
linear dynamics, and neuropsychiatric performance, was assessed in patients with
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cirrhosis to test the following hypotheses:
1. The decreased in HRV correlates with the presence and degree o f  hepatic 
encephalopathy, independently o f  the degree o f  hepatic impairment.
2. The relationship between HRV and hepatic encephalopathy is based on a common 
pathogenic mechanism, mediated by inflammatory cytokines.
124
5.2. Materials and methods IV
Study Subjects
The patient population comprised 75 individuals (51 men: 24 women) o f mean (± SD) 
age 55 ± 9 years, with biopsy-proven cirrhosis. The aetiology o f the liver lesion was 
determined on the basis o f  clinical, laboratory, radiological and histological variables. 
Patients were excluded from the study if they were under 16 or over 80 years o f  age; 
could not speak English or obey spoken commands; had misused alcohol in the 
preceding three months; had a history o f insulin-dependent diabetes mellitus, 
significant head injury, cardiovascular/cerebro-vascular disease or arterial 
hypertension; or were taking neuroactive drugs or drugs known to affect the cardiac 
rhythm, other than propranolol. The reference population comprised eight healthy 
volunteers (three men: five women) o f  mean age 40 ± 12 years. None had a history, 
clinical or laboratory evidence o f  alcohol misuse, chronic liver disease or heart 
disease; none drank alcohol in excess o f 2 0  g/day or took prescription medication.
Ethics
The study was conducted according to the Declaration o f  Helsinki (Hong Kong 
Amendment) and Good Clinical Practice (European guidelines). The protocol was 
approved the Royal Free Hampstead NHS Trust Ethics Committee. All participating 
subjects, or their appropriately appointed guardian, provided written, informed 
consent for study participation.
Assessment o f  the severity o f  hepatic dysfunction (Child score)
The functional severity o f the liver injury was assessed using Pugh’s modification o f  
the Child’s grading system (Pugh et al., 1973). The Child score is a grading system 
which was originally developed by Child and Turocotte (1964) to predict mortality 
during surgery in patients with cirrhosis. It is now widely used to determine the 
functional severity o f the liver injury, as well as the necessity o f  liver transplantation. 
The score employs five clinical measures o f  liver disease. Each measure is scored 1-3, 
with 3 indicating most severe derangement as shown in Table 5.1. Chronic liver 
disease is classified into Child class A, B and C, employing the added score from the 
table. When the total score is 6  or less, the patient is classified as Child A. When the 
score is more than 6  and less than 10, the patients in classified into Child B category 
and patients with Child C usually represent a score equal to or above 10.
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Table 5.1. Modified Child Classification o f severity o f  liver disease according to the 
degree o f ascites, the plasma concentrations o f  bilirrubin and albumin, the 
prothrombin time (NIR), and the degree o f encephalopathy (HE).
Measure 1 point 2 points 3 points
Bilirubin (/ymol/L) <34 34-50 >50
S e ru m  album in  (g/L) >3.5 2.8-3.5 <2.8
INR
(international normalized ratio)
<1.7 1.71-2.20 >2.20
A scites None Suppressed with medication
Refractory
Clinical HE None Overt HE grade l-ll Overt HE grade lll-IV
Assessment o f  neuropsychiatric status
Patients’ mental state was evaluated using the West Haven criteria (Conn et al., 
1977a). Psychometric performance was assessed, under standardized conditions, by 
the same observer, using Number Connection Tests A (NCT-A) and B (NCT-B) 
(Conn et al., 1977b), the Digit Symbol (DS) subtest o f the Wechsler Adult 
Intelligence Scale (Wechsler, 1955) and the Line Tracing (LT) and Serial Dotting 
(SDot) tests (Hamster, 1983; Schomerus et al., 1999). Psychometric test results were 
scored in relation to age- and education-adjusted reference values (Weissenbom et al., 
2001; Amodio et al., 2002) and were considered abnormal if they exceeded two 
standard deviations o f the mean reference values. Psychometric performance was 
classified as impaired if the sum o f  the standard deviations equalled or exceeded four. 
Electroencephalograms (EEGs) were recorded, eyes closed, in a condition o f  relaxed 
wakefulness, using silver-silver chloride electrodes placed according to the 
International 10-20 system (Walter-Graphtec system equipment). The traces were 
analysed visually to exclude abnormal focal activity; they were then subjected to 
automated spectral analysis and classified according to Amodio et al. (Amodio et al., 
1999). Neuropsychiatric status was classified as (i) unimpaired: individuals who had 
no clinical evidence o f hepatic encephalopathy and no defining EEG or psychometric 
abnormalities; (ii) minimal hepatic encephalopathy: individuals who showed no 
clinical evidence o f  hepatic encephalopathy but had an abnormal EEG and/or
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impaired psychometric performance; (iii) overt hepatic encephalopathy: individuals 
with clinically evident neuropsychiatric disturbances (Conn et a l, 1977a).
Assessment o f  HR V 
Data acquisition
A 10-minute, single channel electrocardiogram (ECG) was recorded simultaneously 
with the EEG by placing one silver-silver chloride electrode on each wrist (WG 
PLEEG system). The ECG data were exported - sampling rate 256 Hz - and an ad  
hoc computer program was used to detect the R peaks and to generate the R-R interval 
series. Visual inspection o f all R-R intervals was performed and artefacts removed by 
careful manual editing by a single observer. Five-minute, artefact-free continuous R- 
R interval sections were selected for further analysis (Task Force report on HRV, 
1996).
Linear analysis o f  HRV
The standard deviation o f the R-R intervals (SDNN) was calculated on the selected 
artefact-free traces and used as a measure o f total HRV. Spectral analysis o f  the R-R 
interval time series was carried out by fast Fourier transformation on 1024 sample 
points, applying Welch’s window, using software developed by Niskanen et al. 
(Niskanen et al. 2004). Two bands were identified: i) a low frequency component 
(LF: 0.04-0.15 Hz), which reflects the oscillatory pattern o f the baroreflex loop and is 
jointly mediated by sympathetic and parasympathetic activities (Altimiras 1999) and 
ii) a high frequency component (HF: 0.15-0.40 Hz), which reflects the inhibition o f  
the vagal tone during inspiration (Altimiras, 1999). The LF/HF ratio was calculated 
and used as a measure o f sympatho-vagal balance (Altimiras 1999).
Non-linear analysis o f  HR V
While linear measures o f HRV simply describe the amount o f variability, nonlinear 
HRV analysis attempts to capture the structure or complexity o f the R-R time series. 
Thus, a physiological series o f  heart beats, a random series o f  beats, and a totally 
periodic series o f  beats might have the same SDNN, but their underlying structure o f  
the series will be completely different.
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Poincare plot: The Poincare plot is a graphical representation o f  the 
correlation between consecutive R-R intervals [x axis: R-R<n); y axis: R-R<n+i): Fig. 
4.2]. If the cardiac rhythm is regular, the points on the Poincare plot are located close 
to the line o f  identity. The standard deviation o f  the points perpendicular to the line- 
of-identity (SD1) describes short-term variability, which is mainly related to 
respiratory sinus arrhythmia (Tulppo et al. 1996); the standard deviation along the 
line-of-identity (SD2) describes the long-term R-R interval variations and accounts 
for all other heart rate changes, including those associated with sympathetic 
oscillations, barorefelx loop, thermoregulation and fluctuations in humoral factors 
(Tulppo et al. 1996). The parameters SD1 and SD2 were calculated using the software 
developed by Niskanen et al. (Niskanen et al. 2004).
Sample entropy: The sample entropy (SampEn) is a parameter that quantifies 
the degree o f regularity versus the degree o f  unpredictability o f  a time series. SampEn 
is the logarithmic likelihood o f the repetition o f patterns in the time series; it 
calculates the probability that an epoch o f window length m, with a degree o f  
tolerance r, will be repeated at later time points. Regular time series are characterised 
by low SampEn, while random time series are characterised by high SampEn. In the 
present study, m was fixed at 2 and r at 0.2 ms. (Richman and Moorman, 2000).
Measurement o f  Cytokines Concentration
Plasma samples were collected from a subgroup o f 22 patients with cirrhosis and 
varying degrees o f  hepatic encephalopathy and were kept at -80 until analysed for 
TNF-a, IL-6 , IL-10 and IL-12 using eBioscience ELISA kits (San Diego, CA, USA) 
on Nunc Maxisorb ELISA plates according to the manufacturer's instructions by a 
single investigator, in duplicate, on a single plate for each cytokine to reduce assay 
variability. A standard curve provided by the manufacturer and a quality control 
serum were included on each ELISA plate.
Statistical analysis
The results are presented as mean ± SD. The distributions o f  variables were tested for 
normality using the Shapiro-Wilk’s W test. Differences between normally distributed 
variables were examined by one way ANOVA/ANCOVA, including, where
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necessary, adjustments for the degree o f vagal modulation (SD1, HF); subsequent 
between group comparisons were performed using the Tukey test. Differences 
between non-normally distributed variables were examined using the Kruskal-Wallis 
tests; subsequent between group comparisons were performed using Dunn's test. 
Factorial ANOVA was used to examine the extent to which variable sets differed 
according to the degree o f hepatic and neuropsychiatric impairment. Correlations 
between HRV indices, psychometric performance, EEG spectral variables and 
cytokine levels were tested using the Spearman's R coefficient o f correlation. The 
relationship between HRV indices and survival was examined using Cox’s 
proportional hazards model
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5.3. Results IV
The aetiology o f the cirrhosis was alcohol in 60 (80%); alcohol plus HBV, HCV 
infection in five (7%), cryptogenic in three (4%); non alcoholic steatohepatitis in two 
(3%); primary biliary cirrhosis in two (3%) and chronic hepatitis C infection, chronic 
autoimmune hepatitis and haemochromatosis in one each (1%). Functionally, 43 
(57%) o f the patients were classified as Child’s Grade A, 12 (16%) as Child’s Grade 
B, and 20 (27%) as Child’s Grade C. On the day o f study, 37 (49%) o f the 75 patients 
were classified as neuropsychiatrically unimpaired, eight ( 1 1 %) as having minimal 
hepatic encephalopathy and 30 (40%) as having overt hepatic encephalopathy.
There were no significant differences in mean heart rate between patients and healthy 
controls (Table 5.2). However, HRV was significantly decreased in the patient 
population, whether assessed using linear (SDNN P<0.01; LF P<0.05) or non-linear 
indices (SD1 P<0.05, SD2 P 0 .0 0 1 , SampEn P<0.001) (Table 5.2). Sympathovagal 
balance (as assessed be measuring LF/HF) was significantly increased in the patients 
with cirrhosis compared to the healthy controls, P<0.05 (Table 5.2).
As shown in Table 5.2, we found that among all HRV parameters, SD2 (long-term 
HRV) showed the strongest correlation with degree o f  HE. The striking observation 
was that when we applied multiple analysis o f  variance, the association between SD2 
and the degree o f hepatic encephalopathy was independent o f the degree o f  hepatic 
dysfunction (Fchiid=0.267, P=0.76; F He = 4 . 8 0 1 ,  P<0.05; Fcwid and h e = 0 .4 1 5 ,  P=0.79). 
Details o f  this finding are illustrated in Figs. 5.1, 5.2 and 5.3.
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Table 5.2. Heart rate variability indices in healthy volunteers and patients with cirrhosis by degree o f hepatic encephalopathy (HE) and 
degree o f hepatic dysfunction (Pugh et al, 1973).
Age
(yr)
Pugh’s score HR-Mean(beat/min)
SDNN
(ms)
LF
(m s2)
HF
(m s2) LF/HF
SD1
(ms)
SD2
(ms) SampEn
Healthy volunteers 
(n=8) 40 ± 12 - 67.4 ± 11.0 36.2±  11.3
184 ± 113 199 ±226 1.4 ±0.8 23.4 ± 12.1 56.1 ±11.8 2.90 ±0.33
Patients with cirrhosis 
(n=75) 55 ± 9 M 7.5 ± 2.5 75.8 ± 12.9 19.4 ± 9.5 88
58 ± 60 8 48± 69 2.2 ± 1.7 8 11.3 ± 7 .8 8 31.8 ± 15.5 888 2.25 ± 0.618"
Unimpaired
(n=37) 53 ± 6 “ 5.7 ± 1.8 74.4 ± 12.1 22.5 ± 10.3 88 74 ± 72 66 ± 85 2.0 ± 1.2 13.2 ± 8 .5 " 37.6 ± 15.2" 2.42 ±0.61
Minimal HE 
(n=8) 61 ±6  “ 8 6.1 ±1.7 71.6 ± 12.2 23.8 ± 9.6 8 77 ± 56 46 ± 56 3.6 ±3.1 12.6 ± 7 .3 8 35.9 ± 13.3 8 2.40 ± 0.73
Overt HE 
(n=30) 55 ± 11 8 10.0 ± 2 .7 bbb 78.5 ± 14.2 14.3 ± 7.1 888bb 33 ± 4 9 888 bb 26 ± 38 “ 8 2.1 ±2.1 8.5 ±6.0*“ 23.5 ± 11.5 "*bt* 2.01 ±0.54 “ b
R 0.11 -0.40*** -0.39*** -0.28* -0.06 -0.30** -0.44*** -0.29*
Child A 
(n=43) 56 ± 7 888 5.2 ±0.65 74.4 ± 11.8 21.7 ±9.8 88 65 ± 6 5 “ 59 ± 78 8 2.4 ±2.0 12.6 ± 8 .5 88 39.9 ± 14 .4“ 2.38 ± 0.65
Child B 
(n=12) 59 ± 10 888 8.2 ± 0 .34ccc 74.2 ±11.1 18.4 ± 10.0 888 70 ± 5 9 “ 47 ± 59 8 2.7 ±2.4 10.6 ± 6 .6 “ 28.9 ± 13.8 8“ 2.10 ± 0 .4 8 “
Child C 
(n=20) 50 ± 9 8 11.9 ± 0.9 c“ 79.6 ± 16.1 14.9 ± 8.5 888
36 ± 67 a“ 24 ± 31 88 1.5 ± 1.3 8.7 ± 5.8 888 24.6 ± 15.2 8" 2.06 ± 0.58 88
R 0.12 -0.32* -0.38*** -0.18 -0.20 -0.22 -0.32*** -0.21
Significance
of the differences between the patient population/subpopulations and the healthy volunteers: aP <0.05; ^P  <0.01; 333 P <0.001 
Significance o f the differences between the patients with no HE and those with minimal/overt HE: bP <0.05; bbP <0.01; bbbP <0.001 
Significance o f  the differences between the patients with Child C and those with Child A/B: CP <0.05; CCP <0.01; CCCP <0.001
R: Spearman’s R correlation coefficient between the degree o f HE/hepatic failure and heart rate variability indices in patients with cirrhosis: p<0.05; 
" P O .O l, *** P 0 .0 0 1
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The relationship between long-term HRV (SD2) and the degree o f neuropsychiatric 
impairment held firm even when data were adjusted for indicators o f  vagal 
modulation, namely SD1 and LF (Table 5.3).
As shown in Fig 5.4, significant correlations were observed between HRV indices and 
individual psychometric and spectral EEG variables.
Table 5.3. The relationship between long-term HRV (SD2) and the degree o f  
neuropsychiatric impairment in patients with cirrhosis adjusted for indicators o f  vagal 
modulation o f HRV. Data are expressed as covariate-adjusted.
HRV Parameter Corrected for Covariate mean
HE Classification
F (2,71) P-value
Unimpaired Minimal HE Overt HE
SD2 SD1 11.28 (ms) 35.2 ± 1.7 34.3 ±3.6 26.9 ± 1.9 5.39 0.006
SD2 HF 47.76 (ms2) 35.5 ± 1.7 35.5 ± 3.8 26.6 ± 1.9 5.88 0.004
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F igure 5.1. Poincare plots depicting the correlation between consecutive R-R 
intervals, in four representative patients with cirrhosis, by degree o f  hepatic 
dysfunction and neuropsychiatric status. SD1 and SD2 represent the length and width 
o f the Poincare plot along the line-of-identity, respectively. Diminished scattering o f  
the plot is the hallmark o f a decrease in HRV. The Poincare plot is less scattered in 
patients with overt hepatic encephalopathy (right panel) compared with patients who 
are neuropsychiatrically unimpaired (left panel), independently o f  the degree o f  
hepatic dysfunction.
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Child-A
Figure 5.2. Long-term heart rate variability (SD2, Mean values) in patient with liver 
cirrhosis. Patients are categorized based on both degree o f liver dysfunction (child) 
and hepatic encephalopathy (HE).
Factorial Design for the effect of HE score on SD2
F(2,66)= 4.80, P=0.011
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Figure 5.3. Factorial analysis o f  
long-term HRV (SD2) in patients 
with cirrhosis adjusted for 
neuropsychiatric status (HE) or 
degree o f liver dysfunction 
(Child).
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Figure 5.4. Correlation o f  long-term heart rate variability index (SD2) and 
selected psychometric/EEG variables in patients with cirrhosis.
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Significant correlations were observed, in the patients with cirrhosis, between both 
linear and non-linear HRV indices and plasma concentrations o f IL- 6  (P<0.05; Table 
5.4). Similarly, significant correlations were observed between psychometric 
variables and plasma TN F-a and IL- 6  concentrations (P<0.05; Table 5.4).
Nine patients died during the follow-up period and two underwent orthotopic liver 
transplantation. There was a significant relationship between SD2 and survival (P = 
0.01); the relative risk o f  death increased by 7.7% (95% Cl, 1.8-13.6) for every ms 
drop in SD2.
Table 5.4. Correlations between plasma cytokine levels and heart rate 
variability/hepatic encephalopathy indices in patients with cirrhosis.
T N F -a IL -6 IL -1 0 IL -1 2
P sychom etric perform ance
NCT-A (s) 0.36 0.45 0.24 -0.06
NCT-B (s) 0 .46 0.32 0.29 -0.22
SDot (s) 0.18 0.48 0.084 -0.14
HRV index
SDNN (ms) -0.34 -0.43 -0.34 -0.00
SD1 (ms) -0.33 -0.28 -0.20 -0.09
SD2 (ms) -0.35 -0.49 -0.40 0.07
SampEn -0.38 -0.25 -0.28 0.02
NOTE: Values are correlation coefficients (Spearman’s R); values in bold typeface are 
significant, P<0.05
136
5.4. Discussion IV
Healthy, physiological control o f cardiovascular function is the result o f  complex 
interactions between multiple regulatory processes that operate over different time 
scales. Techniques derived from non-linear dynamics are now being adapted to 
quantify the behaviour o f physiologic time series and to study their changes with age 
and disease (Goldberger et al. 2002). In the present study both linear and non-linear 
methods were used to analyse heart rate dynamics in patients with cirrhosis and 
showed that: 1) HRV is markedly decreased in this patient population compared with 
the healthy controls; 2) Changes in HRV is patients with cirrhosis correlate 
significantly with the severity o f their neuropsychiatric impairment and this 
correlation is independent o f the degree o f hepatic dysfunction; 3) Non-linear 
measures o f  HRV correlate significantly with stand-alone EEG and psychometric 
variables; 4) Plasma levels o f IL - 6  correlate significantly with both indices o f  heart 
rate variability and neuropsychiatric variables in this patient population.
The relationship between decreased HRV and the degree o f hepatic failure is well 
established (Fleisher et al. 2000; Ates et al. 2006). It has also been reported that 
reduced HRV is an independent risk factor for death in cirrhotic patients (Hendrickse 
et al. 1992, Fleisher et al 2000, Ates et al. 2006). The present study demonstrates that 
degree o f neuropsychiatric impairment is more strongly correlated with HRV 
parameters than the degree o f hepatic dysfunction. When the patients were 
categorized by both the Child score and the degree o f hepatic encephalopathy, the 
correlation between reduced HRV and the degree o f hepatic failure disappeared, while 
that between reduced HRV and HE remained significant (Fig 5.2 and 5.3). To our 
knowledge, this is the first study to show that reduced HRV is an independent 
predictor o f  HE in patients with cirrhosis. This is in line with a recent study by 
Newton et al. (2006), showing that HRV was significantly lower in fatigued than in 
non-fatigued patients with primary biliary cirrhosis (Newton et al. 2006). There were 
significant correlations between HRV indices and EEG spectral parameters, 
psychometric variables as well as plasma cytokine levels in patients with cirrhosis. 
These data further support a relationship between neuropsychiatric status and 
decreased HRV in this patient population. These findings are also consistent with 
those o f previous studies showing a correlation between HRV parameters and 
neuropsychiatric abnormalities in different clinical settings, such as depression in
137
patients with ischemic heart disease (Vigo et al 2004), postmenopausal women (Kim 
et al. 2005) and negative symptoms in patients with schizophrenia (Kim et al. 2004).
The physiological mechanism underlying reduced HRV during systemic 
inflammatory response is not known but seems likely to represent dysfunction o f  the 
autonomic nervous system or o f  intracellular signal transduction processes, perhaps 
by circulating cytokines (Kuster et al. 1998, Pavlov et al. 2006). Malave et al. (2003) 
have recently shown that circulating levels o f cytokines correlate with indices o f 
depressed HRV in patients with congestive heart failure (Malave et al. 2003). Since 
inflammatory cytokines can potentially blunt B-adrenergic signalling (Chung et al., 
1990), Malave et al. have also suggested the possibility that over-expression o f  TN F-a 
and subsequent loss o f  B-adrenergic responsiveness contributes to the decrease in 
HRV observed in heart failure (Malave et al., 2003). However, our recent report has 
shown that decreased HRV following endotoxin challenge is independent o f  impaired 
cardiac B-adrenergic signalling in septic mice (Mani et al. 2006a). In addition our 
recent report suggests that loss o f  HRV in animal models o f cirrhosis is not related to 
impaired cardiac B-adrenergic responsiveness observed in cirrhotic rats (Mani et al. 
2006b, Chapter 4). Here we have shown that plasma levels o f  IL- 6  correlate 
significantly with both indices o f  heart rate variability and neuropsychiatric variables 
in patients with cirrhosis. This data do not provide an explicit mechanism for the 
association between IL - 6  and slow R-R oscillations. However it is line with a study by 
Aronson et al. (2001) who showed that plasma IL-6 , and not TNF-a, levels inversely 
correlated with indices o f  reduced HRV in patients with decompensate heart failure. 
Other groups have also shown that amongst the cytokines, IL - 6  exhibit the strongest 
correlation with the indices o f  depressed HRV during inflammation (Gonzalez- 
Clemente et al. 2007, Tateishi et al. 2007). However the mechanism by which IL - 6  
might affect autonomic control o f  cardiac cycle needs further inverstigation.
Although great strides in the last decade have helped to elucidate the mechanism o f  
inflammatory response, the precise mechanism by which inflammation induces 
‘regularisation’ o f  heart rate variability remains elusive. Systemic inflammatory 
response is an example o f  a self-regulating complex system, with multiple cascading 
non-linear interactions and feedbacks, acting in series and in parallel, to form a ‘scale- 
free’ network. Alteration o f heart rate dynamics during inflammation can be
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considered to be a reflection o f these non-linear interactions in the cardiovascular 
regulatory system. Regardless o f the mechanism, these findings are important in 
clinical medicine, as HRV can potentially be considered a candidate measure for 
monitoring at risk patients, either alone or as part o f a multivariable scheme.
HRV analysis has extensively been used to assess autonomic neuropathy in difference 
clinical settings (see Task Force report 1996 on heart rate variability for review). 
Because HE is frequently precipitated by constipation, it has been proposed that 
autonomic dysfunction may contribute to the development o f HE by decreasing gut 
motility and increasing exposure to gastrointestinal bacteria (Maheshwari et al. 2004). 
To address this issue most researchers has assessed autonomic neuropathy by looking 
at heart rate response to deep breathing or Valsalva manoeuvre, which are indirect 
measures o f vagal activity. These studies have shown that vagal neuropathy is 
common in cirrhosis regardless o f the aetiology o f liver disease (Hendrickse et al, 
1992, Fleisher et al. 2000, Maheshwari et al. 2004). In addition, there is a trend 
towards a higher incidence o f HE in patients with autonomic neuropathy (Maheshwari 
et al. 2004). In the present study we employed Poincare plots to distinguish between 
the effects o f  vagal modulation from other causes o f heart rate variations (Tulppo et 
al. 1996). SD1 describes short-term fluctuation o f R-R intervals reflecting vagal drive 
and SD2 describes the long-term R-R interval variations and accounts for all other 
heart rate changes, including those associated with sympathetic oscillations, 
barorefelx loop, thermoregulation and fluctuations in humoral factors (Tulppo et al. 
1996). We found that among all HRV parameters, SD2 showed the strongest 
correlation with degree o f  HE (Table 5.2). In addition, the relationship between long­
term HRV (SD2) and the degree o f neuropsychiatric impairment held firm even when 
control was exercised for vagal drive (SD1). Since the relationship between SD2 and 
the degree o f HE remained essentially unchanged after adjusting for SD1 (Table 5.2), 
we can conclude that the correlation between long-term HRV and the 
neuropsychiatric impairment in cirrhosis can not be simply explained by vagal 
dysfunction. It is likely that systemic inflammation and cytokine might influence the 
complex network o f the autonomic nervous system during systemic inflammation. 
Recent report form Gonzalez-Clemente et al. (2005, 2007) has supported this 
hypothesis by showing that inflammatory cytokines are involved in the pathogenesis 
o f neuropathy in patients with diabetes (Gonzalez-Clemente et al. 2005, 2007).
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The molecular mechanism(s) underlying the pathogenesis o f  HE is poorly understood; 
there is evidence suggesting that inflammatory mediators might play a crucial role 
(Shawcross et al., 2004, O'Beime et al., 2006, Jover et al., 2006). Infection (e.g. 
sepsis or spontaneous bacterial peritonitis) is a well-known precipitating factor for the 
development o f overt HE (Blei 2004). Furthermore, serum levels o f  TN F-a have 
been shown to correlate with severity o f HE in chronic liver failure (Odeh et al., 2004, 
Odeh et al., 2005). More recent data suggest that the subtlest manifestation o f  HE, 
minimal encephalopathy, may also be associated with inflammation. For instance 
Shawcross et al. have reported a significant impairment o f neuropsychiatric status 
following diet-induced hyperammonemia during the inflammatory state, but not after 
its resolution (Shawcross et al. 2004). The present study indicates that the changes 
observed in HRV and in neuropsychiatric status in patients with cirrhosis may have a 
common aetiology, possibly involving cytokines. In fact we could show a significant 
correlation between plasma levels o f IL- 6  and HRV parameters in patients with 
cirrhosis. This report adds evidence to the possible role o f  inflammatory responses in 
the aetiology o f hepatic encephalopathy in patients with chronic liver disease.
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6. Summary and conclusions
Ever since the discovery that nitric oxide (NO) can be generated enzymatically in 
biological systems and give rise to the formation o f reactive nitrogen species (RNS), 
an extensive body o f  studies that address the involvement o f reactive nitrogen species 
(RNS) in physiology and pathology have been published. The discovery that RNS can 
cause nitration or nitrosation within biological targets, such as tyrosine and thiols has 
also led to an expanding number o f studies. Thus, detection o f  nitrotyrosine or related 
nitro adducts is often used as a footprint for the formation o f RNS.
Despite the considerable progress that has been made over the years with respect to 
analytical methodology to determine endogenous protein nitration, which was often 
plagued by considerable sources o f artifact (Frost et al. 2000, Moore and Mani 2002), 
one issue that has remained incompletely resolved to date is what is the most 
appropriate and convenient way to estimate overall protein tyrosine nitration in vivo. 
Measurement o f protein-associated nitrotyrosine may not always provide an accurate 
estimation o f  the extent o f protein nitration that has occurred in vivo, since most 
proteins, and oxidized proteins in particular, have finite life spans and undergo avid 
turnover by proteasomal degradation.
Therefore, analysis o f  accumulated breakdown products in serum or in urine might be 
a better approach to assess the formation o f nitrotyrosine in vivo. We and others have 
identified 3-nitro-4-hydroxyphenylacetic acid (NHPA) as one o f  its major 
metabolites. In the present thesis, one o f the major objectives was to evaluate the use 
o f  urinary NHPA as a biomarker for protein tyrosine nitration.
In one study performed in rats we addressed the possibility that the appearance o f  
urinary NHPA could arise from nitration o f endogenous /wa-hydroxyphenylacetic 
acid (PHPA), rather than tyrosine nitration followed by its metabolism. Using mass 
spectrometry in combination with isotopically labelled PHPA precursors, we 
demonstrated that nitration o f endogenous PHPA accounts for the majority o f  NHPA 
in the urine. To confirm these data we carried out a similar study in human volunteers 
which showed that endogenous PHPA is nitrated in vivo and is the major source o f  
urinary NHPA in humans (The data o f nitration o f PHPA in human volunteers is not 
shown here and is published elsewhere; see Panala et al. 2006).
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Thus urinary NHPA arises from both metabolism o f  nitrotyrosine, and nitration o f
'y
endogenous PHPA. In chapter 2 we showed that measurement o f [ H5]NHPA after 
infusing [2H6]PHPA may be used as an index o f RNS formation in vivo. Our 
observation that endotoxaemia causes a significant increase in [ H5]NHPA excretion 
(Fig. 2.6) supports the validity o f  this novel approach.
We also used this method to examine nitration reactions in experimental cirrhosis and 
demonstrated a significant increase in [ HsjNHPA formation following intravenous 
injection o f [2H6]PHPA in rats with biliary cirrhosis (Fig. 4.12). In order to investigate 
if  enhanced nitration reaction plays a role in cardiac dysfunction is cirrhosis; we 
measured free and protein-bound nitrotyrosine in cardiac tissue o f  bile duct ligated 
rats following pharmacological manipulations. This confirmed the observation that 
cardiac chronotropic function is abnormal in rats with biliary cirrhosis. More 
importantly, it demonstrates that this abnormality is associated with increased levels 
o f  protein-bound nitrotyrosine in cardiac tissue. The administration o f either L-NAME 
or N-acetylcysteine, both o f which decrease the tissue levels o f nitrotyrosine, led to 
normalization o f heart rate as well as cardiac responsiveness to adrenergic stimulation 
in rats with biliary cirrhosis.
Both L-NAME and N-acetylcysteine can improve cardiac function and decrease 
cardiac nitrotyrosine levels in biliary cirrhosis. However, the effects o f  N- 
acetylcysteine are not attributable to down-regulation o f NO synthesis since the 
plasma concentrations o f  nitrite + nitrate (NO end-products) remained significantly 
elevated in rats with cirrhosis treated with N-acetylcysteine whereas L-NAME led to a 
significant decrease in plasma nitrate + nitrite concentrations in both groups. The 
decrease o f protein-bound nitrotyrosine after N-acetylcysteine treatment may be 
related to the ability o f  N-acetylcysteine, to either inhibit the formation o f  reactive 
nitrogen species or to increase the proteolytic degradation o f the nitrated proteins. 
Using ["H6]PHPA as a probe to study formation o f reactive nitrogen species in vivo, 
we could initially show enhanced nitration reactions in vivo and a corresponding 
increased formation o f its nitrated product [2Hs]NHPA in rats with cirrhosis. 
However, based on this approach, we were unable to show decreased reactive 
nitrogen species formation following N-acetylcysteine administration as the urinary 
levels o f [ 2H5]NHPA were un-changed in N-acetylcysteine treated animals (Fig. 4.12).
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Because these data suggest N-acetylcysteine does not scavenge reactive nitrogen 
species in our model, the effect o f N-acetylcysteine on nitrotyrosine levels could be 
explained if  it enhances the degradation o f  nitrated proteins. Thus, whereas these data 
suggest N-acetylcysteine leads to increased proteolysis o f  nitrated proteins, the 
mechanism remains unclear and needs further investigation.
Whereas the observation that increased nitration o f cardiac proteins in cirrhosis is o f  
interest, the question arises which proteins are nitrated and are they functionally 
important? Although we initially tried to use proteomic methods to identify the 
nitrated proteins in the current study, we were unable to obtain reproducible data, and 
at present the identity o f the nitrated proteins remains unknown. One group has 
successfully employed proteomic methods to identify the cardiac proteins that 
undergo age-dependent tyrosine nitration (Kanski et al. 2005). Among the identified 
proteins are mitochondrial enzymes as well as desmin which is involved in the sliding 
o f myocardial filaments.
Apart from identification o f nitrated proteins it is important to know what proportion 
o f the candidate protein is modified by nitration. Because the overall extent o f 
tyrosine nitration in vivo may only amount to one nitrotyrosine per 103 tyrosine 
residues, it appears unlikely that tyrosine nitration in vivo significantly impairs cardiac 
function unless specific tyrosine substrates are preferential targets for nitration. 
Cytoskeletal proteins such as actin have been suggested to represent important targets 
for tyrosine nitration reactions (Aslan et al. 2003). In fact chemical nitration o f  actin or 
neurofilaments has been shown to disrupt assembly o f  these proteins, and 
modification o f  only a few protein subunits appears necessary to cause disruption o f  a 
structure involving thousands o f  subunits (Beckman 1996; Aslan et al. 2003). The 
immunogold studies presented in Fig. 4.13 suggest that cytoskeletal and 
mitochondrial proteins are targets for nitration in the atria o f rats with cirrhosis. 
However, further studies are required in future to examine whether such modifications 
contribute significantly to the pathobiology o f cardiac chronotropic dysfunction in 
cirrhosis.
There can be little doubt that NOS activity is o f  considerable importance 
physiologically, or that overproduction o f NO or increased NOS activity has the 
potential to cause harm either through nitration o f proteins or through enhancement o f
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cGMP-dependent mechanisms (e.g. inhibition o f L-type calcium channels in the 
cardiomyocytes). However, part o f the problem in turning scientific discovery into 
useful therapeutics has been the sheer range o f processes in which NO has been 
implicated, and the opposing effects o f NO even within a single disease. A good 
example is provided in the field o f liver cirrhosis: High-output NO generation in 
systemic vasculature can induce cardiac dysfunction and haemodynamic instability. 
However, decreased NO formation within the hepatic micro circulation promotes 
portal hypertension and its complications. Any systemic administration o f  NOS 
inhibitors (e.g. L-NAME) will have a marked and detrimental effect on hepatic 
microcirculation than a beneficial effect on systemic circulation. In the past, NOS 
inhibitors have been used in humans to explore the physiological mechanisms or as 
potential treatment. For instance, in patients with septic shock, the isoform non­
specific NOS inhibitor, A^-monomethyl-arginine, restores blood pressure and seems 
to improve haemodynamics. However, the largest study so far showed an adverse 
effect on outcome (Vallance and Leiper 2002). Even in genetically modified animals, 
although iNOS knockout mice are reported to be resistant to circulatory dysfunction 
in experimental sepsis (Funakoshi et al., 2002), disruption o f  iNOS does not improve 
the survival following a lethal dose o f endotoxin or cytokines (Nicholson et al., 1999 
and Funakoshi et al., 2002). Likewise, both iNOS and eNOS knockout mice are 
reported to develop cardiovascular dysfunction in a mouse model o f  portal 
hypertension (Iwakiri et al. 2002). This means that developing even isoform specific 
NOS inhibitors might not be a good strategy for management o f  cardiovascular 
abnormalities in patients with liver disease.
The spontaneous variations which occur in heart rate result from a series o f  complex 
interactions between multiple regulatory processes which operate over different time 
scales. Decreased variability and increased regularity o f cardiac rhythm have been 
reported in different clinical settings associated with increased production o f  
inflammatory cytokines and have a negative prognostic value. Heart rate variability 
(HRV) is decreased in patients with chronic liver disease, and is a negative predictor 
o f  outcome in this patient population. The possibility that the changes in HRV 
observed in patients with cirrhosis might be associated with hepatic encephalopathy
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has not been considered previously. This is surprising given that: (i) reductions in 
HRV are known to occur in a number o f neuropsychiatric disorders (chapter 5); (ii) 
reductions in HRV are observed in situation associated with increased circulating 
inflammatory cytokines; inflammatory cytokines are increased in patient with 
cirrhosis and correlate positively with the severity o f hepatic encephalopathy (chapter
5).
As described in chapter 5, HRV was significantly decreased in patients with cirrhosis 
in parallel with the degree o f neuropsychiatric impairment, independently o f  the 
degree o f hepatic dysfunction. Moreover, significant correlations were observed 
between HRV indices and individual EEG spectral parameters and psychometric 
variables. There are several possible explanations for the relationship between HRV 
and neuropsychiatric status in patients with cirrhosis. The two most likely are (i) the 
presence o f an autonomic neuropathy or (ii) the presence o f a mechanism involving 
circulating inflammatory cytokines. The physiological mechanism underlying the 
loss o f  HRV during the systemic inflammatory response is unknown but cytokine- 
induced autonomic dysfunction or disruption o f intracellular signal transduction 
processes undoubtedly plays a role. Amongst the cytokines IL-6 exhibit the strongest 
correlation with the indices o f depressed HRV during inflammation (Gonzalez- 
Clemente et al. 2007; Tateishi et al. 2007; chapter 5). Cytokines can potentially blunt 
B-adrenergic signalling and thus it has been suggested that over-expression o f  
cytokines and subsequent loss o f B-adrenergic responsiveness might contributes to the 
decrease in HRV during inflammation. Although this hypothesis is attractive within 
the context o f ‘cirrhotic cardiomyopathy’, our recent study has shown that decreased 
HRV following endotoxin challenge is not related to alterations in cardiac B- 
adrenergic signalling in endotoxaemic mice (Mani et al. 2006a). In addition, loss o f  
HRV in bile duct ligated rat model o f  cirrhosis occurs independently o f  impaired 
cardiac B-adrenergic responsiveness (chapter 4).
Previous studies have suggested that decreased HRV is an independent risk factor for 
death and has a negative prognostic value in this patient population (Hendrickse et al. 
1992; Ates et al. 2006). This finding was confirmed in the present thesis; the relative 
risk o f  death increased by 7.7 % for every ms drop in SD2. Thus, whatever the causal 
link between changes in HRV and neuropsychiatric status in patients with cirrhosis, a
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reduction in HRV identifies individuals who at risk o f  death and could be used to 
monitor patients over time and perhaps facilitate selection for transplantation. It could 
also be speculated that the decrease in HRV observed in several other 
neuropsychiatric conditions might relate to changes in inflammatory cytokines and 
this possibility should be explored.
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8. Abbreviation
ANOVA: analysis o f variance
ANCOVA: analysis o f co-variance
BDL: bile duct-ligated
CB1: cannabinoid receptor 1
CGRP: calcitonin gene-related polypeptide
CTR: control
CysNO: S-nitrosocysteine
DS: digit symbol
DTPA: diethylenetriamine pentaacetic acid
ECG: electrocardiogram
EDTA: ethylenediamine tetraacetic acid
EEG: electroencephalogram
eNOS: endothelial nitric oxide synthase
GC: gas chromatography
GC/MS: gas chromatography mass spectrometry
GSNO: S-nitroso glutathione
HE: hepatic encephalopathy
HF: high frequency
HRV: heart rate variability
IL-1: interleukin-1
IL-6: interleukin-6
IL-10: interleukin-10
IL-12: interleukin-12
iNOS: inducible nitric oxide synthase
INR: international normalized ratio
LF: low frequency
L-NAME: A^-L-nitro-arginine methyl ester
LPS: lipopolysaccharide
LT: line tracing
MS: mass spectrometry
ms: millisecond
NAC: N-acetylcysteine
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NCT-A: Number Connection Tests A
NCT-B: Number Connection Tests B
NEO: neomycin
NEM: A-ethylmaleimide
NF-kB: nuclear factor kB
NHPA: 3-nitro-4-hydroxyphenylacetic acid
[i3C8]NHPA: [1,2,1 ',2 ',3 ',4 ',5 ',6 '-13C]NHPA
[2H5]NHPA: [2,2,2 ',5 ',6 '-2H]NHPA
NICI: negative-ion chemical ionization
NO: nitric oxide
NO 2 : nitrogen dioxide
NO 2 : nitrite
NO3Y nitrate
N2O3: dinitrogen trioxide
NOS: nitric oxide synthase
nNOS: neuronal nitric oxide synthase
nu: normalized units
O2 ’: superoxide anion
ONOO”: peroxynitrite
PBS: phosphate buffered saline solution
PGI2 : prostacyclin
PHPA: /?ara-hydroxyphenylacetic acid
[ 13 C8]PHPA: [ 1,2,l ' ,2 ' ,3 ',4 ' ,5 ' ,6 13C]PHPA
[2H6]PHPA: [2,2,2 ',3 ',5 ',6 -2H]PHPA
POLYB: polymixin B
PTXF: pentoxyfylline
PVDF: polyvinylidene fluoride
RNS: reactive nitrogen species
SampEn: sample entropy
SD: standard deviation
SDNN: standard deviation o f  beat to beat interval
SDot: serial dotting
SDS: sodium dodecyl sulphate
SDS-PAGE: sodium dodecyl sulphate polyacrylamide gel electrophoresis
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SEM: standard error o f mean
SOD: superoxide desmutase
TFA: trifluoroacetic acid
TNF-C£ tumor necrosis alpha
[ 13C9 ]tyrosine: [ 1,2,3,1 ',2 ',3 ',4 ',5 ' , 6 l3C]tyrosine.
UV: ultraviolet
VLF: very low frequency
VR1: vanilloid receptot 1
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